[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 538
1. Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H: [High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review]. Dtsch Med Wochenschr; 2006 Aug 25;131(34-35):1849-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aggressive B-cell lymphomas consisted of 19 cases of Burkitt's lymphoma, 8 of Castleman's disease and 12 of primary cerebral malignant lymphoma.
  • Of the 200 (52.6%) not-AIDS-defined malignant tumors 133 were 133 solid tumors, 40 of them anal carcinoma (20% of all not-AIDS-defined malignancies) and 67 haematological malignancies, 22 of these Hodgkin's lymphoma (11.0% of all not-AIDS-defined malignancies).
  • The incidence of anal carcinoma is estimated to be 34 (95% CI 24-470) per 100 000 patient-years, that of Hodgkin's lymphoma 19 (95% CI 12-28) per 100 000 patient-years.
  • Of special note is the high incidence of anal carcinoma and Hodgkin's lymphoma, compared with their incidence among the entire German population.
  • [MeSH-major] Anus Neoplasms / epidemiology. HIV Infections / complications. Hodgkin Disease / epidemiology. Neoplasms / epidemiology. Neoplasms / virology


2. Liu J, Lau SK, Varma VA, Kairdolf BA, Nie S: Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots. Anal Chem; 2010 Jul 15;82(14):6237-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots.
  • Here, we report the use of multiplexed QDs and wavelength-resolved imaging to detect and characterize a class of low-abundant tumor cells in Hodgkin's lymphoma.
  • We have also carried out clinical translation studies involving six confirmed Hodgkin's lymphoma patients, two suspicious lymphoma cases, and two patients with reactive lymph nodes (but not lymphoma).
  • The results indicate that a distinct QD staining pattern (CD15 positive, CD30 positive, CD45 negative, and Pax5 positive) can be used to not only detect Hodgkin's lymphoma but also differentiate it from benign lymphoid hyperplasia.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] ACS Nano. 2010 May 25;4(5):2755-65 [20377268.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):162-76 [11896065.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Cancer Detect Prev. 2002;26(4):249-55 [12430629.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117 Suppl:S76-94 [14569804.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):47-52 [14704706.001]
  • [Cites] J Clin Pathol. 1987 Nov;40(11):1298-304 [3320093.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2905-17 [8639911.001]
  • [Cites] J Pathol. 1997 Apr;181(4):462-3 [9196447.001]
  • [Cites] Mol Med Today. 1995 Apr;1(1):26-30 [9415134.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] Curr Opin Biotechnol. 2005 Feb;16(1):63-72 [15722017.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41207 [16178631.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Mar;6(2):231-44 [16512782.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1181-91 [16778828.001]
  • [Cites] Nano Lett. 2006 Dec;6(12):2881-6 [17163724.001]
  • [Cites] Nat Protoc. 2007;2(5):1152-65 [17546006.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):871-7 [17529924.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:257-88 [17439359.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1226-40 [18495291.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 19;374(2):181-6 [18621021.001]
  • [Cites] J Pathol. 2008 Nov;216(3):275-85 [18814189.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Nat Methods. 2009 Feb;6(2):139-41 [19137005.001]
  • [Cites] Biomaterials. 2009 May;30(15):2912-8 [19251316.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Trends Biotechnol. 2009 Jun;27(6):350-8 [19409634.001]
  • [Cites] Biosens Bioelectron. 2009 Aug 15;24(12):3657-62 [19540102.001]
  • [Cites] J Mol Histol. 2009 Aug;40(4):261-8 [19908148.001]
  • [Cites] ACS Nano. 2010 Jan 26;4(1):488-94 [20041634.001]
  • [Cites] N Engl J Med. 2010 Mar 11;362(10):875-85 [20220182.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • (PMID = 20565106.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108468; United States / NCI NIH HHS / CA / CA119338-01; United States / NCI NIH HHS / CA / U54CA119338; United States / NCI NIH HHS / CA / U54 CA119338; United States / NCI NIH HHS / CA / CA108468-01; United States / NCI NIH HHS / CA / R01 CA108468-01; United States / NCI NIH HHS / CA / R01CA108468; United States / NCI NIH HHS / CA / U54 CA119338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS220487; NLM/ PMC2914471
  •  go-up   go-down


3. Miller CS, Foley JD, Bailey AL, Campell CL, Humphries RL, Christodoulides N, Floriano PN, Simmons G, Bhagwandin B, Jacobson JW, Redding SW, Ebersole JL, McDevitt JT: Current developments in salivary diagnostics. Biomark Med; 2010 Feb;4(1):171-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current developments in salivary diagnostics.
  • Salivary diagnostics is an emerging field that has progressed through several important developments in the past decade, including the publication of the human salivary proteome and the infusion of federal funds to integrate nanotechnologies and microfluidic engineering concepts into developing compact point-of-care devices for rapid analysis of this secretion.
  • In this article, we discuss some of these developments and their relevance to the prognosis, diagnosis and management of periodontitis, as an oral target, and cardiovascular disease, as a systemic example for the potential of these biodiagnostics.
  • Our findings suggest that several biomarkers are associated with distinct biological stages of these diseases and demonstrate promise as practical biomarkers in identifying and managing periodontal disease, and acute myocardial infarction.
  • The majority of these studies have progressed through biomarker discovery, with the identified molecules requiring more robust clinical studies to enable substantive validation for disease diagnosis.
  • It is predicted that with continued advances in this field the use of a combination of biomarkers in multiplex panels is likely to yield accurate screening tools for these diagnoses in the near future.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5268-73 [17374724.001]
  • [Cites] Ann N Y Acad Sci. 2007 Mar;1098:411-28 [17435146.001]
  • [Cites] Ann N Y Acad Sci. 2007 Mar;1098:496-7 [17435158.001]
  • [Cites] Adv Med Sci. 2006;51 Suppl 1:158-61 [17458082.001]
  • [Cites] Clin Biochem. 2007 Jun;40(9-10):661-5 [17328883.001]
  • [Cites] Arthritis Res Ther. 2007;9 Suppl 1:S1 [17634140.001]
  • [Cites] J Dent Res. 2007 Aug;86(8):680-93 [17652194.001]
  • [Cites] Circulation. 2008 Jan 29;117(4):e25-146 [18086926.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Feb;34(1):40-6 [18226127.001]
  • [Cites] Toxicology. 2008 Mar 20;245(3):194-205 [18291570.001]
  • [Cites] Arch Oral Biol. 2008 Apr;53(4):346-52 [18155182.001]
  • [Cites] Health Aff (Millwood). 2008 Mar-Apr;27(2):w84-95 [18198184.001]
  • [Cites] Clin Chem. 2005 May;51(5):810-24 [15774573.001]
  • [Cites] Ann Periodontol. 2002 Dec;7(1):8-16 [16013212.001]
  • [Cites] PLoS Med. 2005 Jul;2(7):e182 [16013921.001]
  • [Cites] Compend Contin Educ Dent. 2005 Jun;26(6):381-2, 384, 387-90 passim; quiz 398-9 [16021957.001]
  • [Cites] J Proteome Res. 2008 May;7(5):1994-2006 [18361515.001]
  • [Cites] Mol Diagn Ther. 2008;12(3):157-70 [18510379.001]
  • [Cites] Allergy Asthma Proc. 2008 May-Jun;29(3):345-8 [18534093.001]
  • [Cites] J Clin Periodontol. 2008 Oct;35(10):846-52 [18727653.001]
  • [Cites] J Periodontol. 2008 Oct;79(10):1913-9 [18834246.001]
  • [Cites] Infect Immun. 2009 Feb;77(2):850-9 [19029300.001]
  • [Cites] Horm Res. 2009 Jan;71 Suppl 1:134-8 [19153524.001]
  • [Cites] J Periodontol. 2009 Jan;80(1):106-13 [19228096.001]
  • [Cites] Arch Oral Biol. 2009 May;54(5):445-8 [19321161.001]
  • [Cites] J Periodontol. 2009 Jul;80(7):1146-53 [19563296.001]
  • [Cites] Clin Chem. 2009 Aug;55(8):1530-8 [19556448.001]
  • [Cites] Oral Dis. 2010 Jan;16(1):39-45 [19627514.001]
  • [Cites] J Oral Pathol. 1974;3(6):284-90 [4377156.001]
  • [Cites] Int J Fertil. 1976;21(1):43-8 [8394.001]
  • [Cites] Oral Sci Rev. 1976;(8):25-47 [790252.001]
  • [Cites] Am J Physiol. 1982 Mar;242(3):G231-6 [7065186.001]
  • [Cites] Hoppe Seylers Z Physiol Chem. 1983 Sep;364(9):1323-8 [6195067.001]
  • [Cites] J Periodontal Res. 1983 Nov;18(6):559-69 [6230429.001]
  • [Cites] Nature. 1986 Feb 6-12;319(6053):516-8 [3511389.001]
  • [Cites] Arch Oral Biol. 1985;30(11-12):765-71 [3868965.001]
  • [Cites] J Immunol. 1987 Mar 1;138(5):1464-8 [3492553.001]
  • [Cites] J Periodontal Res. 1987 Sep;22(5):381-9 [2826747.001]
  • [Cites] Ann Biol Clin (Paris). 1988;46(6):361-70 [2459995.001]
  • [Cites] J Periodontal Res. 1989 May;24(3):207-13 [2550604.001]
  • [Cites] Arch Dermatol. 1989 Oct;125(10):1406-12 [2679403.001]
  • [Cites] Immunology. 1989 Sep;68(1):31-6 [2478449.001]
  • [Cites] Princess Takamatsu Symp. 1988;19:193-208 [2908353.001]
  • [Cites] Compend Suppl. 1989;(13):S457-60 [2605592.001]
  • [Cites] J Periodontal Res. 1990 Mar;25(2):81-7 [2139121.001]
  • [Cites] J Oral Pathol Med. 1990 Mar;19(3):119-25 [2187975.001]
  • [Cites] J Periodontal Res. 1990 May;25(3):135-42 [2163444.001]
  • [Cites] J Periodontal Res. 1990 May;25(3):156-63 [2141875.001]
  • [Cites] J Periodontal Res. 1990 Sep;25(5):257-67 [2170617.001]
  • [Cites] Arch Intern Med. 1991 Feb;151(2):260-5 [1992953.001]
  • [Cites] J Periodontal Res. 1991 Mar;26(2):65-74 [1826527.001]
  • [Cites] J Periodontal Res. 1991 Mar;26(2):75-84 [1826528.001]
  • [Cites] Arch Oral Biol. 1990;35 Suppl:193S-196S [1965117.001]
  • [Cites] FASEB J. 1991 May;5(8):2145-54 [1850705.001]
  • [Cites] BMJ. 1992 Jul 25;305(6847):207-8 [1290500.001]
  • [Cites] Matrix Suppl. 1992;1:352-62 [1480060.001]
  • [Cites] J Periodontol. 1993 Feb;64(2):82-8 [8433257.001]
  • [Cites] J Oral Pathol Med. 1993 Feb;22(2):73-6 [8445546.001]
  • [Cites] Biosens Bioelectron. 2005 Oct 15;21(4):574-80 [16202870.001]
  • [Cites] Leuk Lymphoma. 2005 Dec;46(12):1699-707 [16263571.001]
  • [Cites] J Periodontol. 2005 Nov;76(11 Suppl):2066-74 [16277578.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2391-5 [16306107.001]
  • [Cites] J Periodontol. 2005 Dec;76(12):2187-93 [16332229.001]
  • [Cites] Coll Antropol. 2005 Dec;29(2):435-9 [16417140.001]
  • [Cites] Oral Dis. 2006 Mar;12(2):112-6 [16476030.001]
  • [Cites] J Am Dent Assoc. 2006 Mar;137(3):322-9 [16570465.001]
  • [Cites] Br J Haematol. 2006 May;133(3):301-4 [16643432.001]
  • [Cites] Clin Chem Lab Med. 2006;44(5):612-5 [16681433.001]
  • [Cites] Circulation. 2006 May 16;113(19):2335-62 [16702488.001]
  • [Cites] Ann Med. 2006;38(5):306-21 [16938801.001]
  • [Cites] J Oral Pathol Med. 2006 Oct;35(9):530-9 [16968233.001]
  • [Cites] J Periodontal Res. 2006 Dec;41(6):503-12 [17076774.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2006 Nov-Dec;54(6):419-26 [17122880.001]
  • [Cites] J Oral Sci. 2006 Dec;48(4):177-83 [17220614.001]
  • [Cites] FEMS Immunol Med Microbiol. 2007 Mar;49(2):252-60 [17328758.001]
  • [Cites] J Periodontol. 2007 Mar;78(3):498-503 [17335373.001]
  • [Cites] J Bone Miner Metab. 1999;17(4):245-51 [10575588.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):275-86 [10637272.001]
  • [Cites] J Biol Chem. 2000 Feb 18;275(7):4858-64 [10671521.001]
  • [Cites] Clin Chim Acta. 2000 Feb 15;291(2):223-34 [10675725.001]
  • [Cites] Exp Physiol. 2000 Mar;85 Spec No:233S-241S [10795927.001]
  • [Cites] J Clin Periodontol. 2000 Jul;27(7):453-65 [10914885.001]
  • [Cites] Arch Intern Med. 2000 Oct 9;160(18):2749-55 [11025784.001]
  • [Cites] J Clin Periodontol. 2000 Nov;27(11):819-23 [11073324.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] Anal Biochem. 2001 Jun 15;293(2):178-84 [11399030.001]
  • [Cites] Bone. 2001 Jun;28(6):575-6 [11425643.001]
  • [Cites] J Am Chem Soc. 2001 Mar 21;123(11):2559-70 [11456925.001]
  • [Cites] Semin Hematol. 2001 Jul;38(3):276-85 [11486316.001]
  • [Cites] Acta Odontol Scand. 2001 Jun;59(3):167-73 [11501886.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):971-6 [11583751.001]
  • [Cites] Oral Microbiol Immunol. 2002 Apr;17(2):100-7 [11929557.001]
  • [Cites] Crit Rev Oral Biol Med. 2002;13(2):197-212 [12097361.001]
  • [Cites] Oral Dis. 2002 May;8(3):147-59 [12108759.001]
  • [Cites] Anal Chem. 2002 Jul 1;74(13):3030-6 [12141661.001]
  • [Cites] J Am Chem Soc. 2003 Feb 5;125(5):1114-5 [12553782.001]
  • [Cites] J Am Chem Soc. 2003 Mar 12;125(10):2870-1 [12617642.001]
  • [Cites] Periodontol 2000. 2003;31:32-42 [12656994.001]
  • [Cites] J Periodontol. 2003 Mar;74(3):353-9 [12710755.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Bone Miner Res. 2003 May;18(5):859-67 [12733725.001]
  • [Cites] J Periodontal Res. 2003 Aug;38(4):436-9 [12828663.001]
  • [Cites] J Clin Periodontol. 2003 Aug;30(8):752-5 [12887345.001]
  • [Cites] Circulation. 2003 Sep 23;108(12):1440-5 [12952835.001]
  • [Cites] J Periodontol. 2003 Aug;74(8):1237-47 [14514240.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4732-9 [14674448.001]
  • [Cites] J Clin Periodontol. 2003 Dec;30(12):1053-60 [15002891.001]
  • [Cites] Science. 2004 Jun 25;304(5679):1936 [15218140.001]
  • [Cites] JAMA. 2004 Jul 28;292(4):490-5 [15280347.001]
  • [Cites] Dtsch Stomatol. 1966 Dec;16(12):910-7 [5225955.001]
  • [Cites] J Periodontol. 1993 Apr;64(4):297-301 [8483092.001]
  • [Cites] J Periodontol. 1993 May;64(5 Suppl):474-84 [8315570.001]
  • [Cites] Ann N Y Acad Sci. 1993 Sep 20;694:234-7 [8215058.001]
  • [Cites] J Periodontal Res. 1993 Nov;28(6 Pt 2):511-3 [8263721.001]
  • [Cites] Oral Microbiol Immunol. 1993 Oct;8(5):298-305 [8265204.001]
  • [Cites] J Clin Periodontol. 1994 Jan;21(1):26-31 [8126240.001]
  • [Cites] Ann Biol Clin (Paris). 1993;51(10-11):903-10 [8210068.001]
  • [Cites] J Dent Res. 1994 Aug;73(8):1397-406 [8083435.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 10;737:291-307 [7524403.001]
  • [Cites] Ann N Y Acad Sci. 1994 Sep 6;732:112-31 [7978785.001]
  • [Cites] Ann N Y Acad Sci. 1995 Jul 21;762:55-70 [7545378.001]
  • [Cites] J Periodontol. 1995 Oct;66(10):852-9 [8537867.001]
  • [Cites] J Clin Periodontol. 1996 Jan;23(1):30-7 [8636454.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1996 Mar;34(3):171-91 [8721405.001]
  • [Cites] Arch Oral Biol. 1995 Dec;40(12):1151-5 [8850655.001]
  • [Cites] J Periodontol. 1996 Aug;67(8):748-54 [8866313.001]
  • [Cites] J Periodontol. 1996 Aug;67(8):755-62 [8866314.001]
  • [Cites] J Clin Periodontol. 1996 Dec;23(12):1127-32 [8997658.001]
  • [Cites] Indian J Dent Res. 1995 Apr-Jun;6(2):41-6 [9495108.001]
  • [Cites] Cell. 1998 Apr 17;93(2):165-76 [9568710.001]
  • [Cites] Periodontol 2000. 1995 Feb;7:83-99 [9567932.001]
  • [Cites] Periodontol 2000. 1997 Jun;14:144-57 [9567969.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):115-26 [9887164.001]
  • [Cites] J Oral Sci. 1999 Mar;41(1):35-40 [10230159.001]
  • [Cites] Coll Antropol. 1999 Jun;23(1):117-24 [10402713.001]
  • [Cites] Inflamm Res. 2004 Nov;53(11):596-600 [15693607.001]
  • [Cites] Lab Chip. 2005 Mar;5(3):261-9 [15726202.001]
  • [Cites] Cancer Detect Prev. 2005;29(1):42-5 [15734216.001]
  • [Cites] Biosens Bioelectron. 2005 Apr 15;20(10):2079-88 [15741078.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1714-28 [15800970.001]
  • (PMID = 20387312.001).
  • [ISSN] 1752-0363
  • [Journal-full-title] Biomarkers in medicine
  • [ISO-abbreviation] Biomark Med
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / U01 DE017793-04; United States / NIDCR NIH HHS / DE / DE017793-03; United States / NIDCR NIH HHS / DE / DE017793-02; None / None / / U01 DE017793-01; United States / NIDCR NIH HHS / DE / U01 DE017793-03; None / None / / U01 DE017793-04; United States / NIDCR NIH HHS / DE / U01 DE017793-02; United States / NIDCR NIH HHS / DE / U01 DE017793; United States / NIDCR NIH HHS / DE / U01 DE017793-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Inflammation Mediators; 0 / Proteome
  • [Number-of-references] 148
  • [Other-IDs] NLM/ NIHMS180637; NLM/ PMC2857781
  •  go-up   go-down


Advertisement
4. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, Yao JD, Wengenack NL, Rosenblatt JE, Cockerill FR 3rd, Smith TF: Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin Microbiol Rev; 2006 Jan;19(1):165-256
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time PCR in clinical microbiology: applications for routine laboratory testing.
  • Real-time PCR has revolutionized the way clinical microbiology laboratories diagnose many human microbial infections.
  • This testing method combines PCR chemistry with fluorescent probe detection of amplified product in the same reaction vessel.
  • In general, both PCR and amplified product detection are completed in an hour or less, which is considerably faster than conventional PCR detection methods.
  • Real-time PCR assays provide sensitivity and specificity equivalent to that of conventional PCR combined with Southern blot analysis, and since amplification and detection steps are performed in the same closed vessel, the risk of releasing amplified nucleic acids into the environment is negligible.
  • The combination of excellent sensitivity and specificity, low contamination risk, and speed has made real-time PCR technology an appealing alternative to culture- or immunoassay-based testing methods for diagnosing many infectious diseases.
  • This review focuses on the application of real-time PCR in the clinical microbiology laboratory.
  • [MeSH-major] Clinical Laboratory Techniques. Infection / diagnosis. Oligonucleotide Probes. Polymerase Chain Reaction / methods
  • [MeSH-minor] Bacterial Infections / diagnosis. Bacterial Infections / microbiology. Humans. Mycoses / diagnosis. Mycoses / microbiology. Protozoan Infections / diagnosis. Protozoan Infections / parasitology. Virus Diseases / diagnosis. Virus Diseases / virology

  • MedlinePlus Health Information. consumer health - Laboratory Tests.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Virol Methods. 2001 Apr;92(2):183-91 [11226565.001]
  • [Cites] J Microbiol Methods. 2001 Apr;44(3):263-9 [11240049.001]
  • [Cites] J Clin Microbiol. 2001 Mar;39(3):1195-6 [11230458.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):229-38 [11265232.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1264-71 [11283039.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1272-8 [11283040.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1303-10 [11283046.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1456-9 [11283071.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1553-8 [11283086.001]
  • [Cites] J Virol Methods. 2001 Apr;93(1-2):33-42 [11311341.001]
  • [Cites] J Virol Methods. 2001 Apr;93(1-2):105-13 [11311349.001]
  • [Cites] JAMA. 2004 Apr 21;291(15):1875-9 [15100207.001]
  • [Cites] Clin Chem. 2004 May;50(5):846-56 [15010424.001]
  • [Cites] Clin Chem. 2004 May;50(5):819-25 [15010426.001]
  • [Cites] J Infect Dis. 2004 May 1;189(9):1679-83 [15116305.001]
  • [Cites] J Clin Virol. 2004 Jun;30(2):191-5 [15125876.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):1909-14 [15131148.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):1940-6 [15131152.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):2013-9 [15131163.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):2043-7 [15131168.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):2085-93 [15131174.001]
  • [Cites] J Neurooncol. 2003 Dec;65(3):237-46 [14682374.001]
  • [Cites] Transfusion. 2004 Jan;44(1):97-103 [14692974.001]
  • [Cites] CMAJ. 2004 Jan 6;170(1):47-54 [14707219.001]
  • [Cites] Avian Dis. 2003 Oct-Dec;47(4):1406-15 [14708989.001]
  • [Cites] Clin Chem. 2004 Jan;50(1):67-72 [14709637.001]
  • [Cites] J Clin Microbiol. 2004 Jan;42(1):45-51 [14715730.001]
  • [Cites] J Clin Virol. 2004 Feb;29(2):99-104 [14747028.001]
  • [Cites] J Clin Virol. 2004 Feb;29(2):120-6 [14747031.001]
  • [Cites] N Engl J Med. 2004 Jan 29;350(5):443-50 [14749452.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):987-91 [15004042.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1142-8 [15004066.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1176-80 [15004071.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1181-4 [15004072.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1207-13 [15004077.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1214-9 [15004078.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1220-3 [15004079.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1296-7 [15004100.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):1373-5 [15004124.001]
  • [Cites] Clin Microbiol Infect. 2004 Mar;10(3):190-212 [15008940.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1726-32 [15014025.001]
  • [Cites] Curr Opin Infect Dis. 2004 Apr;17(2):81-9 [15021045.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):282-9 [15018857.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):320-2 [15018862.001]
  • [Cites] J Virol Methods. 2004 Apr;117(1):67-74 [15019261.001]
  • [Cites] J Infect Dis. 2004 Apr 1;189(7):1151-7 [15031781.001]
  • [Cites] Clin Infect Dis. 2004 Apr 1;38(7):983-90 [15034830.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):662-6 [15066935.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1409-13 [15070981.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1471-6 [15070991.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1498-504 [15070995.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1564-9 [15071005.001]
  • [Cites] J Virol Methods. 2004 Jun 15;118(2):77-82 [15081602.001]
  • [Cites] J Mol Diagn. 2004 May;6(2):108-14 [15096566.001]
  • [Cites] Mol Pathol. 2001 Apr;54(2):86-90 [11322169.001]
  • [Cites] J Clin Microbiol. 2001 May;39(5):1963-6 [11326023.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):362-6 [11328834.001]
  • [Cites] J Clin Microbiol. 2000 Jun;38(6):2429-33 [10835024.001]
  • [Cites] J Microbiol Methods. 2000 Jun;41(1):45-51 [10856776.001]
  • [Cites] Am J Med. 1997 Mar 17;102(3A):10-8; discussion 25-6 [10868137.001]
  • [Cites] Am J Med. 1997 Mar 17;102(3A):31-6; discussion 42-3 [10868140.001]
  • [Cites] Scand J Infect Dis. 2000;32(3):263-9 [10879596.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2516-9 [10878035.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2536-42 [10878039.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2638-42 [10878056.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2734-7 [10878073.001]
  • [Cites] J Clin Microbiol. 2000 Jul;38(7):2756-9 [10878080.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):175-9 [10900276.001]
  • [Cites] JAMA. 2000 May 24-31;283(20):2680-5 [10819951.001]
  • [Cites] J Clin Microbiol. 2000 Sep;38(9):3194-9 [10970356.001]
  • [Cites] J Clin Microbiol. 2000 Oct;38(10):3860-3 [11015421.001]
  • [Cites] J Clin Microbiol. 2000 Nov;38(11):4006-9 [11060060.001]
  • [Cites] J Clin Microbiol. 2000 Nov;38(11):4066-71 [11060069.001]
  • [Cites] J Clin Microbiol. 2000 Nov;38(11):4108-13 [11060076.001]
  • [Cites] J Clin Microbiol. 2001 Jan;39(1):196-200 [11136770.001]
  • [Cites] Acta Virol. 2000 Jun-Aug;44(3):137-43 [11155355.001]
  • [Cites] J Infect Dis. 2001 Feb 1;183(3):377-82 [11133368.001]
  • [Cites] J Med Microbiol. 2001 Feb;50(2):165-72 [11211224.001]
  • [Cites] J Virol Methods. 2001 Mar;92(1):55-64 [11164918.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):564-9 [11158107.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):765-8 [11158147.001]
  • [Cites] J Clin Microbiol. 2001 Feb;39(2):772-5 [11158149.001]
  • [Cites] J Clin Virol. 2001 Jan;20(1-2):15-21 [11163578.001]
  • [Cites] J Mol Diagn. 2001 Feb;3(1):1-10 [11227065.001]
  • [Cites] J Mol Diagn. 2000 Aug;2(3):158-66 [11229521.001]
  • [Cites] J Clin Microbiol. 2000 Aug;38(8):2829-36 [10921935.001]
  • [Cites] J Clin Microbiol. 2000 Aug;38(8):2929-32 [10921953.001]
  • [Cites] J Clin Microbiol. 2000 Aug;38(8):3116-8 [10921993.001]
  • [Cites] Clin Transplant. 2000 Aug;14(4 Pt 1):308-17 [10945201.001]
  • [Cites] Hepatology. 2000 Sep;32(3):626-9 [10960459.001]
  • [Cites] J Clin Microbiol. 2000 Sep;38(9):3187-9 [10970354.001]
  • [Cites] J Clin Microbiol. 2001 Aug;39(8):2904-10 [11474011.001]
  • [Cites] Blood. 2001 Aug 15;98(4):972-8 [11493441.001]
  • [Cites] Transpl Infect Dis. 2001 Sep;3(3):138-48 [11493396.001]
  • [Cites] Clin Chem. 1999 Nov;45(11):1932-7 [10545062.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):103-10 [10602730.001]
  • [Cites] J Biotechnol. 1999 Oct 8;75(2-3):291-5 [10617337.001]
  • [Cites] Clin Infect Dis. 2000 Jan;30(1):176-8 [10619748.001]
  • [Cites] J Infect Dis. 2000 Jan;181(1):395-9 [10608796.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):586-90 [10655350.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):712-5 [10655372.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):795-9 [10655387.001]
  • [Cites] Medicina (B Aires). 1999;59 Suppl 2:176-8 [10668261.001]
  • [Cites] J Med Virol. 2000 Apr;60(4):455-62 [10686030.001]
  • [Cites] Clin Chem. 2000 Mar;46(3):324-31 [10702518.001]
  • [Cites] J Virol Methods. 2000 Mar;85(1-2):75-82 [10716340.001]
  • [Cites] Clin Chem. 2000 May;46(5):631-5 [10794744.001]
  • [Cites] FEMS Immunol Med Microbiol. 2000 Jun;28(2):173-9 [10799809.001]
  • [Cites] Lancet. 2000 May 6;355(9215):1614-5 [10821368.001]
  • [Cites] Biomed Pharmacother. 2001 Sep;55(7):362-5 [11669497.001]
  • [Cites] J Clin Microbiol. 2001 Nov;39(11):3819-22 [11682492.001]
  • [Cites] J Clin Microbiol. 2001 Nov;39(11):4093-6 [11682535.001]
  • [Cites] J Clin Microbiol. 2001 Nov;39(11):4131-7 [11682541.001]
  • [Cites] J Viral Hepat. 2001 Nov;8(6):465-71 [11703579.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Dec;45(12):3474-81 [11709327.001]
  • [Cites] Clin Ther. 2001 Oct;23(10):1615-27 [11726001.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] J Clin Virol. 2002 Feb;24(1-2):107-15 [11744435.001]
  • [Cites] J Clin Virol. 2002 Feb;24(1-2):131-4 [11744437.001]
  • [Cites] Bone Marrow Transplant. 2001 Nov;28(10):975-80 [11753554.001]
  • [Cites] J Clin Microbiol. 2002 Jan;40(1):52-60 [11773092.001]
  • [Cites] J Clin Microbiol. 2002 Jan;40(1):96-100 [11773099.001]
  • [Cites] J Clin Microbiol. 2002 Jan;40(1):198-204 [11773116.001]
  • [Cites] Transfusion. 2001 Dec;41(12):1500-4 [11778063.001]
  • [Cites] Infect Dis Clin North Am. 2001 Dec;15(4):1047-71 [11780267.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4264-8 [11724830.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4339-43 [11724842.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4357-61 [11724845.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4362-9 [11724846.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4413-9 [11724854.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4472-6 [11724864.001]
  • [Cites] J Clin Microbiol. 2001 Dec;39(12):4529-31 [11724876.001]
  • [Cites] J Med Virol. 2002 Mar;66(3):360-9 [11793388.001]
  • [Cites] Arch Pathol Lab Med. 2002 Feb;126(2):173-6 [11825113.001]
  • [Cites] J Clin Microbiol. 2002 Feb;40(2):490-4 [11825961.001]
  • [Cites] J Clin Microbiol. 2002 Feb;40(2):575-83 [11825973.001]
  • [Cites] J Clin Microbiol. 2004 Jan;42(1):79-82 [14715735.001]
  • [Cites] J Clin Microbiol. 2004 Jan;42(1):347-50 [14715775.001]
  • [Cites] Emerg Infect Dis. 2003 Dec;9(12):1613-6 [14720405.001]
  • [Cites] Clin Infect Dis. 2004 Feb 1;38(3):391-7 [14727210.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1137-9 [14525779.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S5 [14730263.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S6-10 [14730264.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S11-8 [14730265.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S19-24 [14730266.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S25-32 [14730267.001]
  • [Cites] J Eukaryot Microbiol. 2003;50 Suppl:651 [14736203.001]
  • [Cites] J Clin Microbiol. 2004 May;42(5):2101-7 [15131176.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):78-85 [14679451.001]
  • [Cites] J Mol Diagn. 2004 Feb;6(1):37-41 [14736825.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):324-7 [14736922.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):342-50 [14736926.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):361-6 [14736928.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1):1-7; quiz 8-10 [14743038.001]
  • [Cites] Pediatr Infect Dis J. 2004 Jan;23(1):74-6 [14743053.001]
  • [Cites] J Infect Dis. 2002 Apr 15;185(8):1203-6 [11930335.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):183-91 [11936911.001]
  • [Cites] Med Klin (Munich). 2002 Mar 15;97(3):123-7 [11957786.001]
  • [Cites] Clin Chem. 2004 Feb;50(2):339-45 [14684618.001]
  • [Cites] J Antimicrob Chemother. 2004 Feb;53(2):217-24 [14688046.001]
  • [Cites] J Clin Microbiol. 2004 Feb;42(2):585-90 [14766820.001]
  • [Cites] J Clin Microbiol. 2004 Feb;42(2):601-9 [14766823.001]
  • [Cites] J Clin Microbiol. 2004 Feb;42(2):636-8 [14766829.001]
  • [Cites] J Clin Microbiol. 2004 Feb;42(2):778-83 [14766853.001]
  • [Cites] J Clin Microbiol. 2004 Feb;42(2):841-3 [14766868.001]
  • [Cites] J Clin Microbiol. 2004 Feb;42(2):844-6 [14766869.001]
  • [Cites] J Clin Virol. 2004 Mar;29(3):171-8 [14962786.001]
  • [Cites] J Clin Virol. 2004 Mar;29(3):179-88 [14962787.001]
  • [Cites] J Clin Virol. 2004 Mar;29(3):194-201 [14962789.001]
  • [Cites] J Neurovirol. 2004 Feb;10(1):1-11 [14982723.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2004 Feb 27;53(7):154-7 [14985654.001]
  • [Cites] Biotechniques. 2004 Feb;36(2):266-70, 272, 274-5 [14989091.001]
  • [Cites] J Clin Microbiol. 2004 Mar;42(3):981-6 [15004041.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(9):777-82 [12040476.001]
  • [Cites] Int J Hematol. 2002 May;75(4):416-20 [12041675.001]
  • [Cites] Jpn J Ophthalmol. 2002 May-Jun;46(3):254-60 [12063034.001]
  • [Cites] BMC Microbiol. 2002 Jun 9;2:12 [12069697.001]
  • [Cites] Pediatr Infect Dis J. 2002 Apr;21(4):283-6 [12075757.001]
  • [Cites] Transfusion. 2002 Apr;42(4):403-8 [12076285.001]
  • [Cites] J Clin Microbiol. 2002 Jul;40(7):2381-6 [12089251.001]
  • [Cites] J Clin Microbiol. 2002 Jul;40(7):2392-7 [12089253.001]
  • [Cites] J Clin Microbiol. 2002 Jul;40(7):2609-11 [12089286.001]
  • [Cites] J Clin Microbiol. 2002 Jul;40(7):2659-61 [12089301.001]
  • [Cites] J Clin Virol. 2002 Jul;25 Suppl 1:S5-11 [12091076.001]
  • [Cites] J Clin Virol. 2002 Jul;25 Suppl 1:S45-51 [12091081.001]
  • [Cites] J Clin Virol. 2002 Jul;25 Suppl 1:S59-70 [12091083.001]
  • [Cites] J Clin Virol. 2002 Jul;25 Suppl 1:S79-85 [12091085.001]
  • [Cites] Clin Microbiol Rev. 2002 Jul;15(3):485-505 [12097253.001]
  • [Cites] Mayo Clin Proc. 2002 Jul;77(7):624-8 [12108599.001]
  • [Cites] BMC Microbiol. 2002 Jul 9;2:17 [12106506.001]
  • [Cites] J Med Virol. 2002 Jul;67(3):349-53 [12116026.001]
  • [Cites] J Med Virol. 2002 Aug;67(4):555-62 [12116004.001]
  • [Cites] J Clin Virol. 2002 Jul;25(1):93-4 [12126725.001]
  • [Cites] J Clin Microbiol. 2002 Aug;40(8):2897-902 [12149348.001]
  • [Cites] J Clin Microbiol. 2002 Aug;40(8):2989-93 [12149363.001]
  • [Cites] Ann Intern Med. 2002 Aug 6;137(3):173-9 [12160365.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Jul;21(7):532-6 [12172744.001]
  • [Cites] Hepatology. 2002 Sep;36(3):723-8 [12198666.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3256-60 [12202562.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3364-73 [12202580.001]
  • [Cites] J Med Microbiol. 2001 May;50(5):436-40 [11339251.001]
  • [Cites] J Clin Lab Anal. 2001;15(3):122-6 [11344526.001]
  • [Cites] Mol Cell Probes. 2001 Jun;15(3):129-38 [11352593.001]
  • [Cites] Mol Cell Probes. 2001 Jun;15(3):177-82 [11352599.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Jun;45(6):1730-6 [11353618.001]
  • [Cites] J Clin Microbiol. 2001 Jun;39(6):2233-6 [11376062.001]
  • [Cites] J Virol Methods. 2001 Jun;95(1-2):111-9 [11377718.001]
  • [Cites] J Virol Methods. 2001 Jun;95(1-2):121-31 [11377719.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):814-21 [11380475.001]
  • [Cites] J Viral Hepat. 2001 May;8(3):217-22 [11380800.001]
  • [Cites] Nat Med. 2001 Jun;7(6):719-24 [11385510.001]
  • [Cites] J Virol Methods. 2000 Jul;88(1):81-7 [10921845.001]
  • [Cites] Arch Pediatr Adolesc Med. 2000 Aug;154(8):817-21 [10922279.001]
  • [Cites] J Clin Microbiol. 2001 Jun;39(6):2364-5 [11414242.001]
  • [Cites] J Clin Microbiol. 2001 Jul;39(7):2618-26 [11427579.001]
  • [Cites] Transplantation. 2001 Jun 15;71(11):1609-15 [11435973.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1856-9 [11448896.001]
  • [Cites] Appl Environ Microbiol. 2001 Aug;67(8):3720-7 [11472954.001]
  • [Cites] J Clin Microbiol. 2001 Aug;39(8):2856-9 [11474003.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):4143-7 [12409388.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):4343-5 [12409427.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):4346-8 [12409428.001]
  • [Cites] J Neurol. 2001 Jun;248(6):469-77 [11499636.001]
  • [Cites] Diagn Microbiol Infect Dis. 2001 Jul;40(3):107-10 [11502377.001]
  • [Cites] J Clin Microbiol. 2001 Sep;39(9):3056-9 [11526128.001]
  • [Cites] J Clin Microbiol. 2001 Sep;39(9):3129-34 [11526140.001]
  • [Cites] J Clin Microbiol. 2001 Sep;39(9):3350-2 [11526175.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):733-5 [11544440.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Aug;16(8):904-9 [11555105.001]
  • [Cites] Ultrasound Obstet Gynecol. 2001 Sep;18(3):280-8 [11555463.001]
  • [Cites] Brain Pathol. 2001 Oct;11(4):440-51 [11556690.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3491-4 [11574561.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3649-55 [11574586.001]
  • [Cites] Transplantation. 2001 Sep 27;72(6):1012-9 [11579293.001]
  • [Cites] Clin Infect Dis. 2001 Nov 1;33(9):1504-12 [11588697.001]
  • [Cites] J Med Virol. 2001 Nov;65(3):543-52 [11596092.001]
  • [Cites] Clin Chem Lab Med. 2001 Sep;39(9):789-94 [11601674.001]
  • [Cites] Transplantation. 2002 Dec 15;74(11):1497-504 [12490781.001]
  • [Cites] Emerg Infect Dis. 2002 Dec;8(12):1367-71 [12498649.001]
  • [Cites] Appl Environ Microbiol. 2003 Jan;69(1):593-9 [12514046.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):100-5 [12517833.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):149-54 [12517840.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):187-91 [12517846.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):242-9 [12517855.001]
  • [Cites] J Clin Microbiol. 2003 Jan;41(1):254-60 [12517857.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):38-44 [12520695.001]
  • [Cites] Physiol Genomics. 2003 Jan 15;12(2):163-74 [12419855.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2002 Dec 20;51(50):1133-5 [12537288.001]
  • [Cites] Transplantation. 2003 Jan 15;75(1):105-12 [12544881.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):15-20 [12552075.001]
  • [Cites] Diagn Microbiol Infect Dis. 2003 Jan;45(1):81-4 [12573556.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):576-80 [12574249.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):592-600 [12574252.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):730-4 [12574274.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):896-9 [12574311.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Jan;22(1):54-7 [12582746.001]
  • [Cites] J Clin Virol. 2003 Jan;26(1):85-93 [12589838.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):92-5 [12605372.001]
  • [Cites] Diagn Microbiol Infect Dis. 2003 Feb;45(2):85-95 [12614979.001]
  • [Cites] J Med Microbiol. 2003 Mar;52(Pt 3):229-38 [12621088.001]
  • [Cites] J Clin Microbiol. 2003 Mar;41(3):919-25 [12624010.001]
  • [Cites] J Clin Microbiol. 2003 Mar;41(3):1248-51 [12624059.001]
  • [Cites] J Clin Microbiol. 2003 Mar;41(3):1252-5 [12624060.001]
  • [Cites] J Clin Microbiol. 2003 Mar;41(3):1295-8 [12624071.001]
  • [Cites] J Clin Microbiol. 2002 Feb;40(2):682-4 [11825996.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):864-7 [11850866.001]
  • [Cites] Mol Cell Probes. 2001 Dec;15(6):375-83 [11851381.001]
  • [Cites] J Clin Virol. 2002 Apr;24(3):161-72 [11856617.001]
  • [Cites] Diagn Microbiol Infect Dis. 2002 Feb;42(2):99-105 [11858904.001]
  • [Cites] Appl Environ Microbiol. 2002 Mar;68(3):1351-7 [11872487.001]
  • [Cites] Clin Diagn Lab Immunol. 2002 Mar;9(2):461-9 [11874894.001]
  • [Cites] J Viral Hepat. 2002 Mar;9(2):101-6 [11876791.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):988-95 [11880428.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):1060-2 [11880439.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):1119-20 [11880458.001]
  • [Cites] J Eukaryot Microbiol. 2003;50 Suppl:658-60 [14736207.001]
  • [Cites] J Eukaryot Microbiol. 2003;50 Suppl:668-9 [14736211.001]
  • [Cites] Vox Sang. 2001 Nov;81(4):228-35 [11903998.001]
  • [Cites] J Virol Methods. 2002 May;103(1):51-6 [11906732.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):173-9 [11908724.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Jan;21(1):22-6 [11913497.001]
  • [Cites] J Clin Microbiol. 2002 Apr;40(4):1436-40 [11923369.001]
  • [Cites] Transplantation. 2002 Mar 27;73(6):968-73 [11923702.001]
  • [Cites] Rev Med Virol. 2003 May-Jun;13(3):155-71 [12740831.001]
  • [Cites] Arthritis Rheum. 2003 May;48(5):1223-8 [12746895.001]
  • [Cites] Infect Control Hosp Epidemiol. 2003 May;24(5):362-86 [12785411.001]
  • [Cites] Clin Transplant. 2002 Apr;16(2):107-12 [11966780.001]
  • [Cites] Jpn J Infect Dis. 2002 Feb;55(1):6-13 [11971155.001]
  • [Cites] Bone Marrow Transplant. 2002 Apr;29(7):599-606 [11979310.001]
  • [Cites] J Clin Microbiol. 2002 May;40(5):1719-22 [11980949.001]
  • [Cites] J Clin Microbiol. 2002 May;40(5):1728-32 [11980951.001]
  • [Cites] Diagn Microbiol Infect Dis. 2002 Apr;42(4):227-36 [12007439.001]
  • [Cites] J Virol Methods. 2002 May 16;103(2):201-12 [12008014.001]
  • [Cites] J Med Virol. 2002 Jun;67(2):259-66 [11992588.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4364-9 [12036863.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):1958-62 [12037048.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):1985-8 [12037052.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2046-50 [12037062.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2224-7 [12037092.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2240-3 [12037097.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2273-4 [12037108.001]
  • [Cites] Diagn Microbiol Infect Dis. 2003 Jul;46(3):189-95 [12867094.001]
  • [Cites] J Gen Virol. 2003 Aug;84(Pt 8):2217-28 [12867654.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1114-20 [12702513.001]
  • [Cites] Transfusion. 2003 Aug;43(8):1018-22 [12869105.001]
  • [Cites] Pediatr Transplant. 2003 Aug;7(4):305-14 [12890010.001]
  • [Cites] Lancet. 2003 Jul 26;362(9380):263-70 [12892955.001]
  • [Cites] J Infect Dis. 2003 Aug 15;188(4):578-80 [12898446.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3503-8 [12904346.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3532-6 [12904351.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3631-5 [12904367.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3661-7 [12904372.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3835-9 [12904397.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3840-5 [12904398.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3870-2 [12904406.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3922-5 [12904419.001]
  • [Cites] Pediatr Infect Dis J. 2003 Aug;22(8):736-9 [12913777.001]
  • [Cites] Clin Microbiol Infect. 2003 Jul;9(7):640-4 [12925104.001]
  • [Cites] Clin Microbiol Infect. 2003 Jul;9(7):746-9 [12925123.001]
  • [Cites] J Clin Virol. 2003 Sep;28(1):51-8 [12927751.001]
  • [Cites] Hepatology. 2003 Sep;38(3):613-8 [12939587.001]
  • [Cites] Clin Infect Dis. 2003 Sep 1;37(5):634-43 [12942393.001]
  • [Cites] J Virol. 2003 Sep;77(18):10119-24 [12941923.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1112-20 [12946235.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4016-21 [12958219.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4121-6 [12958235.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4160-5 [12958241.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4231-7 [12958250.001]
  • [Cites] FEMS Microbiol Lett. 2002 Aug 27;214(1):51-9 [12204372.001]
  • [Cites] J Microbiol Methods. 2002 Nov;51(3):283-93 [12223288.001]
  • [Cites] J Microbiol Methods. 2002 Nov;51(3):295-9 [12223289.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2637-41 [12239179.001]
  • [Cites] Mol Cell Probes. 2002 Aug;16(4):257-60 [12270266.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3654-9 [12354861.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3666-70 [12354863.001]
  • [Cites] J Clin Microbiol. 2002 Oct;40(10):3814-7 [12354888.001]
  • [Cites] J Microbiol Methods. 2001 Jun;45(2):113-8 [11311396.001]
  • [Cites] J Clin Virol. 2002 Aug;25(2):155-64 [12367649.001]
  • [Cites] J Clin Virol. 2002 Aug;25(2):171-5 [12367651.001]
  • [Cites] N Engl J Med. 2001 Jun 21;344(25):1917-28 [11419430.001]
  • [Cites] Diagn Microbiol Infect Dis. 2001 Apr;39(4):233-6 [11404066.001]
  • [Cites] Ann N Y Acad Sci. 2002 Oct;969:106-11 [12381573.001]
  • [Cites] Emerg Infect Dis. 2002 Oct;8(10):1178-82 [12396935.001]
  • [Cites] J Neurovirol. 2002 Oct;8(5):432-8 [12402169.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):3922-8 [12409353.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):3956-63 [12409358.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):3986-92 [12409363.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4630-5 [14532194.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4636-41 [14532195.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4666-70 [14532200.001]
  • [Cites] J Clin Microbiol. 2002 Nov;40(11):4399 [12409444.001]
  • [Cites] Med Microbiol Immunol. 2002 Oct;191(2):119-25 [12410352.001]
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Arch Ophthalmol. 2002 Nov;120(11):1534-9 [12427068.001]
  • [Cites] Virology. 2002 Oct 25;302(2):224-8 [12441066.001]
  • [Cites] Clin Chem. 2002 Dec;48(12):2147-54 [12446470.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4413-7 [12454128.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4428-34 [12454131.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4531-5 [12454147.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4547-53 [12454150.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4646-51 [12454166.001]
  • [Cites] J Clin Microbiol. 2002 Dec;40(12):4713-9 [12454177.001]
  • [Cites] J Clin Virol. 2002 Dec;25 Suppl 3:S3-12 [12467772.001]
  • [Cites] J Clin Virol. 2002 Dec;25 Suppl 3:S13-21 [12467773.001]
  • [Cites] J Clin Virol. 2002 Dec;25 Suppl 3:S47-53 [12467777.001]
  • [Cites] Diagn Microbiol Infect Dis. 2003 Nov;47(3):487-96 [14596967.001]
  • [Cites] J Virol Methods. 2003 Dec;114(1):55-64 [14599679.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5080-4 [14605142.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5121-6 [14605148.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5245-9 [14605174.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5273-6 [14605182.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5313-6 [14605193.001]
  • [Cites] Mil Med. 2003 Oct;168(10):852-5 [14620654.001]
  • [Cites] J Med Microbiol. 2003 Dec;52(Pt 12):1071-6 [14614065.001]
  • [Cites] Med Microbiol Immunol. 2003 Nov;192(4):197-204 [14615888.001]
  • [Cites] J Virol Methods. 2003 Dec;114(2):135-44 [14625048.001]
  • [Cites] Clin Chem. 2003 Dec;49(12):1976-80 [14633867.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1290-6 [14652014.001]
  • [Cites] Lancet. 2003 Nov 22;362(9397):1733-45 [14643124.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5619-22 [14662951.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5660-4 [14662958.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5676-82 [14662960.001]
  • [Cites] J Virol Methods. 2004 Feb;115(2):183-9 [14667534.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2003 Dec 12;52(49):1202-6 [14668711.001]
  • [Cites] Clin Infect Dis. 2004 Jan 1;38(1):45-52 [14679447.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Jun;48(6):2124-31 [15155210.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1420-7 [15156481.001]
  • [Cites] Clin Infect Dis. 2004 Jun 1;38(11):1521-5 [15156436.001]
  • [Cites] J Hepatol. 2004 Jun;40(6):986-92 [15158340.001]
  • [Cites] J Hepatol. 2004 Jun;40(6):1008-17 [15158343.001]
  • [Cites] J Virol Methods. 2004 Jun 1;118(1):39-47 [15158067.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2359-65 [15184405.001]
  • [Cites] J Clin Virol. 2003 Apr;26(3):369-73 [12637087.001]
  • [Cites] Diagn Microbiol Infect Dis. 2003 Mar;45(3):207-12 [12663163.001]
  • [Cites] J Virol Methods. 2003 Apr;109(1):39-45 [12668266.001]
  • [Cites] J Clin Microbiol. 2003 Apr;41(4):1386-90 [12682118.001]
  • [Cites] J Clin Microbiol. 2003 Apr;41(4):1529-35 [12682141.001]
  • [Cites] J Clin Microbiol. 2003 Apr;41(4):1565-8 [12682146.001]
  • [Cites] J Med Virol. 2003 Feb;69(2):225-31 [12683412.001]
  • [Cites] J Med Virol. 2003 Jun;70(2):228-39 [12696109.001]
  • [Cites] Int J Tuberc Lung Dis. 2003 Jan;7(1):78-83 [12701839.001]
  • [Cites] Antimicrob Agents Chemother. 2003 May;47(5):1719-26 [12709346.001]
  • [Cites] J Virol Methods. 2003 May;109(2):227-33 [12711067.001]
  • [Cites] J Virol Methods. 2002 Apr;102(1-2):119-28 [11879700.001]
  • [Cites] J Virol Methods. 2002 Apr;102(1-2):157-60 [11879703.001]
  • [Cites] J Med Microbiol. 2003 May;52(Pt 5):397-402 [12721315.001]
  • [Cites] J Clin Virol. 2003 May;27(1):30-7 [12727526.001]
  • [Cites] J Clin Microbiol. 2003 May;41(5):1811-8 [12734210.001]
  • [Cites] J Clin Microbiol. 2003 May;41(5):2040-6 [12734246.001]
  • [Cites] J Clin Microbiol. 2003 May;41(5):2126-31 [12734258.001]
  • [Cites] J Clin Microbiol. 2003 May;41(5):2135-7 [12734260.001]
  • [Cites] Biochemistry. 1979 Nov 27;18(24):5294-9 [518835.001]
  • [Cites] J Clin Microbiol. 1988 Jul;26(7):1298-303 [2842370.001]
  • [Cites] Lancet. 1990 Feb 10;335(8685):357-8 [1967796.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2465-70 [12791866.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2483-6 [12791869.001]
  • [Cites] Eur Respir J. 2003 Jun;21(6):944-51 [12797486.001]
  • [Cites] Mol Biochem Parasitol. 2003 Jun;129(1):53-9 [12798506.001]
  • [Cites] Cell Microbiol. 2003 Jul;5(7):445-53 [12814435.001]
  • [Cites] Clin Infect Dis. 2003 Jul 1;37(1):1-6 [12830402.001]
  • [Cites] Mayo Clin Proc. 2003 Jul;78(7):882-90 [12839084.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):2894-9 [12843018.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3167-74 [12843059.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3246-51 [12843071.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3252-9 [12843072.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3293-8 [12843077.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3299-305 [12843078.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3327-30 [12843084.001]
  • [Cites] Pediatr Nephrol. 2003 Aug;18(8):743-8 [12802640.001]
  • [Cites] J Clin Microbiol. 1997 Nov;35(11):2869-72 [9350749.001]
  • [Cites] J Clin Microbiol. 1997 Nov;35(11):2873-7 [9350750.001]
  • [Cites] Nat Biotechnol. 1998 Apr;16(4):359-63 [9555727.001]
  • [Cites] J Clin Microbiol. 1998 Jul;36(7):1964-8 [9650945.001]
  • [Cites] Leukemia. 1998 Aug;12(8):1324-5 [9697891.001]
  • [Cites] J Clin Microbiol. 1999 Jan;37(1):132-6 [9854077.001]
  • [Cites] J Clin Microbiol. 1999 Feb;37(2):327-32 [9889212.001]
  • [Cites] J Virol Methods. 1999 Jan;77(1):1-9 [10029319.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):636-42 [10029622.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1188-91 [10096545.001]
  • [Cites] J Clin Microbiol. 1999 May;37(5):1352-5 [10203485.001]
  • [Cites] J Clin Microbiol. 1999 May;37(5):1415-8 [10203497.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):1764-70 [10325321.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):1941-7 [10325351.001]
  • [Cites] J Med Virol. 1999 Jun;58(2):121-6 [10335858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6394-9 [10339598.001]
  • [Cites] JAMA. 1999 Jun 9;281(22):2127-37 [10367824.001]
  • [Cites] J Clin Microbiol. 1999 Jul;37(7):2127-36 [10364574.001]
  • [Cites] Antimicrob Agents Chemother. 1999 Jul;43(7):1600-8 [10390210.001]
  • [Cites] AIDS. 1999 Jun 18;13(9):1071-5 [10397537.001]
  • [Cites] J Clin Microbiol. 1999 Sep;37(9):2899-903 [10449472.001]
  • [Cites] Clin Infect Dis. 1999 Aug;29(2):239-44 [10476719.001]
  • [Cites] J Appl Microbiol. 1999 Aug;87(2):218-23 [10475953.001]
  • [Cites] Pediatr Infect Dis J. 1999 Oct;18(10):869-74 [10530582.001]
  • [Cites] J Clin Microbiol. 2004 Nov;42(11):5277-85 [15528726.001]
  • [Cites] Med Microbiol Immunol. 2004 Nov;193(4):189-93 [12884037.001]
  • [Cites] Am J Transplant. 2005 Feb;5(2):366-73 [15643997.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4304-11 [12958261.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4366-71 [12958270.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4378-81 [12958272.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4382-7 [12958273.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3431-4 [12960133.001]
  • [Cites] Mayo Clin Proc. 2003 Sep;78(9):1137-43; quiz 1144 [12962168.001]
  • [Cites] APMIS. 2003 Jun;111(6):625-33 [12969018.001]
  • [Cites] J Med Microbiol. 2003 Oct;52(Pt 10):893-6 [12972584.001]
  • [Cites] FEMS Immunol Med Microbiol. 2003 Sep 22;38(2):117-26 [13129646.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):2048-51 [14499786.001]
  • [Cites] Clin Chem. 2003 Oct;49(10):1683-5 [14500600.001]
  • [Cites] J Med Virol. 2002 Dec;68(4):494-9 [12376956.001]
  • [Cites] J Immunol Methods. 2002 Dec 15;270(2):259-67 [12379330.001]
  • [Cites] Brain. 2004 Sep;127(Pt 9):1970-8 [15215217.001]
  • [Cites] J Clin Microbiol. 2004 Sep;42(9):4204-8 [15365012.001]
  • [Cites] J Clin Microbiol. 2004 Sep;42(9):4307-9 [15365029.001]
  • [Cites] Diagn Microbiol Infect Dis. 2004 Sep;50(1):25-32 [15380275.001]
  • [Cites] J Hepatol. 2004 Oct;41(4):659-66 [15464248.001]
  • [Cites] Antimicrob Agents Chemother. 2004 Nov;48(11):4293-300 [15504855.001]
  • [Cites] Curr Opin Gastroenterol. 2005 Jan;21(1):85-9 [15687890.001]
  • [Cites] Am J Transplant. 2005 Mar;5(3):614-20 [15707418.001]
  • [Cites] J Clin Microbiol. 2005 Mar;43(3):1059-63 [15750060.001]
  • [Cites] J Clin Microbiol. 2005 Apr;43(4):1843-5 [15815006.001]
  • [Cites] Lancet. 1990 Feb 24;335(8687):440-1 [1968171.001]
  • [Cites] J Infect Dis. 1990 Oct;162(4):858-61 [2169500.001]
  • [Cites] Cancer. 1991 Jan 15;67(2):444-8 [1845947.001]
  • [Cites] J Med Virol. 1990 Oct;32(2):77-82 [2177775.001]
  • [Cites] N Engl J Med. 1991 Oct 10;325(15):1082-5 [1653900.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1992 Mar;11(3):253-4 [1317800.001]
  • [Cites] Mol Cell Probes. 1992 Oct;6(5):367-73 [1335547.001]
  • [Cites] Pathol Res Pract. 1993 Mar;189(2):163-73 [8321744.001]
  • [Cites] Clin Infect Dis. 1993 Dec;17(6):995-7 [8110958.001]
  • [Cites] J Clin Microbiol. 1994 Jul;32(7):1757-62 [7929770.001]
  • [Cites] J Infect Dis. 1995 Apr;171(4):857-63 [7706811.001]
  • [Cites] J Clin Microbiol. 1995 Oct;33(10):2792-5 [8567930.001]
  • [Cites] Semin Respir Infect. 1995 Dec;10(4):189-98 [8668846.001]
  • [Cites] J Clin Microbiol. 1996 Nov;34(11):2791-4 [8897184.001]
  • [Cites] Diagn Microbiol Infect Dis. 1996 Jan;24(1):7-14 [8988757.001]
  • [Cites] J Microbiol Methods. 2003 Oct;55(1):149-53 [14500006.001]
  • [Cites] J Virol Methods. 2003 Oct;113(1):43-9 [14500126.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Sep;22(9):558-60 [12938011.001]
  • [Cites] J Infect Dis. 2003 Oct 1;188(7):967-72 [14513415.001]
  • [Cites] Emerg Infect Dis. 2003 Sep;9(9):1058-63 [14519240.001]
  • [Cites] J Clin Virol. 2003 Dec;28(3):233-8 [14522060.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4531-6 [14532178.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4565-72 [14532183.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2445-9 [15184417.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2636-43 [15184445.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2644-50 [15184446.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4671-5 [14532201.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4683-7 [14532203.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4783-6 [14532220.001]
  • [Cites] J Clin Microbiol. 2003 Oct;41(10):4815-6 [14532229.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Nov;18(11):1264-71 [14535983.001]
  • [Cites] Pediatr Infect Dis J. 2003 Oct;22(10):923-4 [14551495.001]
  • [Cites] J Med Virol. 2003 Dec;71(4):557-60 [14556269.001]
  • [Cites] J Virol Methods. 2003 Nov;113(2):113-6 [14553897.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):1172-7 [14557960.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):e129-31 [14557983.001]
  • [Cites] Mol Cell Probes. 2003 Oct;17(5):223-5 [14580396.001]
  • [Cites] Nephrologie. 2003;24(6):309-15 [14584298.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Oct;19(10):865-74 [14585218.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2003 Oct 31;52(43):1037-40 [14586295.001]
  • [Cites] J Infect Dis. 2003 Nov 1;188(9):1345-51 [14593592.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2733-41 [15184460.001]
  • [Cites] J Med Microbiol. 2004 Jul;53(Pt 7):603-7 [15184529.001]
  • [Cites] N Engl J Med. 2004 Jun 10;350(24):2461-70 [15190138.001]
  • [Cites] Emerg Infect Dis. 2004 May;10(5):825-31 [15200815.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3159-63 [15243076.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3284-7 [15243094.001]
  • [Cites] Mol Genet Genomics. 2004 Jul;271(6):667-77 [15138890.001]
  • [Cites] J Antimicrob Chemother. 2004 Aug;54(2):538-41 [15231761.001]
  • [Cites] J Clin Microbiol. 2004 Aug;42(8):3438-40 [15297480.001]
  • [Cites] J Clin Microbiol. 2004 Aug;42(8):3809-12 [15297535.001]
  • [Cites] Clin Infect Dis. 2003 May 1;36(9):1162-70 [12715312.001]
  • [Cites] J Infect Dis. 2003 May 1;187(9):1469-74 [12717629.001]
  • [ErratumIn] Clin Microbiol Rev. 2006 Jul;19(3):595
  • (PMID = 16418529.001).
  • [ISSN] 0893-8512
  • [Journal-full-title] Clinical microbiology reviews
  • [ISO-abbreviation] Clin. Microbiol. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotide Probes
  • [Number-of-references] 562
  • [Other-IDs] NLM/ PMC1360278
  •  go-up   go-down


6. Taub AF: Photodynamic therapy: other uses. Dermatol Clin; 2007 Jan;25(1):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many other dermatologic entities have been treated with PDT, including psoriasis, lichen planus, lichen sclerosus, scleroderma, cutaneous T cell lymphoma, alopecia areata, verruca vulgaris, Darier's disease and tinea infections.
  • Nondermatologic applications include anal and vulva carcinoma, palliation of metastatic breast cancer to skin, Barrett's esophagus, and macular degeneration of the retina.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126748.001).
  • [ISSN] 0733-8635
  • [Journal-full-title] Dermatologic clinics
  • [ISO-abbreviation] Dermatol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 59
  •  go-up   go-down


7. Mancini N, Carletti S, Ghidoli N, Cichero P, Burioni R, Clementi M: The era of molecular and other non-culture-based methods in diagnosis of sepsis. Clin Microbiol Rev; 2010 Jan;23(1):235-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The era of molecular and other non-culture-based methods in diagnosis of sepsis.
  • Sepsis, a leading cause of morbidity and mortality throughout the world, is a clinical syndrome with signs and symptoms relating to an infectious event and the consequent important inflammatory response.
  • From a clinical point of view, sepsis is a continuous process ranging from systemic inflammatory response syndrome (SIRS) to multiple-organ-dysfunction syndrome (MODS).
  • Blood cultures are the current "gold standard" for diagnosis, and they are based on the detection of viable microorganisms present in blood.
  • However, on some occasions, blood cultures have intrinsic limitations in terms of sensitivity and rapidity, and it is not expected that these drawbacks will be overcome by significant improvements in the near future.
  • For these principal reasons, other approaches are therefore needed in association with blood culture to improve the overall diagnostic yield for septic patients.
  • These considerations have represented the rationale for the development of highly sensitive and fast laboratory methods.
  • This review addresses non-culture-based techniques for the diagnosis of sepsis, including molecular and other non-culture-based methods.
  • In particular, the potential clinical role for the sensitive and rapid detection of bacterial and fungal DNA in the development of new diagnostic algorithms is discussed.
  • [MeSH-major] Bacterial Infections / diagnosis. Blood / microbiology. Clinical Laboratory Techniques / methods. Molecular Diagnostic Techniques / methods. Mycoses / diagnosis. Sepsis / diagnosis. Sepsis / microbiology
  • [MeSH-minor] Humans. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Blood.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Laboratory Tests.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 1996 Jul;34(7):1637-40 [8784560.001]
  • [Cites] Clin Infect Dis. 1996 Jul;23(1):40-6 [8816127.001]
  • [Cites] J Clin Microbiol. 1996 Aug;34(8):1985-91 [8818895.001]
  • [Cites] Pediatr Infect Dis J. 1996 Jul;15(7):615-20 [8823857.001]
  • [Cites] Infect Immun. 1996 Nov;64(11):4850-3 [8890251.001]
  • [Cites] J Clin Microbiol. 1999 Aug;37(8):2479-82 [10405388.001]
  • [Cites] Biotechniques. 1999 Aug;27(2):248-50, 252 [10457823.001]
  • [Cites] J Clin Microbiol. 2005 Jan;43(1):299-305 [15634986.001]
  • [Cites] Clin Microbiol Infect. 2005 Feb;11(2):101-8 [15679483.001]
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):339-45 [15716229.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):376-84 [16825512.001]
  • [Cites] Clin Microbiol Infect. 2006 Aug;12(8):745-53 [16842569.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2006 Aug;25(8):522-6 [16896827.001]
  • [Cites] J Clin Microbiol. 2006 Sep;44(9):3381-3 [16954279.001]
  • [Cites] Crit Care Med. 2006 Oct;34(10):2576-82 [16915108.001]
  • [Cites] Crit Care Med. 2006 Oct;34(10):2596-602 [16915118.001]
  • [Cites] J Med Microbiol. 2006 Nov;55(Pt 11):1505-9 [17030909.001]
  • [Cites] Clin Microbiol Rev. 2006 Oct;19(4):788-802 [17041144.001]
  • [Cites] Med Mycol. 2006 Dec;44(8):733-9 [17127630.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2006 Oct;25(10):619-26 [17047905.001]
  • [Cites] J Clin Microbiol. 2001 Apr;39(4):1661-4 [11283112.001]
  • [Cites] Mol Pathol. 2001 Apr;54(2):86-90 [11322169.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1103-7 [11323674.001]
  • [Cites] J Clin Microbiol. 2001 Jun;39(6):2098-101 [11376041.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7):1303-10 [11445675.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3159-63 [15243076.001]
  • [Cites] Pediatr Clin North Am. 2004 Aug;51(4):939-59, viii-ix [15275982.001]
  • [Cites] Clin Infect Dis. 2004 Jul 15;39(2):199-205 [15307029.001]
  • [Cites] Crit Care. 2004 Aug;8(4):R234-42 [15312223.001]
  • [Cites] J Clin Microbiol. 1976 Jun;3(6):643-5 [820714.001]
  • [Cites] Transplant Proc. 2008 Jan-Feb;40(1):92-3 [18261555.001]
  • [Cites] J Med Microbiol. 2008 Mar;57(Pt 3):296-303 [18287291.001]
  • [Cites] J Appl Microbiol. 2008 Apr;104(4):1228-37 [18028360.001]
  • [Cites] J Med Microbiol. 2008 May;57(Pt 5):601-4 [18436593.001]
  • [Cites] Crit Care Med. 2008 May;36(5):1487-92 [18434904.001]
  • [Cites] Med Microbiol Immunol. 2008 Sep;197(3):313-24 [18008085.001]
  • [Cites] Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120 [18512336.001]
  • [Cites] Clin Chem Lab Med. 2008;46(7):888-908 [18624614.001]
  • [Cites] J Clin Microbiol. 2008 Aug;46(8):2717-22 [18508940.001]
  • [Cites] J Clin Microbiol. 2008 Sep;46(9):2924-9 [18614649.001]
  • [Cites] J Clin Microbiol. 2001 Oct;39(10):3578-82 [11574575.001]
  • [Cites] Anal Chem. 2001 Sep 15;73(18):4514-21 [11575801.001]
  • [Cites] Clin Infect Dis. 2002 Jan 1;34(1):7-14 [11731939.001]
  • [Cites] J Clin Microbiol. 2002 Jan;40(1):247-51 [11773123.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7039-44 [11983869.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2182-6 [12037084.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2224-7 [12037092.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2240-3 [12037097.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2266-9 [12037106.001]
  • [Cites] Am J Emerg Med. 2002 Jul;20(4):271-4 [12098170.001]
  • [Cites] Proteomics. 2002 Jun;2(6):740-6 [12112857.001]
  • [Cites] Chest. 2002 Jul;122(1):262-8 [12114368.001]
  • [Cites] J Clin Microbiol. 2002 Aug;40(8):2786-90 [12149330.001]
  • [Cites] J Infect Dis. 2002 Dec 1;186(11):1677-81 [12447747.001]
  • [Cites] Diagn Microbiol Infect Dis. 2002 Nov;44(3):235-40 [12493169.001]
  • [Cites] J Clin Microbiol. 2003 Feb;41(2):889-91 [12574309.001]
  • [Cites] Heart. 2003 Mar;89(3):258-62 [12591823.001]
  • [Cites] J Med Microbiol. 2003 Mar;52(Pt 3):229-38 [12621088.001]
  • [Cites] Pediatr Crit Care Med. 2003 Jan;4(1):21-5 [12656537.001]
  • [Cites] Crit Care Med. 2003 Apr;31(4):1250-6 [12682500.001]
  • [Cites] Chest. 2003 Apr;123(4):1142-50 [12684305.001]
  • [Cites] N Engl J Med. 2003 Apr 17;348(16):1546-54 [12700374.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1418-23 [12766837.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2440-3 [12791861.001]
  • [Cites] J Clin Microbiol. 2003 Jul;41(7):3119-25 [12843051.001]
  • [Cites] Clin Microbiol Infect. 2003 May;9(5):412-8 [12848754.001]
  • [Cites] J Infect. 2003 Jul;47(1):1-11 [12850156.001]
  • [Cites] J Clin Microbiol. 1982 Apr;15(4):558-61 [7068835.001]
  • [Cites] J Clin Microbiol. 1988 Jul;26(7):1335-8 [3410948.001]
  • [Cites] Blood. 1989 Oct;74(5):1704-10 [2790194.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1989 Sep;8(9):838-42 [2512159.001]
  • [Cites] Clin Microbiol Rev. 1990 Jul;3(3):269-79 [2200606.001]
  • [Cites] Chest. 1992 Jun;101(6):1644-55 [1303622.001]
  • [Cites] Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):295-300 [1611845.001]
  • [Cites] Ann Intern Med. 1993 Aug 15;119(4):270-2 [8328734.001]
  • [Cites] Ann Surg. 1993 Jul;218(1):74-8 [8328832.001]
  • [Cites] J Trauma. 1993 Sep;35(3):335-9 [8371288.001]
  • [Cites] APMIS. 1993 Aug;101(8):595-601 [8217112.001]
  • [Cites] Am J Med. 1994 Mar;96(3):200-9 [8154507.001]
  • [Cites] J Clin Microbiol. 1995 Feb;33(2):497-500 [7714217.001]
  • [Cites] Clin Infect Dis. 1995 Mar;20(3):501-6 [7756467.001]
  • [Cites] Mol Microbiol. 1995 Mar;15(6):1055-67 [7623662.001]
  • [Cites] J Pediatr. 1996 Feb;128(2):190-5 [8636810.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4815-20 [8648129.001]
  • [Cites] Diagn Microbiol Infect Dis. 2010 Jan;66(1):41-9 [18722072.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2010;118:65-83 [19475368.001]
  • [Cites] Anal Bioanal Chem. 2008 May;391(2):507-14 [18188543.001]
  • [Cites] Circulation. 2005 Mar 22;111(11):1415-21 [15753218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 31;102(22):8012-7 [15911764.001]
  • [Cites] Ann Surg. 1996 Nov;224(5):647-64 [8916880.001]
  • [Cites] Clin Infect Dis. 1997 Apr;24(4):584-602 [9145732.001]
  • [Cites] Arthritis Rheum. 1997 Jul;40(7):1250-6 [9214425.001]
  • [Cites] Clin Microbiol Rev. 1997 Jul;10(3):444-65 [9227861.001]
  • [Cites] Crit Care Med. 1997 Nov;25(11):1813-9 [9366763.001]
  • [Cites] J Clin Microbiol. 1997 Dec;35(12):3311-2 [9399543.001]
  • [Cites] Nature. 1998 Feb 12;391(6668):703-7 [9490415.001]
  • [Cites] J Clin Microbiol. 1998 May;36(5):1169-75 [9574670.001]
  • [Cites] Crit Care Med. 1998 Jun;26(6):1001-6 [9635646.001]
  • [Cites] J Intern Med. 2000 Mar;247(3):341-5 [10762450.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10):2810-6 [9738025.001]
  • [Cites] J Intern Med. 1998 Nov;244(5):379-86 [9845853.001]
  • [Cites] Med Mycol. 1998 Oct;36(5):299-303 [10075499.001]
  • [Cites] J Clin Microbiol. 1999 Apr;37(4):1200-2 [10074553.001]
  • [Cites] J Clin Microbiol. 1999 Jun;37(6):1797-801 [10325326.001]
  • [Cites] Clin Chem. 2007 Jan;53(1):104-10 [17110475.001]
  • [Cites] Oral Dis. 2007 Jan;13(1):56-62 [17241431.001]
  • [Cites] J Microbiol Methods. 2007 Feb;68(2):296-302 [17046087.001]
  • [Cites] J Clin Microbiol. 2007 Feb;45(2):421-5 [17166966.001]
  • [Cites] J Microbiol Methods. 2007 Mar;68(3):468-77 [17141897.001]
  • [Cites] Lancet Infect Dis. 2007 Mar;7(3):210-7 [17317602.001]
  • [Cites] J Clin Microbiol. 2007 Mar;45(3):906-14 [17251398.001]
  • [Cites] Intensive Care Med. 2007 Apr;33(4):606-18 [17323051.001]
  • [Cites] Crit Care Med. 2007 Mar;35(3):763-8 [17255870.001]
  • [Cites] Crit Care Med. 2007 May;35(5):1244-50 [17414736.001]
  • [Cites] Pediatrics. 2007 May;119(5):891-6 [17473088.001]
  • [Cites] J Clin Microbiol. 2007 Jun;45(6):1920-6 [17460050.001]
  • [Cites] Curr Opin Infect Dis. 2007 Aug;20(4):353-9 [17609593.001]
  • [Cites] Medicine (Baltimore). 2007 Jul;86(4):195-202 [17632260.001]
  • [Cites] J Clin Microbiol. 2007 Aug;45(8):2691-4 [17537945.001]
  • [Cites] Clin Infect Dis. 2007 Sep 1;45 Suppl 2:S99-S111 [17683022.001]
  • [Cites] J Clin Microbiol. 2007 Sep;45(9):2765-9 [17567782.001]
  • [Cites] New Microbiol. 2007 Jul;30(3):308-12 [17802916.001]
  • [Cites] Diagn Microbiol Infect Dis. 2007 Sep;59(1):113-5 [17662550.001]
  • [Cites] Diagn Microbiol Infect Dis. 2007 Oct;59(2):165-71 [17574786.001]
  • [Cites] Int J Antimicrob Agents. 2007 Nov;30 Suppl 1:S7-15 [17707613.001]
  • [Cites] BMJ. 2007 Oct 27;335(7625):879-83 [17962288.001]
  • [Cites] Br J Haematol. 2007 Nov;139(4):519-31 [17979942.001]
  • [Cites] J Clin Microbiol. 2007 Nov;45(11):3641-6 [17881553.001]
  • [Cites] J Chemother. 2007 Oct;19 Suppl 2:31-4 [18073177.001]
  • [Cites] Diagn Microbiol Infect Dis. 2008 Jan;60(1):117-20 [17889483.001]
  • [Cites] Crit Care Med. 2008 Jan;36(1):296-327 [18158437.001]
  • [Cites] J Clin Microbiol. 2008 Jan;46(1):50-5 [17977998.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Feb 1;177(3):279-84 [17975201.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2008 Feb;27(2):109-14 [17973130.001]
  • [Cites] Clin Microbiol Infect. 2008 Mar;14(3):213-20 [18093238.001]
  • [Cites] Mycoses. 2008 Mar;51(2):129-35 [18254749.001]
  • [Cites] J Clin Microbiol. 2003 Sep;41(9):4324-7 [12958264.001]
  • [Cites] Intensive Care Med. 2003 Oct;29(10):1688-95 [13680115.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):513-20 [10655337.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):586-90 [10655350.001]
  • [Cites] J Clin Microbiol. 2000 Feb;38(2):830-8 [10655393.001]
  • [Cites] J Med Microbiol. 2000 Mar;49(3):295-300 [10707951.001]
  • [Cites] FEMS Microbiol Rev. 2000 Apr;24(2):193-219 [10717314.001]
  • [Cites] Crit Care Med. 2000 Apr;28(4):950-7 [10809265.001]
  • [Cites] Crit Care Med. 2000 Apr;28(4):977-83 [10809269.001]
  • [Cites] APMIS. 2000 May;108(5):385-92 [10937778.001]
  • [Cites] J Microbiol Methods. 2000 Oct;42(2):139-47 [11018270.001]
  • [Cites] J Exp Med. 2000 Nov 6;192(9):1353-64 [11067883.001]
  • [Cites] J Clin Microbiol. 2005 Jun;43(6):2909-12 [15956416.001]
  • [Cites] J Clin Microbiol. 2005 Jun;43(6):2920-2 [15956419.001]
  • [Cites] Pediatr Res. 2005 Jul;58(1):143-8 [15985688.001]
  • [Cites] Anal Chem. 2005 Jul 15;77(14):4563-70 [16013874.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):654-9 [16080087.001]
  • [Cites] FEMS Immunol Med Microbiol. 2005 Sep 1;45(3):361-8 [16054349.001]
  • [Cites] J Clin Microbiol. 2005 Oct;43(10):5256-62 [16207992.001]
  • [Cites] Crit Care Med. 2005 Nov;33(11):2555-62 [16276180.001]
  • [Cites] Pediatrics. 2006 Apr;117(4):e711-6 [16533892.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1245-9 [16597846.001]
  • [Cites] Curr Opin Pediatr. 2006 Apr;18(2):125-31 [16601490.001]
  • [Cites] Clin Infect Dis. 2006 May 15;42(10):1417-27 [16619154.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 2006 May;91(3):F208-12 [16632649.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40(3):209-12 [16633121.001]
  • [Cites] J Clin Microbiol. 2006 May;44(5):1828-30 [16672413.001]
  • [Cites] Crit Care Med. 2006 Jun;34(6):1589-96 [16625125.001]
  • [Cites] Biotechnol Prog. 2006 May-Jun;22(3):853-9 [16739971.001]
  • [Cites] Heart. 2006 Jul;92(7):879-85 [16216860.001]
  • [Cites] Haematologica. 2006 Jul;91(7):986-9 [16757415.001]
  • [Cites] J Clin Microbiol. 2006 Jul;44(7):2389-97 [16825354.001]
  • [Cites] Clin Chim Acta. 2003 Nov;337(1-2):11-21 [14568176.001]
  • [Cites] J Clin Microbiol. 2003 Nov;41(11):5094-8 [14605144.001]
  • [Cites] Med Mycol. 2003 Oct;41(5):369-81 [14653513.001]
  • [Cites] J Clin Microbiol. 2004 Jan;42(1):435-8 [14715799.001]
  • [Cites] Mol Biotechnol. 2004 Feb;26(2):133-46 [14764939.001]
  • [Cites] Nat Rev Microbiol. 2004 Feb;2(2):151-9 [15040262.001]
  • [Cites] Inflamm Res. 2004 Apr;53(4):158-63 [15060722.001]
  • [Cites] Diagn Microbiol Infect Dis. 2004 Apr;48(4):229-41 [15062914.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1512-25 [15070906.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1466-70 [15070990.001]
  • [Cites] Emerg Infect Dis. 2004 Jan;10(1):76-81 [15078600.001]
  • [Cites] Am J Transplant. 2004 May;4(5):796-802 [15084177.001]
  • [Cites] Clin Infect Dis. 2004 Jun 15;38(12):1724-30 [15227618.001]
  • [Cites] Ann Intern Med. 2004 Jul 6;141(1):9-15 [15238365.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3147-52 [15243074.001]
  • [Cites] Acta Paediatr. 2008 Oct;97(10):1376-80 [18624992.001]
  • [Cites] Curr Pharm Des. 2008;14(24):2439-44 [18781993.001]
  • [Cites] J Med Microbiol. 2008 Oct;57(Pt 10):1306-7 [18809565.001]
  • [Cites] Antimicrob Agents Chemother. 2008 Oct;52(10):3558-63 [18663022.001]
  • [Cites] Ann N Y Acad Sci. 2008 Sep;1138:329-50 [18837909.001]
  • [Cites] J Infect. 2008 Oct;57(4):307-16 [18760842.001]
  • [Cites] J Clin Pathol. 2009 Jan;62(1):64-9 [19103864.001]
  • [Cites] Transplantation. 2009 Jan 27;87(2):256-60 [19155981.001]
  • [Cites] Lancet Infect Dis. 2009 Feb;9(2):89-96 [19179225.001]
  • [Cites] BMC Pediatr. 2009;9:5 [19152691.001]
  • [Cites] J Clin Microbiol. 2009 Feb;47(2):368-72 [19091813.001]
  • [Cites] J Clin Microbiol. 2009 Feb;47(2):379-84 [19109479.001]
  • [Cites] J Clin Microbiol. 2009 Mar;47(3):830-2 [19116347.001]
  • [Cites] Comp Immunol Microbiol Infect Dis. 2009 May;32(3):207-19 [18261798.001]
  • [Cites] J Med Microbiol. 2009 Apr;58(Pt 4):533-4 [19273654.001]
  • [Cites] J Clin Microbiol. 2009 Apr;47(4):1274-5 [19171685.001]
  • [Cites] Clin Lab Sci. 2009 Winter;22(1):30-3 [19354026.001]
  • [Cites] Med Mycol. 2009;47 Suppl 1:S241-7 [19253138.001]
  • [Cites] Clin Infect Dis. 2009 May 15;48 Suppl 4:S238-45 [19374579.001]
  • [Cites] Transpl Infect Dis. 2009 Apr;11(2):175-8 [19210691.001]
  • [Cites] J Infect. 2009 May;58(5):346-51 [19362374.001]
  • [Cites] Leuk Lymphoma. 2009 May;50(5):703-15 [19337880.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2009 Jun;28(6):569-73 [19048317.001]
  • [Cites] Crit Care. 2009;13(1):R28 [19250547.001]
  • [Cites] Curr Opin Infect Dis. 2009 Aug;22(4):385-93 [19506476.001]
  • [Cites] Clin Microbiol Infect. 2009 Jun;15(6):544-51 [19392905.001]
  • [Cites] J Clin Microbiol. 2009 Aug;47(8):2405-10 [19571034.001]
  • [Cites] Clin Microbiol Infect. 2009 Jul;15(7):656-61 [19438623.001]
  • [Cites] Bone Marrow Transplant. 2009 Nov;44(9):595-9 [19308034.001]
  • (PMID = 20065332.001).
  • [ISSN] 1098-6618
  • [Journal-full-title] Clinical microbiology reviews
  • [ISO-abbreviation] Clin. Microbiol. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 218
  • [Other-IDs] NLM/ PMC2806664
  •  go-up   go-down


8. Bailer AJ, Noble RB, Wheeler MW: Model uncertainty and risk estimation for experimental studies of quantal responses. Risk Anal; 2005 Apr;25(2):291-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Bayes Theorem. Biomedical Research / methods. Data Interpretation, Statistical. Disease Models, Animal. Dose-Response Relationship, Drug. Ethylene Glycol / adverse effects. Humans. Kidney Tubules / drug effects. Lymphoma / pathology. Mice. Models, Statistical. Models, Theoretical. Neoplasms / pathology. Probability. Rats. Risk

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ETHYLENE GLYCOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876205.001).
  • [ISSN] 0272-4332
  • [Journal-full-title] Risk analysis : an official publication of the Society for Risk Analysis
  • [ISO-abbreviation] Risk Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] FC72KVT52F / Ethylene Glycol
  •  go-up   go-down


9. Strik H, Luthe H, Nagel I, Ehrlich B, Bahr M: Automated cerebrospinal fluid cytology: limitations and reasonable applications. Anal Quant Cytol Histol; 2005 Jun;27(3):167-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automated cerebrospinal fluid cytology: limitations and reasonable applications.
  • OBJECTIVE: To evaluate the precision and clinical applicability of the Bayer ADVIA 120 cytometer (Bayer Healthcare, Fernwald, Germany) for cerebrospinal fluid (CSF) cell count and differentiation.
  • STUDY DESIGN: One hundred six analyses of CSF from 98 patients by the ADVIA 120 were compared with routine cell count and microscopic differentiation.
  • Correlation coefficients were calculated.
  • RESULTS: In general, the total cell counts of both methods correlated well.
  • The best correlations were seen at higher cell counts, > or = 100 cells per microliter with < 100 erythrocytes per microliter.
  • The best correlations of cell differentiation were seen for lymphocytes and neutrophils, while the results for monocytes and eosinophils were less precise.
  • In some cases, considerable differences between automated and microscopic cell counts and differentiation were seen that were relevant to clinical decision making.
  • The detection of pathologic cell types, such as hemosiderophages, mitoses and neoplastic cells, was not provided by automated cytometry.
  • CONCLUSION: When experienced personnel are not available, a preliminary cell count and differentiation between neutrophilic and lymphocytic reactions by automated cytometry may be valuable in allowing initial therapeutic decision making.
  • Since the detection of pathologic cell types is not provided and the precision at low cell counts is only moderate, a personal microscopic evaluation of each sample is still indispensable to avoid misdiagnoses.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121639.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Richards NG, Kilberg MS: Asparagine synthetase chemotherapy. Annu Rev Biochem; 2006;75:629-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asparagine synthetase chemotherapy.
  • Modern clinical treatments of childhood acute lymphoblastic leukemia (ALL) employ enzyme-based methods for depletion of blood asparagine in combination with standard chemotherapeutic agents.
  • Significant side effects can arise in these protocols and, in many cases, patients develop drug-resistant forms of the disease that may be correlated with up-regulation of the enzyme glutamine-dependent asparagine synthetase (ASNS).
  • Though the precise molecular mechanisms that result in the appearance of drug resistance are the subject of active study, potent ASNS inhibitors may have clinical utility in treating asparaginase-resistant forms of childhood ALL.
  • This review provides an overview of recent developments in our understanding of (a) the structure and catalytic mechanism of ASNS, and (b) the role that ASNS may play in the onset of drug-resistant childhood ALL.
  • In addition, the first successful, mechanism-based efforts to prepare and characterize nanomolar ASNS inhibitors are discussed, together with the implications of these studies for future efforts to develop useful drugs.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7975-9 [10713115.001]
  • [Cites] Biochemistry. 2000 May 23;39(20):6003-11 [10821672.001]
  • [Cites] Plant Physiol. 2000 Jun;123(2):725-32 [10859202.001]
  • [Cites] Annu Rev Biochem. 1999;68:1015-68 [10872471.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1094-9 [10910927.001]
  • [Cites] J Biol Chem. 2000 Sep 1;275(35):26976-85 [10856289.001]
  • [Cites] Bioorg Med Chem Lett. 2000 Aug 21;10(16):1871-4 [10969988.001]
  • [Cites] Curr Opin Struct Biol. 2000 Aug;10(4):401-4 [10981625.001]
  • [Cites] Annu Rev Biochem. 2000;69:617-50 [10966471.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Aug;9(8):1767-75 [11060775.001]
  • [Cites] J Org Chem. 2000 Dec 1;65(24):8229-38 [11101378.001]
  • [Cites] Protein Sci. 2000 Dec;9(12):2329-37 [11206054.001]
  • [Cites] Biochemistry. 2001 Jun 12;40(23):6795-804 [11389593.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4347-68 [11390663.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):321-8 [11415466.001]
  • [Cites] Nat Struct Biol. 2001 Aug;8(8):684-9 [11473258.001]
  • [Cites] Biochem J. 2001 Aug 15;358(Pt 1):59-67 [11485552.001]
  • [Cites] Biochemistry. 2001 Sep 18;40(37):11168-75 [11551215.001]
  • [Cites] J Mol Biol. 2001 Nov 9;313(5):1093-102 [11700065.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47387-93 [11584022.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48100-7 [11677247.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Annu Rev Biochem. 2001;70:149-80 [11395405.001]
  • [Cites] Annu Rev Biochem. 2001;70:209-46 [11395407.001]
  • [Cites] Int J Biochem. 1980;11(6):519-39 [6103827.001]
  • [Cites] Annu Rev Biochem. 1980;49:877-919 [6250450.001]
  • [Cites] Cancer Res. 1981 Aug;41(8):3104-6 [6113889.001]
  • [Cites] Biochemistry. 1981 Dec 8;20(25):7226-32 [6119111.001]
  • [Cites] Anal Biochem. 1983 Apr 1;130(1):134-45 [6688159.001]
  • [Cites] Arch Biochem Biophys. 1985 Mar;237(2):335-46 [2858178.001]
  • [Cites] Arch Biochem Biophys. 1985 May 1;238(2):410-7 [2859838.001]
  • [Cites] J Biol Chem. 1986 Feb 5;261(4):1914-9 [2868008.001]
  • [Cites] Biochemistry. 1985 Feb 26;24(5):1104-10 [2869778.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1321-3 [3464352.001]
  • [Cites] Am J Clin Oncol. 1986 Oct;9(5):411-5 [3465228.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Mar;84(6):1565-9 [3470743.001]
  • [Cites] J Biol Chem. 1987 Aug 25;262(24):11565-70 [2887559.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] Leukemia. 1989 Apr;3(4):294-7 [2564453.001]
  • [Cites] Mol Cell Biol. 1989 Jun;9(6):2350-9 [2569668.001]
  • [Cites] Biochem Int. 1989 Mar;18(3):661-6 [2569873.001]
  • [Cites] Biochemistry. 1999 Dec 7;38(49):16146-57 [10587437.001]
  • [Cites] Protein Sci. 1999 Nov;8(11):2424-7 [10595545.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36498-504 [10593947.001]
  • [Cites] Bioorg Med Chem. 1999 Nov;7(11):2473-85 [10632057.001]
  • [Cites] Genetics. 2000 Feb;154(2):787-801 [10655230.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 1):C1691-9 [9176161.001]
  • [Cites] Trends Biochem Sci. 1997 Jun;22(6):211-6 [9204708.001]
  • [Cites] Biochemistry. 1997 Aug 19;36(33):10168-77 [9254614.001]
  • [Cites] J Biol Chem. 1997 Aug 29;272(35):21661-4 [9268289.001]
  • [Cites] Nat Prod Rep. 1997 Aug;14(4):309-33 [9281835.001]
  • [Cites] Biochemistry. 1997 Sep 16;36(37):11061-8 [9333323.001]
  • [Cites] Nat Struct Biol. 1998 Jan;5(1):15-9 [9437423.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:87-144 [9559052.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1998;72:145-98 [9559053.001]
  • [Cites] Cell Mol Life Sci. 1998 Mar;54(3):205-22 [9575335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9082-6 [9689037.001]
  • [Cites] Biochemistry. 1998 Sep 22;37(38):13230-8 [9748330.001]
  • [Cites] Annu Rev Biochem. 1998;67:693-720 [9759501.001]
  • [Cites] Crit Rev Oncol Hematol. 1998 Aug;28(2):97-113 [9768345.001]
  • [Cites] J Biol Chem. 1998 Nov 27;273(48):31691-701 [9822630.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Biochem J. 1999 Apr 1;339 ( Pt 1):135-41 [10085237.001]
  • [Cites] Biochem J. 1999 Apr 1;339 ( Pt 1):151-8 [10085239.001]
  • [Cites] Chem Biol. 1999 Apr;6(4):R91-R105 [10099128.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9479-84 [10449718.001]
  • [Cites] Acc Chem Res. 2003 Jul;36(7):539-48 [12859215.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Sep 26;55(10):1293-302 [14499708.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):38402-12 [12881527.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2003;32:335-73 [12574069.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40996-1002 [12890666.001]
  • [Cites] Biochemistry. 2004 Jan 13;43(1):9-18 [14705926.001]
  • [Cites] Leukemia. 2004 Mar;18(3):434-41 [14724653.001]
  • [Cites] Bioorg Chem. 2004 Apr;32(2):63-75 [14990305.001]
  • [Cites] Curr Top Med Chem. 2004;4(7):653-69 [15032680.001]
  • [Cites] Cell Mol Life Sci. 2004 Mar;61(6):669-81 [15052410.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Biochemistry. 2004 Jun 1;43(21):6447-63 [15157079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10000-5 [15220480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11269-74 [15277680.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Biochemistry. 2004 Aug 17;43(32):10328-42 [15301531.001]
  • [Cites] J Cell Biol. 2004 Oct 11;167(1):27-33 [15479734.001]
  • [Cites] J Biol Chem. 1968 Jan 25;243(2):376-80 [4295091.001]
  • [Cites] Science. 1968 May 3;160(3827):533-5 [5689413.001]
  • [Cites] Biochem Biophys Res Commun. 1968 Apr 5;31(1):43-7 [4869945.001]
  • [Cites] Biochemistry. 1969 Jun;8(6):2681-5 [5799144.001]
  • [Cites] J Biol Chem. 1969 Aug 10;244(15):4112-21 [4895361.001]
  • [Cites] J Biol Chem. 1989 Sep 15;264(26):15494-500 [2768274.001]
  • [Cites] Biochemistry. 1990 Jan 16;29(2):366-72 [1967948.001]
  • [Cites] Somat Cell Mol Genet. 1990 Jan;16(1):59-65 [1968681.001]
  • [Cites] Nucleic Acids Res. 1990 Jun 25;18(12):3509-13 [1972978.001]
  • [Cites] Protein Eng. 1990 Aug;3(8):739-44 [1977158.001]
  • [Cites] Biochemistry. 1991 Jun 25;30(25):6135-41 [1676298.001]
  • [Cites] Mol Cell Biol. 1991 Dec;11(12):6059-66 [1682798.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):144-9 [1346128.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Feb 28;183(1):265-72 [1543496.001]
  • [Cites] Arch Biochem Biophys. 1992 May 15;295(1):120-5 [1349469.001]
  • [Cites] Biosci Biotechnol Biochem. 1992 Mar;56(3):376-9 [1369484.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1992 May;14(2):136-9 [1530118.001]
  • [Cites] Protein Eng. 1992 Apr;5(3):279-83 [1357656.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1993;66:203-309 [8430515.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3202-12 [8098842.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16771-80 [8102140.001]
  • [Cites] Biochemistry. 1994 Jan 25;33(3):675-81 [7904828.001]
  • [Cites] J Biol Chem. 1994 Mar 11;269(10):7450-7 [7907328.001]
  • [Cites] J Biol Chem. 1994 Sep 30;269(39):24304-9 [7929087.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26789-95 [7929415.001]
  • [Cites] Nature. 1995 Jan 19;373(6511):264-8 [7816145.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):16585-91 [11867623.001]
  • [Cites] J Org Chem. 2002 May 17;67(10):3290-300 [12003538.001]
  • [Cites] J Org Chem. 2002 Jun 14;67(12):4372-5 [12054978.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24120-7 [11960987.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24579-83 [11967268.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jan;1(1):26-36 [12119606.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):161-80; discussion 200-2 [12196214.001]
  • [Cites] Cancer. 1970 Feb;25(2):306-20 [4905155.001]
  • [Cites] Annu Rev Pharmacol. 1970;10:421-40 [4911021.001]
  • [Cites] Ann Intern Med. 1971 Jun;74(6):893-901 [5281051.001]
  • [Cites] Cancer. 1971 Oct;28(4):819-24 [5286444.001]
  • [Cites] Transplantation. 1971 Nov;12(5):368-76 [4948688.001]
  • [Cites] Cancer. 1972 Aug;30(2):376-81 [4559405.001]
  • [Cites] J Biol Chem. 1973 Jun 10;248(11):3997-4002 [4145324.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1973;39:91-183 [4355768.001]
  • [Cites] Enzyme. 1975;19(5-6):314-28 [237754.001]
  • [Cites] J Med Chem. 1975 Sep;18(9):888-91 [240024.001]
  • [Cites] Cancer Treat Rep. 1976 Oct;60(10):1493-557 [14784.001]
  • [Cites] Cancer. 1979 Mar;43(3):1089-94 [284840.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3893-6 [383278.001]
  • [Cites] Methods Enzymol. 1980;64:47-59 [7374457.001]
  • [Cites] Mol Cell Biol. 1999 Oct;19(10):6566-74 [10490596.001]
  • [Cites] Nat Rev Drug Discov. 2004 Nov;3(11):935-49 [15520816.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50829-39 [15385533.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):855-61 [15602551.001]
  • [Cites] Med Res Rev. 2005 Mar;25(2):186-228 [15478125.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Mass Spectrom Rev. 2005 Mar-Apr;24(2):168-200 [15389855.001]
  • [Cites] Nat Rev Drug Discov. 2005 Apr;4(4):345-50 [15789121.001]
  • [Cites] Plant Physiol. 2005 Apr;137(4):1487 [15824288.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4223-5 [15718422.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(19):6681-8 [12215525.001]
  • [Cites] Nat Rev Drug Discov. 2002 Nov;1(11):882-94 [12415248.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14752-7 [12409610.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7639-44 [12496246.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2743-7 [12433682.001]
  • [Cites] Arch Biochem Biophys. 2003 May 1;413(1):23-31 [12706338.001]
  • [Cites] Appl Microbiol Biotechnol. 2003 May;61(4):278-88 [12743756.001]
  • [Cites] Biochem J. 2003 Jun 1;372(Pt 2):603-9 [12628003.001]
  • [Cites] Org Lett. 2003 Jun 12;5(12):2033-6 [12790521.001]
  • [Cites] Biochemistry. 2003 Jun 17;42(23):7013-22 [12795596.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):22964-71 [12684518.001]
  • [Cites] Biochem J. 1994 Dec 15;304 ( Pt 3):745-50 [7818476.001]
  • [Cites] Blood. 1995 Feb 1;85(3):751-6 [7833478.001]
  • [Cites] Proteins. 1994 Dec;20(4):347-55 [7731953.001]
  • [Cites] Methods Enzymol. 1995;249:284-312 [7791615.001]
  • [Cites] Nature. 1995 Nov 23;378(6555):416-9 [7477383.001]
  • [Cites] Nat Struct Biol. 1995 Dec;2(12):1102-8 [8846222.001]
  • [Cites] Nat Struct Biol. 1996 Jan;3(1):74-86 [8548458.001]
  • [Cites] J Bacteriol. 1996 Apr;178(8):2459-61 [8636057.001]
  • [Cites] J Med Chem. 1996 Jun 7;39(12):2367-78 [8691431.001]
  • [Cites] Med Res Rev. 1996 Jan;16(1):3-50 [8788213.001]
  • [Cites] Crit Rev Oncol Hematol. 1997 Jan;25(1):11-26 [9134309.001]
  • [Cites] J Biol Chem. 1997 May 9;272(19):12384-92 [9139684.001]
  • [Cites] Annu Rev Biochem. 2005;74:739-89 [15952902.001]
  • [Cites] Annu Rev Nutr. 2005;25:59-85 [16011459.001]
  • [Cites] Arch Biochem Biophys. 2005 Aug 1;440(1):18-27 [16023613.001]
  • [Cites] Nat Rev Drug Discov. 2005 Aug;4(8):649-63 [16056391.001]
  • (PMID = 16756505.001).
  • [ISSN] 0066-4154
  • [Journal-full-title] Annual review of biochemistry
  • [ISO-abbreviation] Annu. Rev. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA09126; United States / NIDDK NIH HHS / DK / DK52064; United States / NCI NIH HHS / CA / T32 CA009126; United States / NIDDK NIH HHS / DK / R01 DK052064; United States / NCI NIH HHS / CA / CA107437; United States / NCI NIH HHS / CA / R21 CA107437
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Sulfonamides; 7006-34-0 / Asparagine; EC 6.3.1.1 / Aspartate-Ammonia Ligase
  • [Number-of-references] 187
  • [Other-IDs] NLM/ NIHMS447419; NLM/ PMC3587692
  •  go-up   go-down


11. Guennoun N, Tahri A, Krati K, Bellabah A, Bouras N, Benider A, Cherkaoui A: [Primary non hodgkin lymphoma of the anus and esophagus: a case report]. Gastroenterol Clin Biol; 2006 Mar;30(3):487-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non hodgkin lymphoma of the anus and esophagus: a case report].
  • [MeSH-major] Anus Neoplasms. Esophageal Neoplasms. Lymphoma, B-Cell, Marginal Zone


12. Barton HA, Cogliano VJ, Flowers L, Valcovic L, Setzer RW, Woodruff TJ: Assessing susceptibility from early-life exposure to carcinogens. Environ Health Perspect; 2005 Sep;113(9):1125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The geometric mean ratio for acute studies is 1.5, which was influenced by tissue-specific results [geometric mean ratios for kidney, leukemia, liver, lymph, mammary, nerve, reticular tissue, thymic lymphoma, and uterus/vagina > 1 (range, 1.6-8.1); forestomach, harderian gland, ovaries, and thyroid < 1 (range, 0.033-0.45)].

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 1991 Nov;258(3):259-83 [1719404.001]
  • [Cites] Fundam Appl Toxicol. 1992 Apr;18(3):405-17 [1597265.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2557-61 [9635578.001]
  • [Cites] JAMA. 1998 Aug 19;280(7):630-4 [9718055.001]
  • [Cites] IARC Sci Publ. 1999;(146):499-536 [10353401.001]
  • [Cites] Cancer Res. 1968 Apr;28(4):727-38 [4968106.001]
  • [Cites] Prog Exp Tumor Res. 1969;11:334-63 [4890072.001]
  • [Cites] Int J Cancer. 1969 Jul 15;4(4):480-6 [5346885.001]
  • [Cites] Carcinogenesis. 1992 Aug;13(8):1351-7 [1499087.001]
  • [Cites] Risk Anal. 1992 Dec;12(4):569-77 [1480801.001]
  • [Cites] Fundam Appl Toxicol. 1993 Aug;21(2):174-86 [8405780.001]
  • [Cites] Fundam Appl Toxicol. 1993 Nov;21(4):451-60 [8253298.001]
  • [Cites] Toxicology. 1995 Sep 1;102(1-2):53-70 [7482562.001]
  • [Cites] Carcinogenesis. 1995 Nov;16(11):2743-50 [7586194.001]
  • [Cites] Carcinogenesis. 1996 Aug;17(8):1577-82 [8761412.001]
  • [Cites] Pharmacol Ther. 1996;71(1-2):225-52 [8910956.001]
  • [Cites] Regul Toxicol Pharmacol. 1997 Oct;26(2):230-40 [9356286.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2293-8 [9450472.001]
  • [Cites] Food Addit Contam. 1998;15 Suppl:17-35 [9602909.001]
  • [Cites] Br J Cancer. 1970 Sep;24(3):588-98 [4319944.001]
  • [Cites] J Natl Cancer Inst. 1970 Oct;45(4):687-96 [5513498.001]
  • [Cites] Cancer Res. 1974 Oct;34(10):2530-8 [4412784.001]
  • [Cites] Cancer Res. 1975 Oct;35(10):2814-9 [1157051.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt 1):2948-53 [1182688.001]
  • [Cites] Br J Cancer. 1976 Apr;33(4):427-39 [1268033.001]
  • [Cites] Am J Pathol. 1979 Sep;96(3):721-36 [112872.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):123-58 [225667.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):239-50 [384263.001]
  • [Cites] Natl Cancer Inst Monogr. 1979 May;(51):271-8 [225670.001]
  • [Cites] Cancer Res. 1979 Nov;39(11):4378-80 [498070.001]
  • [Cites] Cancer Res. 1979 Dec;39(12):4965-70 [498122.001]
  • [Cites] Gan. 1981 Aug;72(4):569-77 [7308669.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:274-89 [6953795.001]
  • [Cites] Biol Res Pregnancy Perinatol. 1983;4(1):22-5 [6303459.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(1):60-5 [6746718.001]
  • [Cites] IARC Sci Publ. 1984;(57):627-65 [6533057.001]
  • [Cites] Toxicol Lett. 1989 Feb;45(2-3):231-9 [2919404.001]
  • [Cites] Mutat Res. 1999 Jul 15;443(1-2):183-221 [10415440.001]
  • [Cites] J Exp Med. 1951 May;93(5):427-49 [14832393.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:308-17 [13735601.001]
  • [Cites] Cancer Res. 1959 Nov;19:1109-13 [14409690.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Nov 15;161(1):82-99 [10558926.001]
  • [Cites] Environ Mol Mutagen. 2000;35(3):234-52 [10737958.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):793-7 [10753217.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:463-73 [10852846.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108 Suppl 3:573-94 [10852857.001]
  • [Cites] Radiat Res. 2000 Dec;154(6):733-4;discussion 734-5 [11187021.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4325-8 [11389053.001]
  • [Cites] Breast Cancer Res. 2001;3(4):218-23 [11434872.001]
  • [Cites] Toxicol Pathol. 2001;29 Suppl:128-37 [11695548.001]
  • [Cites] Toxicol Sci. 2002 Apr;66(2):185-200 [11896285.001]
  • [Cites] Regul Toxicol Pharmacol. 2002 Jun;35(3):429-47 [12202057.001]
  • [Cites] Mutat Res. 2002 Sep;512(1):1-35 [12220588.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5183-8 [12234982.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5189-95 [12234983.001]
  • [Cites] Int J Toxicol. 2002 Sep-Oct;21(5):403-18 [12396687.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 1;186(1):7-17 [12583988.001]
  • [Cites] Risk Anal. 2003 Feb;23(1):19-34 [12635720.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):389-94 [12676588.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):259-65 [12680222.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2425-33 [12750262.001]
  • [Cites] Birth Defects Res B Dev Reprod Toxicol. 2003 Aug;68(4):321-34 [14666995.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Jul 15;198(2):95-110 [15236948.001]
  • [Cites] Environ Health Perspect. 2004 Aug;112(11):1152-8 [15289159.001]
  • [Cites] Toxicol Sci. 2004 Sep;81(1):112-20 [15159527.001]
  • [Cites] Br J Cancer. 1966 Mar;20(1):148-60 [5936676.001]
  • [Cites] J Natl Cancer Inst. 1966 Jun;36(6):1111-20 [4287622.001]
  • [Cites] Br J Cancer. 1962 Dec;16:686-9 [14025688.001]
  • [Cites] Br J Cancer. 1963 Dec;17:672-80 [14111604.001]
  • [Cites] J Natl Cancer Inst. 1964 Dec;33:971-7 [14241789.001]
  • [Cites] Cancer Res. 1964 Dec;24:1869-79 [14247497.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1962;18:134-9 [13893052.001]
  • [Cites] J Toxicol Environ Health. 1990;29(3):269-78 [2313739.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7677-81 [2174729.001]
  • [Cites] Carcinogenesis. 1991 Aug;12(8):1409-15 [1860162.001]
  • (PMID = 16140616.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Mutagens
  • [Number-of-references] 92
  • [Other-IDs] NLM/ PMC1280390
  •  go-up   go-down


13. Weerasinghe SV, Wambua M, Pflum MK: A histone deacetylase-dependent screen in yeast. Bioorg Med Chem; 2010 Nov 1;18(21):7586-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histone deacetylase (HDAC) proteins are promising targets for cancer treatment, as shown by the recent FDA approval of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA, Vorinostat) for the treatment of cutaneous T-cell lymphoma.

  • COS Scholar Universe. author profiles.
  • Saccharomyces Genome Database. Saccharomyces Genome Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • [Cites] Chembiochem. 2003 Jan 3;4(1):101-7 [12512083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7835-40 [10869435.001]
  • [Cites] Life Sci. 2004 Apr 16;74(22):2693-705 [15043985.001]
  • [Cites] J Mol Biol. 2004 Apr 16;338(1):17-31 [15050820.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(5):409-13 [15104139.001]
  • [Cites] J Med Chem. 2004 May 6;47(10):2635-44 [15115404.001]
  • [Cites] Structure. 2004 Jul;12(7):1325-34 [15242608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15064-9 [15477595.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11181-9 [7538113.001]
  • [Cites] Science. 1996 Apr 19;272(5260):408-11 [8602529.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12845-50 [8917507.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3565-70 [9108016.001]
  • [Cites] Nature. 1997 Sep 25;389(6649):349-52 [9311776.001]
  • [Cites] J Biol Chem. 1997 Oct 31;272(44):28001-7 [9346952.001]
  • [Cites] Genes Dev. 1998 Mar 15;12(6):797-805 [9512514.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3519-24 [9520398.001]
  • [Cites] J Bacteriol. 1998 Aug;180(15):3735-40 [9683465.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):4868-73 [10220385.001]
  • [Cites] Appl Environ Microbiol. 1999 Aug;65(8):3325-7 [10427014.001]
  • [Cites] Nature. 1999 Sep 9;401(6749):188-93 [10490031.001]
  • [Cites] Comb Chem High Throughput Screen. 2004 Nov;7(7):661-8 [15578928.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):892-7 [15642944.001]
  • [Cites] Med Res Rev. 2005 May;25(3):261-309 [15717297.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):17038-45 [15684413.001]
  • [Cites] J Biol Chem. 2005 Apr 29;280(17):17187-95 [15749705.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3912-22 [15851766.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Methods Mol Biol. 2005;310:253-71 [16353379.001]
  • [Cites] Nat Rev Drug Discov. 2007 Jan;6(1):21-2 [17269160.001]
  • [Cites] FEBS Lett. 2000 Jul 28;478(1-2):77-83 [10922473.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10572-7 [11535832.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38837-43 [11483616.001]
  • [Cites] J Biol Chem. 2001 Dec 14;276(50):47733-41 [11602581.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15113-8 [11752457.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25748-55 [11948178.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Mar 1;17(5):1221-5 [17196388.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Apr 15;17(8):2216-9 [17307359.001]
  • [Cites] Mol Cancer Res. 2007 Oct;5(10):981-9 [17951399.001]
  • [Cites] FEMS Yeast Res. 2007 Dec;7(8):1371-80 [17627775.001]
  • [Cites] Biochem J. 2008 Jan 15;409(2):581-9 [17868033.001]
  • [Cites] J Biol Chem. 2008 Apr 25;283(17):11355-63 [18285338.001]
  • [Cites] Chem Soc Rev. 2008 Jul;37(7):1402-13 [18568166.001]
  • [Cites] Mol Cells. 2008 Jul 31;26(1):93-9 [18525239.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):180-92 [18691552.001]
  • [Cites] J Cell Sci. 2008 Sep 1;121(Pt 17):2860-70 [18697832.001]
  • [Cites] J Med Chem. 2008 Sep 25;51(18):5542-51 [18729444.001]
  • [Cites] J Biol Chem. 2008 Sep 26;283(39):26694-704 [18614528.001]
  • [Cites] J Allergy Clin Immunol. 2010 Feb;125(2):449-460.e14 [19864008.001]
  • [Cites] Carcinogenesis. 2010 Mar;31(3):382-7 [19995796.001]
  • [Cites] J Biol Chem. 2010 Mar 12;285(11):8340-51 [20061378.001]
  • [Cites] J Biol Chem. 2010 Apr 16;285(16):12255-67 [20177060.001]
  • [Cites] Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5 [20392638.001]
  • [Cites] Biochemistry. 2010 May 18;49(19):4244-54 [20392081.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12356-61 [10535926.001]
  • [Cites] Genes Dev. 2000 Jan 1;14(1):55-66 [10640276.001]
  • [Cites] Anal Biochem. 2003 Oct 15;321(2):202-8 [14511685.001]
  • (PMID = 20863708.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM067657; United States / NIGMS NIH HHS / GM / GM067657
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Histone Deacetylase Inhibitors; 0 / Saccharomyces cerevisiae Proteins; 37340-57-1 / zymolyase; EC 3.- / Hydrolases; EC 3.5.1.- / RPD3 protein, S cerevisiae; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ NIHMS234396; NLM/ PMC3033752
  •  go-up   go-down


14. Cai J, Wei R, Cheng J: Preparation and characterization of a novel chimeric protein VEGI-CTT in Escherichia coli. J Biomed Biotechnol; 2008;2008:564969
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The preliminarily in vivo study demonstrated that chimeric protein VEGI-CTT had more potent antitumor activity than VEGI and/or CTT peptide against CA46 human lymphoma xenografts in nude mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2002 Sep;34(5):571-5 [12198558.001]
  • [Cites] FASEB J. 2002 May;16(7):742-4 [11923219.001]
  • [Cites] J Biotechnol. 2003 Apr 24;102(2):177-89 [12697395.001]
  • [Cites] J Immunother. 2004 Mar-Apr;27(2):161-75 [14770088.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] Nature. 1980 Mar 6;284(5751):67-8 [6243750.001]
  • [Cites] Anal Biochem. 1981 Sep 15;116(2):439-43 [7032356.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Eur Cytokine Netw. 1996 Apr-Jun;7(2):93-124 [8688493.001]
  • [Cites] Cell. 1997 Jan 24;88(2):277-85 [9008168.001]
  • [Cites] Invasion Metastasis. 1997;17(3):158-68 [9702942.001]
  • [Cites] FASEB J. 1999 Jan;13(1):181-9 [9872942.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1479-86 [9880523.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 24;255(3):735-9 [10049780.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):148-55 [10077166.001]
  • [Cites] Int J Cancer. 1999 Jul 2;82(1):131-6 [10360832.001]
  • [Cites] Nat Biotechnol. 1999 Aug;17(8):749 [10429233.001]
  • [Cites] Nat Biotechnol. 1999 Aug;17(8):768-74 [10429241.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):496-507 [15563312.001]
  • [Cites] J Biol Chem. 2000 Jan 14;275(2):1209-15 [10625665.001]
  • [Cites] J Biol Chem. 2000 Aug 4;275(31):23745-50 [10837460.001]
  • [Cites] Circ Res. 2001 Dec 7;89(12):1161-7 [11739281.001]
  • [Cites] Science. 2002 Jan 4;295(5552):140-3 [11778052.001]
  • [Cites] Immunity. 2002 Mar;16(3):479-92 [11911831.001]
  • [Cites] Biochim Biophys Acta. 2003 Jan 20;1619(2):139-43 [12527109.001]
  • (PMID = 18769489.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / CTTHWGFTLC peptide; 0 / Peptides, Cyclic; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor Ligand Superfamily Member 15; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2519132
  •  go-up   go-down


15. Spadavecchia S, Gonzalez-Lopez O, Carroll KD, Palmeri D, Lukac DM: Convergence of Kaposi's sarcoma-associated herpesvirus reactivation with Epstein-Barr virus latency and cellular growth mediated by the notch signaling pathway in coinfected cells. J Virol; 2010 Oct;84(20):10488-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiologic agent of primary effusion lymphoma (PEL).
  • EBV transformation of primary B cells requires EBV nuclear antigen 2 (EBNA-2) to interact with RBP-Jk to direct the latent viral and cellular gene expression program.

  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1997 Nov 3;16(21):6478-85 [9351829.001]
  • [Cites] Blood. 1998 Feb 1;91(3):747-55 [9446632.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2835-44 [9566902.001]
  • [Cites] Oncogene. 1998 Apr 2;16(13):1731-42 [9582021.001]
  • [Cites] J Gen Virol. 1998 Jun;79 ( Pt 6):1445-52 [9634087.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] Virology. 1999 Sep 15;262(1):18-30 [10489337.001]
  • [Cites] J Virol. 1999 Nov;73(11):9348-61 [10516043.001]
  • [Cites] Science. 1999 Oct 8;286(5438):300-3 [10514374.001]
  • [Cites] J Virol. 2005 Mar;79(6):3479-87 [15731242.001]
  • [Cites] J Virol. 2005 Nov;79(22):14371-82 [16254371.001]
  • [Cites] Blood. 2006 Jan 1;107(1):277-84 [16150942.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Physiol Rev. 2007 Jan;87(1):99-163 [17237344.001]
  • [Cites] J Virol. 2007 Jun;81(11):6068-78 [17376914.001]
  • [Cites] J Virol. 2007 Jun;81(11):5788-806 [17392367.001]
  • [Cites] Anal Biochem. 2007 Jul 15;366(2):197-206 [17512890.001]
  • [Cites] J Virol. 2007 Aug;81(16):8451-67 [17537858.001]
  • [Cites] J Virol. 2007 Dec;81(24):13299-314 [17913801.001]
  • [Cites] PLoS One. 2008;3(2):e1569 [18253508.001]
  • [Cites] J Virol. 2008 Nov;82(21):10709-23 [18715905.001]
  • [Cites] J Virol. 2009 May;83(10):5014-27 [19264782.001]
  • [Cites] Dev Cell. 2009 May;16(5):633-47 [19460341.001]
  • [Cites] J Virol. 1999 Dec;73(12):10525-30 [10559372.001]
  • [Cites] Leuk Lymphoma. 2000 Jul;38(3-4):401-9 [10830748.001]
  • [Cites] J Virol. 2000 Nov;74(21):10187-93 [11024147.001]
  • [Cites] J Virol. 2001 Mar;75(5):2033-40 [11160707.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1195-203 [11031256.001]
  • [Cites] J Virol. 2001 Apr;75(8):3537-46 [11264343.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71 [9724796.001]
  • [Cites] Leukemia. 1998 Oct;12(10):1507-17 [9766492.001]
  • [Cites] Virology. 1998 Dec 20;252(2):304-12 [9878608.001]
  • [Cites] J Virol. 1999 Apr;73(4):2770-80 [10074124.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):16085-96 [10347160.001]
  • [Cites] J Virol. 2001 Jul;75(13):5899-912 [11390591.001]
  • [Cites] Genes Dev. 2002 Aug 1;16(15):1977-89 [12154127.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3694-704 [12446712.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8490-5 [12832621.001]
  • [Cites] Blood. 2004 Jan 1;103(1):313-6 [12969959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):141-6 [14691250.001]
  • [Cites] J Virol. 2004 Apr;78(8):3941-52 [15047810.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2681-93 [14767477.001]
  • [Cites] J Exp Med. 1984 May 1;159(5):1554-9 [6325575.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):61-8 [2162905.001]
  • [Cites] J Virol. 1992 Nov;66(11):6496-501 [1404600.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24157-60 [1332946.001]
  • [Cites] J Exp Med. 1993 Mar 1;177(3):763-74 [8382256.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] EMBO J. 1995 Jan 3;14(1):88-96 [7828599.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):549-60 [7845680.001]
  • [Cites] Cell. 1995 Feb 10;80(3):389-99 [7859281.001]
  • [Cites] J Virol. 1995 May;69(5):2968-76 [7707523.001]
  • [Cites] Blood. 1995 Oct 1;86(7):2708-14 [7670109.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] J Virol. 1996 Jan;70(1):549-58 [8523568.001]
  • [Cites] EMBO J. 1996 Jan 15;15(2):375-82 [8617212.001]
  • [Cites] Nat Med. 1996 Mar;2(3):342-6 [8612236.001]
  • [Cites] Blood. 1996 Jul 15;88(2):645-56 [8695812.001]
  • [Cites] Nat Med. 1996 Aug;2(8):918-24 [8705863.001]
  • [Cites] Nat Med. 1996 Aug;2(8):925-8 [8705864.001]
  • [Cites] Br J Haematol. 1996 Sep;94(3):533-43 [8790156.001]
  • [Cites] Lancet. 1996 Oct 26;348(9035):1133-8 [8888167.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1739-44 [8939871.001]
  • [Cites] Cytometry. 1996 Dec 1;25(4):333-40 [8946140.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2243-54 [8950992.001]
  • [Cites] J Virol. 1997 Jan;71(1):314-24 [8985352.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):7070-8 [9003782.001]
  • [Cites] Blood. 1997 Aug 1;90(3):1186-91 [9242551.001]
  • [Cites] Development. 1997 Oct;124(20):4133-41 [9374409.001]
  • (PMID = 20686042.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI078138; United States / NIAID NIH HHS / AI / AI 078138
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / DNA Primers; 0 / EBNA-2 protein, Human herpesvirus 4; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Epstein-Barr Virus Nuclear Antigens; 0 / Immediate-Early Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Receptors, Notch; 0 / Rta protein, Human herpesvirus 8; 0 / Trans-Activators; 0 / Viral Matrix Proteins; 0 / Viral Proteins
  • [Other-IDs] NLM/ PMC2950570
  •  go-up   go-down


16. Fend F, Bock O, Kremer M, Specht K, Quintanilla-Martinez L: Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies. Virchows Arch; 2005 Dec;447(6):909-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current indications for molecular BM diagnostics range from the confirmation of lymphoma involvement with gene rearrangement analysis, demonstration of tumor-specific translocations in lymphoid and chronic myeloproliferative disorders along to the detection of microorganisms or marrow involvement by soft tissue sarcomas.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Mar 15;97(6):1560-5 [11238091.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):741-6 [10797300.001]
  • [Cites] J Mol Diagn. 2000 Nov;2(4):178-90 [11232108.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:306-12 [12095956.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):335-42 [15507672.001]
  • [Cites] Mod Pathol. 1997 Jan;10(1):33-7 [9021724.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):91-7 [11235910.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):179-84 [9930138.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3343-56 [11071626.001]
  • [Cites] Virchows Arch. 2001 Oct;439(4):504-11 [11710637.001]
  • [Cites] J Clin Lab Anal. 2002;16(1):47-51 [11835531.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):634-42 [12760281.001]
  • [Cites] Pathol Res Pract. 2003;199(6):425-30 [12924445.001]
  • [Cites] J Pathol. 2001 Sep;195(1):66-71 [11568892.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):737-42 [11577117.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):745-50 [1401199.001]
  • [Cites] Acta Haematol. 2004;112(1-2):111-9 [15179011.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):761-5 [9670837.001]
  • [Cites] Histopathology. 2000 Sep;37(3):199-211 [10971695.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):56-60 [9495359.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1701-7 [11535500.001]
  • [Cites] J Clin Pathol. 1990 May;43(5):429-32 [2370312.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):231-6 [14573782.001]
  • [Cites] Acta Haematol. 1993;90(1):5-7 [8237276.001]
  • [Cites] Blood. 2004 Aug 15;104(4):1120-6 [15090460.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1961-71 [12466110.001]
  • [Cites] Adv Cancer Res. 2001;82:133-85 [11447762.001]
  • [Cites] J Virol Methods. 1993 Jul;43(2):189-204 [8396155.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 15;27(22):4436-43 [10536153.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2343-55 [11289094.001]
  • [Cites] Mod Pathol. 2004 Dec;17(12):1521-30 [15257312.001]
  • [Cites] J Mol Med (Berl). 1995 May;73(5):235-41 [7670927.001]
  • [Cites] Virchows Arch. 2000 Jul;437(1):46-51 [10963379.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2902-11 [12231535.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1047-56 [9298881.001]
  • [Cites] Br J Haematol. 2000 Dec;111(4):1109-11 [11167748.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1857-66 [10362812.001]
  • [Cites] Mol Diagn. 1997 Sep;2(3):217-230 [10462613.001]
  • [Cites] Leuk Lymphoma. 2000 Jan;36(3-4):347-52 [10674907.001]
  • [Cites] Mol Pathol. 2000 Feb;53(1):19-23 [10884917.001]
  • [Cites] Adv Anat Pathol. 2003 Jan;10(1):8-26 [12502965.001]
  • [Cites] Diagn Mol Pathol. 1992 Sep;1(3):173-9 [1342963.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):84-91 [11272893.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):850-5 [7801903.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):194-200 [11040942.001]
  • [Cites] J Mol Diagn. 2000 May;2(2):92-6 [11272894.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Lymphoma. 1993 Jun;10(3):223-9 [8220121.001]
  • [Cites] Mol Pathol. 1999 Apr;52(2):104-10 [10474690.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Semin Diagn Pathol. 2003 Aug;20(3):196-210 [14552431.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Pathol. 1992 Sep;45(9):763-5 [1401203.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):581-6 [10583263.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Ann Hematol. 1991 Apr;62(4):108-14 [2031973.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Clin Pathol. 1999 Apr;52(4):294-300 [10474523.001]
  • [Cites] Mod Pathol. 1999 Mar;12(3):272-8 [10102612.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Feb;37(2):169-77 [2649233.001]
  • [Cites] J Mol Diagn. 2003 Feb;5(1):54-60 [12552081.001]
  • [Cites] Int J Hematol. 1999 Dec;70(4):283-9 [10643155.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3889-96 [10572105.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):794-805 [10463482.001]
  • [Cites] Leukemia. 1991 Aug;5(8):726-30 [1909411.001]
  • [Cites] Hum Pathol. 2000 Jul;31(7):847-53 [10923923.001]
  • [Cites] Scand J Infect Dis. 1997;29(3):271-4 [9255888.001]
  • [Cites] Oncogene. 1991 Dec;6(12):2271-6 [1766674.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Jul;54(1):10-8 [12827663.001]
  • [Cites] J Pathol. 2000 Jan;190(1):55-60 [10640992.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 1995 May 1;85(9):2528-36 [7727781.001]
  • [Cites] Leukemia. 1994 Jan;8(1):186-9 [8289486.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Sep;15(3):549-62 [12468405.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):355-63 [10433929.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):737-46 [12598308.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1536-43 [11861265.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1309-14 [7992836.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2023-9 [11733353.001]
  • [Cites] Diagn Mol Pathol. 2003 Sep;12(3):119-23 [12960692.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):274-82 [15475934.001]
  • [Cites] Histopathology. 2001 Jan;38(1):37-44 [11135045.001]
  • [Cites] Lab Invest. 2003 Jan;83(1):107-14 [12533691.001]
  • (PMID = 16231178.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Number-of-references] 86
  •  go-up   go-down


17. Ang D, Luman W, Ooi CJ: Early experience with double balloon enteroscopy: a leap forward for the gastroenterologist. Singapore Med J; 2007 Jan;48(1):50-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: DBE was carried out via the oral approach (19 patients), anal approach (eight patients), and both approaches (three patients).
  • A positive diagnosis was achieved in 19 patients: jejunal gastrointestinal stromal tumour (GIST) (one), jejunal sarcoma (one), jejunal adenocarcinoma (one), duodenal adenocarcinoma (one), malignant lymphangioma (one), eosinophilic enteritis (one), pseudomembranous ileitis (one), tuberculous ileitis (one), jejunitis/ileitis (seven), lymphangiectasia attributed to relapsed Non-Hodgkins lymphoma (one), combination of angiodysplastic lesions and apthous jejunal/ileal lesions (one), and focal villous atrophy (two).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245517.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


18. Reddy LH, Adhikari JS, Dwarakanath BS, Sharma RK, Murthy RR: Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice. AAPS J; 2006;8(2):E254-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice.
  • The tumoricidal effects of etoposide incorporated into lipid nanoparticles after single-dose administration were investigated in Dalton's lymphoma ascites bearing mice.
  • [MeSH-major] Etoposide / pharmacokinetics. Etoposide / therapeutic use. Lymphoma / drug therapy. Nanostructures

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS PharmSciTech. 2005;6(2):E158-66 [16353973.001]
  • [Cites] AAPS J. 2004;6(3):e23 [15760108.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1989 Mar;37(3):802-4 [2752497.001]
  • [Cites] Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2743-7 [2782886.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):1033-40 [2808036.001]
  • [Cites] Gan To Kagaku Ryoho. 1991 May;18(6):959-63 [2029199.001]
  • [Cites] Gan To Kagaku Ryoho. 1991 Aug;18(11):2033-7 [1652233.001]
  • [Cites] J Neurooncol. 1993 Feb;15(2):133-9 [8509818.001]
  • [Cites] World J Surg. 1994 Jan-Feb;18(1):150-5 [8197772.001]
  • [Cites] Toxicol Lett. 2000 Jul 27;116(1-2):51-9 [10906422.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):165-96 [11311991.001]
  • [Cites] J Control Release. 2002 Apr 23;80(1-3):295-307 [11943406.001]
  • [Cites] Mutat Res. 1976 Dec;41(2-3):321-32 [796719.001]
  • [Cites] Indian J Med Res. 1985 Sep;82:266-8 [4077168.001]
  • [Cites] Anal Biochem. 1994 May 1;218(2):314-9 [8074286.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(3):211-6 [7781140.001]
  • [Cites] Int J Radiat Biol. 1995 Jun;67(6):677-85 [7608631.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1922-7 [8656261.001]
  • [Cites] Eur J Pharm Biopharm. 1998 Sep;46(2):145-51 [9795036.001]
  • [Cites] J Microencapsul. 1999 Mar-Apr;16(2):205-13 [10080114.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1125-33 [10192364.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):232-7 [3121165.001]
  • (PMID = 16796375.001).
  • [ISSN] 1550-7416
  • [Journal-full-title] The AAPS journal
  • [ISO-abbreviation] AAPS J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide
  • [Other-IDs] NLM/ PMC3231564
  •  go-up   go-down


19. Aldo S, Salmaso L, El Barmi H, Pesarin F: Conditional tests in a competing risks model. Lifetime Data Anal; 2008 Jun;14(2):154-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Computer Simulation. Lymphoma, T-Cell / mortality. Male. Mice. Sarcoma / mortality

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lifetime Data Anal. 2002 Sep;8(3):277-88 [12182123.001]
  • [Cites] Lifetime Data Anal. 2002 Dec;8(4):401-12 [12471948.001]
  • [Cites] Biometrics. 1972 Jun;28(2):475-88 [4556703.001]
  • (PMID = 17943442.001).
  • [ISSN] 1380-7870
  • [Journal-full-title] Lifetime data analysis
  • [ISO-abbreviation] Lifetime Data Anal
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


21. Li X, He Y, Ruiz CH, Koenig M, Cameron MD, Vojkovsky T: Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos; 2009 Jun;37(6):1242-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways.
  • Dasatinib was approved in 2006 for the treatment of imatinib-resistant chronic myelogenous leukemia and functions primarily through the inhibition of BCR-ABL and Src kinase.
  • Dasatinib is extensively metabolized in humans by CYP3A4.
  • In this study, we report that the bioactivation of dasatinib by CYP3A4 proceeds through a reactive intermediate that leads to CYP3A4 inactivation with K(I) = 6.3 microM and k(inact) = 0.034 min(-1).
  • The major mechanism of inactivation proceeds through hydroxylation at the para-position of the 2-chloro-6-methylphenyl ring followed by further oxidation, forming a reactive quinone-imine, similar to the reactive intermediates formed by acetaminophen and diclofenac.
  • Formation of a reactive imine-methide was also detected but appears to be a minor pathway.
  • When glutathione was added to human liver microsomal incubations, dasatinib-glutathione adducts were detected.
  • Numerous dasatinib analogs were synthesized in an effort to understand what modifications would block the formation of reactive intermediates during dasatinib metabolism.
  • It is interesting to note that blocking the site of hydroxylation with a methyl group was not effective because a reactive imine-methide was formed, nor was blocking the site with fluorine because the fluorine was removed through an oxidative defluorination mechanism and the reactive quinone-imine was still formed.
  • Numerous analogs are presented that did effectively block the formation of glutathione adducts and prevent the inactivation of CYP3A4.
  • [MeSH-major] Cytochrome P-450 CYP3A Inhibitors. Enzyme Activation / drug effects. Microsomes, Liver / metabolism. Protein Kinase Inhibitors / pharmacology. Pyrimidines / pharmacology. Thiazoles / pharmacology
  • [MeSH-minor] Benzamides. Chromatography, High Pressure Liquid / methods. Cytochrome P-450 CYP3A / genetics. Cytochrome P-450 CYP3A / metabolism. Dasatinib. Diclofenac / pharmacology. Enzyme Inhibitors / pharmacology. Glutathione / chemistry. Humans. Imatinib Mesylate. K562 Cells. Piperazines / metabolism. Spectrometry, Mass, Electrospray Ionization

  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Leuk Lymphoma. 2008 Aug;49(8):1630-2 [18608866.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:55-63 [12505285.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4010-22 [14982876.001]
  • [Cites] Nature. 1982 Dec 23;300(5894):765-7 [6960256.001]
  • [Cites] Clin Exp Immunol. 1984 Mar;55(3):561-70 [6368059.001]
  • [Cites] Nature. 1985 Jun 13-19;315(6020):550-4 [2989692.001]
  • [Cites] Am J Psychiatry. 1985 Aug;142(8):974-5 [3161347.001]
  • [Cites] Postgrad Med J. 1986 Jan;62(723):63-5 [3797366.001]
  • [Cites] Eur J Haematol Suppl. 1996;60:89-92 [8987248.001]
  • [Cites] Immunol Today. 1998 Mar;19(3):133-41 [9540273.001]
  • [Cites] Semin Immunol. 1998 Oct;10(5):399-415 [9840976.001]
  • [Cites] J Immunol. 1999 Mar 15;162(6):3256-62 [10092777.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2640-53 [15618470.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4500-5 [15930265.001]
  • [Cites] Crit Rev Toxicol. 2005 Apr-May;35(4):325-61 [15989140.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1267-9 [15858616.001]
  • [Cites] J Allergy Clin Immunol. 2006 Jul;118(1):233-41 [16815161.001]
  • [Cites] N Engl J Med. 2006 Dec 7;355(23):2408-17 [17151364.001]
  • [Cites] Chem Res Toxicol. 2007 Mar;20(3):344-69 [17302443.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2007 Jun;3(3):407-20 [17539747.001]
  • [Cites] Crit Rev Toxicol. 2007 Jun;37(5):389-412 [17612953.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76 [17429625.001]
  • [Cites] Anal Chem. 2008 Mar 1;80(5):1788-99 [18251522.001]
  • [Cites] J Mass Spectrom. 2009 Jan;44(1):90-100 [18720456.001]
  • [Cites] Drug Metab Dispos. 2008 May;36(5):841-50 [18238857.001]
  • [Cites] Drug Metab Dispos. 2008 Jul;36(7):1357-64 [18420784.001]
  • [Cites] Drug Metab Dispos. 2008 Jul;36(7):1341-56 [18420785.001]
  • [Cites] Drug Metab Dispos. 2008 Sep;36(9):1828-39 [18556438.001]
  • [Cites] Lancet. 2008 Aug 30;372(9640):713-4 [18761212.001]
  • [ErratumIn] Drug Metab Dispos. 2009 Oct;37(10):2118. Vojkovsky, Tomas [added]
  • (PMID = 19282395.001).
  • [ISSN] 1521-009X
  • [Journal-full-title] Drug metabolism and disposition: the biological fate of chemicals
  • [ISO-abbreviation] Drug Metab. Dispos.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / U54 MH084512
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Cytochrome P-450 CYP3A Inhibitors; 0 / Enzyme Inhibitors; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Thiazoles; 144O8QL0L1 / Diclofenac; 8A1O1M485B / Imatinib Mesylate; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; GAN16C9B8O / Glutathione; RBZ1571X5H / Dasatinib
  • [Other-IDs] NLM/ PMC3202349
  •  go-up   go-down


22. Nagamine CM, Jackson CN, Beck KA, Marini RP, Fox JG, Nambiar PR: Acute paraplegia in a young adult long-evans rat resulting from T-cell lymphoma. Contemp Top Lab Anim Sci; 2005 Nov;44(6):53-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute paraplegia in a young adult long-evans rat resulting from T-cell lymphoma.
  • We describe an unusual case of acute paraplegia in a young adult (7.5-month-old) Long-Evans rat that resulted from a spontaneous T-cell lymphoma.
  • At presentation, a neurologic exam revealed normal pelvic limb flexor reflexes, the absence of an anal reflex, and deep pain recognition.
  • Although the lymphoma did not invade the meninges of the spinal cord, its impingement on the central and peripheral nervous systems resulted in foci of Wallerian degeneration that contributed to the paraplegia.
  • This case report highlights the importance of having lymphoma and leukemia among the differential diagnoses in cases of acute paralysis in rodents.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16370582.001).
  • [ISSN] 1060-0558
  • [Journal-full-title] Contemporary topics in laboratory animal science
  • [ISO-abbreviation] Contemp Top Lab Anim Sci
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / T32-RR07036
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


23. Kupumbati TS, Cattoretti G, Marzan C, Farias EF, Taneja R, Mira-y-Lopez R: Dominant negative retinoic acid receptor initiates tumor formation in mice. Mol Cancer; 2006 Mar 24;5:12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our work makes available to the research community a new animal resource that should prove useful as an experimental model of aggressive sporadic lymphoma in immunologically uncompromised hosts.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLYCINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2000 Mar;16(3):561-5 [10675490.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 15;92(6):475-80 [10716965.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1556-63 [10734315.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):826-32 [10814678.001]
  • [Cites] J Exp Med. 2000 Oct 16;192(8):1183-90 [11034608.001]
  • [Cites] Nutrition. 2000 Nov-Dec;16(11-12):1084-9 [11118831.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7064-72 [11704830.001]
  • [Cites] Oncogene. 2001 Oct 29;20(49):7186-203 [11704847.001]
  • [Cites] Carcinogenesis. 2001 Dec;22(12):1955-63 [11751425.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):54-60 [11801540.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):467-74 [12010861.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5902-5 [12384555.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1220-35 [12393483.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3684-92 [12881317.001]
  • [Cites] Cell. 2004 May 28;117(5):663-76 [15163413.001]
  • [Cites] Mol Cancer. 2004 Apr 27;3:13 [15113415.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Cell. 1986 May 23;45(4):485-95 [3011271.001]
  • [Cites] Cell. 1986 Oct 10;47(1):11-8 [3093082.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] J Exp Med. 1988 Feb 1;167(2):353-71 [3258007.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2718-22 [1313565.001]
  • [Cites] Cell. 1992 Sep 18;70(6):1007-19 [1326406.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 [1359541.001]
  • [Cites] Genes Dev. 1992 Dec;6(12A):2258-69 [1334022.001]
  • [Cites] Recent Prog Horm Res. 1993;48:99-121 [8382832.001]
  • [Cites] Development. 1993 Oct;119(2):363-75 [8287793.001]
  • [Cites] Cell Growth Differ. 1994 Feb;5(2):133-41 [8180126.001]
  • [Cites] J Biol Chem. 1994 Jul 22;269(29):19101-7 [7913468.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4614-7 [8062253.001]
  • [Cites] EMBO J. 1994 Dec 1;13(23):5570-80 [7988554.001]
  • [Cites] Nature. 1995 Mar 9;374(6518):159-62 [7533262.001]
  • [Cites] Blood. 1995 Jul 1;86(1):45-53 [7795255.001]
  • [Cites] Development. 1994 Oct;120(10):2723-48 [7607067.001]
  • [Cites] Cell Growth Differ. 1995 Jun;6(6):737-48 [7669729.001]
  • [Cites] Cell Growth Differ. 1995 Sep;6(9):1077-88 [8519684.001]
  • [Cites] FASEB J. 1996 Jul;10(9):940-54 [8801176.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):723-31 [9001226.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2507-15 [9116296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3240-4 [9096377.001]
  • [Cites] Biol Reprod. 1997 Apr;56(4):985-90 [9096882.001]
  • [Cites] Nat Genet. 1997 Jun;16(2):161-70 [9171827.001]
  • [Cites] Cell Growth Differ. 1997 Jun;8(6):631-41 [9185997.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2642-50 [9205071.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4158-61 [9331065.001]
  • [Cites] Exp Cell Res. 1997 Oct 10;236(1):16-28 [9344581.001]
  • [Cites] Cancer Res. 1997 Nov 15;57(22):4992-6 [9371489.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):1012-9 [9486971.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7491-6 [9636177.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3226-39 [9787159.001]
  • [Cites] J Biol Chem. 2005 Jan 28;280(4):3012-21 [15528198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):790-8 [15824145.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4094-105 [15897912.001]
  • [Cites] Dev Dyn. 2005 Dec;234(4):892-9 [16217742.001]
  • [Cites] Mol Carcinog. 2005 Dec;44(4):252-61 [16273555.001]
  • (PMID = 16563162.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA054273; United States / NCI NIH HHS / CA / R24 CA088302; United States / NCI NIH HHS / CA / CA54273; United States / NCI NIH HHS / CA / CA88302
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Retinoic Acid; 0 / retinoic acid receptor alpha; TE7660XO1C / Glycine
  • [Other-IDs] NLM/ PMC1444935
  •  go-up   go-down


24. Corna G, Galy B, Hentze MW, Cairo G: IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice. J Mol Med (Berl); 2006 Jul;84(7):551-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice.
  • Iron aggravates the cardiotoxicity of doxorubicin (DOX), a widely used anticancer anthracycline.
  • The amount of iron in the cell is regulated by the iron regulatory proteins (IRPs)-1 and -2 that control the posttranscriptional expression of key iron metabolism genes.
  • In vitro and cell culture studies revealed the ability of DOX to modulate the activity of both IRPs.
  • However, conflicting data were obtained from different cell types and experimental conditions.
  • To investigate the connection between acute DOX cardiotoxicity and the IRPs in a mammalian organism, we analyzed IRP activity and the expression of IRP target genes in the heart of mice subjected to DOX treatment.
  • DOX exposure elicits a differential modulation of the two IRPs with reduced IRP2 activity and unchanged IRP1 activity.
  • IRP2 downmodulation is associated with the upregulation of the ferritin L and H genes and decreased expression of the transferrin receptor 1 (TfR1).
  • To directly test the role of IRP1 in DOX cardiotoxicity, the DOX response was analyzed in mice lacking IRP1.
  • DOX-mediated IRP2 downmodulation and regulation of ferritin and TfR1 expression is identical in Irp1 (-/-) mice compared to wild type, as is the degree of oxidative damage of the heart assessed by thioredoxin and thiobarbituric acid reactive substance levels and by brain natriuretic peptide mRNA expression.
  • These data demonstrate that the alterations of cardiac iron homeostasis related to acute anthracycline cardiotoxicity occur independently of IRP1.
  • The observed IRP2 downmodulation could serve as a means to counteract DOX cardiotoxicity by reducing the "free" cellular iron pool.
  • [MeSH-major] Doxorubicin / pharmacology. Heart / drug effects. Iron / metabolism. Myocardium / metabolism
  • [MeSH-minor] Animals. Ferritins / genetics. Ferritins / metabolism. Gene Deletion. Gene Expression Regulation. Iron Regulatory Protein 1 / deficiency. Iron Regulatory Protein 1 / genetics. Iron Regulatory Protein 1 / metabolism. Mice. Mice, Knockout

  • MedlinePlus Health Information. consumer health - Iron.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Steroids. 1990 Aug;55(8):330-52 [2237942.001]
  • [Cites] Ann N Y Acad Sci. 2004 Mar;1012:65-83 [15105256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Nov;84(21):7438-42 [3478702.001]
  • [Cites] Leuk Lymphoma. 1993 Oct;11(3-4):207-14 [8260895.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4592-8 [12183413.001]
  • [Cites] J Am Coll Cardiol. 1998 Oct;32(4):1118-25 [9768741.001]
  • [Cites] Genesis. 2005 Dec;43(4):181-8 [16283625.001]
  • [Cites] Lancet. 1998 Jan 3;351(9095):9-13 [9433422.001]
  • [Cites] Biochim Biophys Acta. 2003 Feb 17;1593(2-3):209-18 [12581865.001]
  • [Cites] J Biol Chem. 1995 Jan 13;270(2):700-3 [7822298.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2574-80 [12805055.001]
  • [Cites] FASEB J. 1998 May;12(7):541-52 [9576481.001]
  • [Cites] Nature. 2005 Aug 18;436(7053):1035-39 [16110529.001]
  • [Cites] Mol Pharmacol. 2002 Oct;62(4):888-900 [12237336.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1084-91 [15831703.001]
  • [Cites] J Biol Chem. 1984 Apr 10;259(7):4327-34 [6546756.001]
  • [Cites] Cardiovasc Res. 2004 Nov 1;64(2):308-14 [15485690.001]
  • [Cites] J Lab Clin Med. 1993 Sep;122(3):245-51 [8409700.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8422-8 [11731422.001]
  • [Cites] N Engl J Med. 1998 Sep 24;339(13):900-5 [9744975.001]
  • [Cites] Mol Pharmacol. 2005 Aug;68(2):261-71 [15883202.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2377-83 [14615379.001]
  • [Cites] J Biol Chem. 1997 Oct 10;272(41):25941-50 [9325328.001]
  • [Cites] EMBO J. 2004 Jan 28;23(2):386-95 [14726953.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4161-6 [10945624.001]
  • [Cites] Protein Expr Purif. 2000 Jun;19(1):212-8 [10833409.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203 [8695634.001]
  • [Cites] Semin Oncol. 1996 Aug;23(4 Suppl 8):23-34 [8783663.001]
  • [Cites] Pharmacol Rev. 2004 Jun;56(2):185-229 [15169927.001]
  • [Cites] J Lab Clin Med. 1996 Mar;127(3):272-8 [9273360.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):209-14 [11175792.001]
  • [Cites] Anal Biochem. 1979 Jun;95(2):351-8 [36810.001]
  • [Cites] J Biol Chem. 2002 May 10;277(19):17179-87 [11856741.001]
  • [Cites] Cell. 2004 Apr 30;117(3):285-97 [15109490.001]
  • [Cites] RNA. 2004 Jul;10(7):1019-25 [15208438.001]
  • [Cites] Circulation. 2002 Sep 10;106(11):1403-9 [12221060.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2580-9 [15956281.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13738-45 [14739295.001]
  • [Cites] Haematologica. 2006 Mar;91(3):303-10 [16503547.001]
  • [Cites] J Clin Invest. 2003 Nov;112(9):1395-406 [14597765.001]
  • [Cites] Cell. 1989 Jul 28;58(2):373-82 [2752428.001]
  • [Cites] Ann Clin Biochem. 2001 Mar;38(Pt 2):83-93 [11269760.001]
  • [Cites] Blood. 2002 May 15;99(10):3505-16 [11986201.001]
  • (PMID = 16770644.001).
  • [ISSN] 0946-2716
  • [Journal-full-title] Journal of molecular medicine (Berlin, Germany)
  • [ISO-abbreviation] J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 9007-73-2 / Ferritins; E1UOL152H7 / Iron; EC 4.2.1.3 / Iron Regulatory Protein 1
  •  go-up   go-down


25. Nada EM, Alshoaiby AN, Alaskar AS, Khan AN: Severe anal and abdominal pain due to typhlitis in a leukemic patient. J Pain Symptom Manage; 2007 Nov;34(5):457-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe anal and abdominal pain due to typhlitis in a leukemic patient.
  • [MeSH-major] Abdominal Pain / etiology. Anal Canal. Leukemia-Lymphoma, Adult T-Cell / complications. Pain / etiology. Typhlitis / complications

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976570.001).
  • [ISSN] 0885-3924
  • [Journal-full-title] Journal of pain and symptom management
  • [ISO-abbreviation] J Pain Symptom Manage
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Antineoplastic Agents; 76I7G6D29C / Morphine
  •  go-up   go-down


26. Trubiani O, Salvolini E, Santoleri F, D'Arcangelo C, Spoto G, Primio RD, Mazzanti L: Changes of plasma membrane properties in a human pre-T cell line undergoing apoptosis. J Membr Biol; 2005 Mar;204(2):77-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes of plasma membrane properties in a human pre-T cell line undergoing apoptosis.
  • A variety of cellular functions are modulated by the physical properties of the cell membrane, and the modification of intracellular transfer, resulting from loss of membrane integrity, may contribute toward setting the cell onto the pathway of apoptosis.
  • Apoptosis in lymphoid cells can be induced in different ways and biochemical modifications occur at an early phase of cell death, while the morphological features of apoptosis are evident later.
  • We previously reported that DMSO is an efficient apoptosis-inducing factor in the human RPMI-8402 pre-T cell line.
  • The aim of the present study was to verify the effect of DMSO on the plasma membrane fluidity, the intracellular calcium concentration and the phosphodiesterase activity in DMSO-induced apoptosis.
  • Our results show a modification of membrane fluidity associated with an increase of intracellular Ca(2+) concentration.
  • Moreover, we demonstrate that these modifications are related to a decrease in the phosphodiesterase (PDE) activity.
  • The correlation between the proceedings of added DMSO and the induction of apoptosis will provide significant information regarding the first part of the apoptotic process.
  • [MeSH-major] Apoptosis / drug effects. Cell Membrane / metabolism. Cryoprotective Agents / pharmacology. Dimethyl Sulfoxide / pharmacology. Membrane Fluidity / drug effects. T-Lymphocytes / metabolism
  • [MeSH-minor] Calcium / metabolism. Cell Cycle / drug effects. Humans. Phosphoric Diester Hydrolases / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1995 Oct;9(13):1277-87 [7557017.001]
  • [Cites] Mol Cell Biol. 2003 Nov;23(22):8042-57 [14585965.001]
  • [Cites] J Immunol. 1987 Nov 15;139(10):3199-206 [3680944.001]
  • [Cites] FASEB J. 1999 Oct;13(13):1647-57 [10506569.001]
  • [Cites] Ciba Found Symp. 1992;164:98-108; discussion 108-12 [1356716.001]
  • [Cites] Cancer Detect Prev. 1998;22(5):463-9 [9727628.001]
  • [Cites] J Cell Physiol. 1988 Jan;134(1):117-23 [3335580.001]
  • [Cites] Curr Opin Cell Biol. 2001 Aug;13(4):405-11 [11454444.001]
  • [Cites] Biochim Biophys Acta. 1985 Apr 22;845(1):60-7 [3978130.001]
  • [Cites] Leuk Lymphoma. 2000 Mar;37(1-2):39-51 [10721768.001]
  • [Cites] Trends Biochem Sci. 1994 Jan;19(1):26-30 [8140617.001]
  • [Cites] Immunol Today. 1994 Apr;15(4):147-51 [7911020.001]
  • [Cites] Curr Opin Cell Biol. 1993 Apr;5(2):269-73 [8507499.001]
  • [Cites] J Biol Chem. 1990 Mar 25;265(9):5280-4 [1690738.001]
  • [Cites] Anal Biochem. 1991 Aug 1;196(2):207-10 [1663707.001]
  • [Cites] Curr Opin Cell Biol. 1995 Jun;7(3):337-43 [7662363.001]
  • [Cites] Cell Prolif. 1999 Apr-Jun;32(2-3):119-29 [10535358.001]
  • [Cites] Virology. 2001 Nov 25;290(2):329-41 [11883197.001]
  • [Cites] Immunol Lett. 1996 Apr;50(1-2):51-7 [8793559.001]
  • [Cites] Anal Biochem. 1988 Mar;169(2):400-4 [3382012.001]
  • [Cites] Biochim Biophys Acta. 1990 Aug 13;1054(1):114-8 [2166588.001]
  • [Cites] FEBS Lett. 1999 Mar 5;446(1):113-6 [10100625.001]
  • [Cites] Cytometry. 2000 Feb 1;39(2):151-7 [10679733.001]
  • [Cites] Blood. 2002 May 1;99(9):3390-7 [11964308.001]
  • [Cites] Trends Biochem Sci. 1996 Oct;21(10):359-64 [8918187.001]
  • [Cites] Therapie. 2000 Jan-Feb;55(1):165-9 [10860020.001]
  • [Cites] Annu Rev Immunol. 1992;10:267-93 [1590988.001]
  • [Cites] J Biol Chem. 1985 Mar 25;260(6):3440-50 [3838314.001]
  • [Cites] J Natl Cancer Inst. 1974 Sep;53(3):655-60 [4547172.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2172-82 [8822937.001]
  • [Cites] Adv Exp Med Biol. 1994;370:815-20 [7661030.001]
  • [Cites] Biophys J. 1995 Mar;68(3):988-96 [7756561.001]
  • [Cites] Physiol Rev. 1994 Jul;74(3):595-636 [8036248.001]
  • [Cites] Chem Phys Lipids. 1991 Mar;57(2-3):375-99 [2054913.001]
  • [Cites] Eur J Immunol. 1995 Jun;25(6):1798-801 [7615011.001]
  • [Cites] Pharmacol Ther. 1994;63(1):37-122 [7972344.001]
  • [Cites] Annu Rev Biochem. 2000;69:217-45 [10966458.001]
  • [Cites] Int Rev Exp Pathol. 1991;32:223-54 [1677933.001]
  • [Cites] J Biol Chem. 1994 Jul 1;269(26):17359-62 [8021233.001]
  • [Cites] Biophys J. 1996 Jan;70(1):358-69 [8770212.001]
  • [Cites] Int Immunopharmacol. 2001 Jan;1(1):63-74 [11367518.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1564-71 [11587214.001]
  • (PMID = 16151703.001).
  • [ISSN] 0022-2631
  • [Journal-full-title] The Journal of membrane biology
  • [ISO-abbreviation] J. Membr. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cryoprotective Agents; 0 / Proto-Oncogene Proteins c-bcl-2; EC 3.1.4.- / Phosphoric Diester Hydrolases; SY7Q814VUP / Calcium; YOW8V9698H / Dimethyl Sulfoxide
  •  go-up   go-down


27. Gaujoux R, Seoighe C: A flexible R package for nonnegative matrix factorization. BMC Bioinformatics; 2010;11:367
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Humans. Leukemia, Myeloid, Acute / genetics. Oligonucleotide Array Sequence Analysis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Software

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1999 Oct 21;401(6755):788-91 [10548103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12323-8 [19590007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9 [15016911.001]
  • [Cites] Genome Biol. 2004;5(10):R80 [15461798.001]
  • [Cites] BMC Bioinformatics. 2005;6:162 [15987504.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):3970-5 [16244221.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2006 Mar;28(3):403-15 [16526426.001]
  • [Cites] BMC Bioinformatics. 2006;7:78 [16503973.001]
  • [Cites] BMC Bioinformatics. 2006;7:175 [16569230.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5959-64 [17389406.001]
  • [Cites] Bioinformatics. 2007 Jun 15;23(12):1495-502 [17483501.001]
  • [Cites] Pac Symp Biocomput. 2008;:267-78 [18229692.001]
  • [Cites] PLoS Comput Biol. 2008;4(7):e1000029 [18654623.001]
  • [Cites] Bioinformatics. 2008 Dec 1;24(23):2684-90 [18852176.001]
  • [Cites] Bioinformatics. 2009 Feb 15;25(4):545-7 [19131367.001]
  • [Cites] Genome Res. 2003 Jul;13(7):1706-18 [12840046.001]
  • (PMID = 20598126.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2912887
  •  go-up   go-down


28. Ilić V, Milosević-Jovcić N, Petrović S, Marković D, Stefanović G, Ristić T: Glycosylation of IgG B cell receptor (IgG BCR) in multiple myeloma: relationship between sialylation and the signal activity of IgG BCR. Glycoconj J; 2008 May;25(4):383-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycosylation of IgG B cell receptor (IgG BCR) in multiple myeloma: relationship between sialylation and the signal activity of IgG BCR.
  • Little is known about the glycosylation of the isotype switched B cell receptor (BCR) in multiple myeloma, and the way it might affect receptor function.
  • In this work IgG BCRs isolated from the individual lysates of peripheral blood lymphocytes (PBL) of 32 patients with IgG multiple myeloma and healthy controls were investigated for the expression of sialic acid (SA), galactose (Gal) and N-acetylglucosamine (GlcNAc), the sugars known to specify the glycoforms of human serum IgG.
  • The degree of glycosylation and signaling status of all 32 isolated myeloma IgG BCRs were correlated and compared with the glycosylation of the IgG paraproteins isolated from sera of the same patients.
  • It was shown that BCR IgG in myeloma is more heavily sialylated when compared with normal controls, that the increased sialylation of IgG BCR is associated with higher levels of tyrosine phosphorylation (signaling activity) of the IgG BCR supramolecular complex and that BCR IgG and serum IgG paraprotein from the same patient differed in all cases in the levels of terminal sugar expression.
  • The results suggest that the development of the malignant clone in MM from post-switch B cells expressing IgG BCR at their surfaces to plasma cells secreting IgG paraprotein may be followed by permanent glycosylation changes in the IgG molecules.
  • [MeSH-major] Immunoglobulin G / metabolism. Multiple Myeloma / immunology. N-Acetylneuraminic Acid / metabolism. Receptors, Antigen, B-Cell / metabolism. Signal Transduction / immunology
  • [MeSH-minor] Acetylglucosamine / metabolism. Galactose / metabolism. Glycosylation. Humans. Lectins / metabolism. Paraproteins / immunology. Phosphorylation. Phosphotyrosine / metabolism

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2007 Apr 16;204(4):759-69 [17420266.001]
  • [Cites] Adv Exp Med Biol. 1998;435:95-103 [9498069.001]
  • [Cites] J Immunol Methods. 1990 Jul 20;131(1):127-36 [2199577.001]
  • [Cites] Eur J Haematol. 1989 Sep;43(3):191-4 [2806473.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):549-58 [10759713.001]
  • [Cites] Cancer Res. 1990 Sep 1;50(17):5345-50 [2386941.001]
  • [Cites] Science. 2006 Aug 4;313(5787):670-3 [16888140.001]
  • [Cites] Mol Immunol. 1991 Jan-Feb;28(1-2):51-6 [2011129.001]
  • [Cites] Science. 1995 Jul 14;269(5221):242-4 [7618087.001]
  • [Cites] J Exp Med. 2002 May 6;195(9):1199-205 [11994425.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Aug;21(8):913-7 [4043176.001]
  • [Cites] Haematologica. 2004 May;89(5):541-6 [15136216.001]
  • [Cites] Immunol Invest. 1998 Jan-Feb;27(1-2):57-72 [9561918.001]
  • [Cites] Biochemistry. 1987 Feb 24;26(4):1137-44 [3567160.001]
  • [Cites] J Exp Med. 2007 Apr 16;204(4):747-58 [17420268.001]
  • [Cites] J Clin Pathol. 1998 Nov;51(11):825-30 [10193323.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):182-8 [11812996.001]
  • [Cites] Eur J Haematol. 1989 Mar;42(3):289-92 [2924892.001]
  • [Cites] Leuk Lymphoma. 1995 Jul;18(3-4):221-9 [8535186.001]
  • [Cites] Science. 2002 Dec 20;298(5602):2392-5 [12493916.001]
  • [Cites] Ann Hematol. 2007 Dec;86(12):905-12 [17701175.001]
  • [Cites] J Immunol Methods. 2007 Sep 30;326(1-2):116-26 [17714731.001]
  • [Cites] Eur J Immunol. 1992 May;22(5):1149-55 [1577059.001]
  • [Cites] J Immunol. 1994 Mar 1;152(5):2157-62 [8133032.001]
  • [Cites] J Immunol. 1990 Jun 1;144(11):4101-9 [2187925.001]
  • [Cites] Leuk Lymphoma. 1996 Aug;22(5-6):375-83 [8882950.001]
  • [Cites] Clin Chem. 1988 Sep;34(9):1839-42 [3138046.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2933-40 [15591116.001]
  • [Cites] Biochem J. 1990 Jun 15;268(3):529-37 [2363690.001]
  • [Cites] Glycoconj J. 1997 Jun;14(4):489-92 [9249147.001]
  • [Cites] Immunol Rev. 1998 Jun;163:59-76 [9700502.001]
  • [Cites] Mol Immunol. 1995 Sep;32(13):931-40 [7476998.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Immunol Res. 1998;17(1-2):155-62 [9479577.001]
  • [Cites] J Immunol. 1982 Nov;129(5):2016-20 [6811655.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2562-8 [11895794.001]
  • [Cites] Immunity. 1997 May;6(5):509-17 [9175829.001]
  • [Cites] Leukemia. 2006 Mar;20(3):530-4 [16437152.001]
  • [Cites] Br J Haematol. 2005 Sep;130(6):878-89 [16156858.001]
  • [Cites] Lab Invest. 1997 Oct;77(4):333-44 [9354768.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7405-15 [17197448.001]
  • [Cites] Int Immunol. 2006 Apr;18(4):603-11 [16497829.001]
  • [Cites] Cell Immunol. 1998 Feb 25;184(1):1-11 [9626330.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):945-56 [12461567.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):529-38 [10024532.001]
  • (PMID = 18188696.001).
  • [ISSN] 1573-4986
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G; 0 / Lectins; 0 / Paraproteins; 0 / Receptors, Antigen, B-Cell; 21820-51-9 / Phosphotyrosine; GZP2782OP0 / N-Acetylneuraminic Acid; V956696549 / Acetylglucosamine; X2RN3Q8DNE / Galactose
  •  go-up   go-down


29. Rubin CS, Holmes AK, Belson MG, Jones RL, Flanders WD, Kieszak SM, Osterloh J, Luber GE, Blount BC, Barr DB, Steinberg KK, Satten GA, McGeehin MA, Todd RL: Investigating childhood leukemia in Churchill County, Nevada. Environ Health Perspect; 2007 Jan;115(1):151-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Environmental Exposure / analysis. Leukemia, Myeloid, Acute / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Epidemiol. 2000 Feb 1;151(3):231-40 [10670547.001]
  • [Cites] Epidemiology. 1995 Nov;6(6):575-6 [8589086.001]
  • [Cites] Cancer Causes Control. 2000 Apr;11(4):303-7 [10843442.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2000 Nov-Dec;10(6 Pt 2):672-81 [11138659.001]
  • [Cites] Arch Environ Health. 2001 Mar-Apr;56(2):157-66 [11339680.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Int Arch Occup Environ Health. 1996;68(3):183-7 [8919847.001]
  • [Cites] Lancet. 1997 Feb 1;349(9048):344-9 [9024390.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):3-16 [9045302.001]
  • [Cites] IARC Sci Publ. 1996;(135):1-20 [9103929.001]
  • [Cites] Blood. 1997 Dec 1;90(11):4243-51 [9373234.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):585-90 [10408870.001]
  • [Cites] Environ Health Perspect. 2005 Feb;113(2):192-200 [15687057.001]
  • [Cites] Cancer Invest. 2005;23(1):60-75 [15779869.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):138-45 [17366834.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):158-64 [17366837.001]
  • [Cites] J Anal Toxicol. 2002 Jul-Aug;26(5):245-52 [12166810.001]
  • [Cites] Cancer Invest. 2002;20(5-6):810-6 [12206154.001]
  • [Cites] Anal Chem. 2004 May 1;76(9):2453-61 [15117183.001]
  • [Cites] Environ Health Perspect. 2004 May;112(6):766-71 [15121523.001]
  • [Cites] Arch Environ Contam Toxicol. 2004 Apr;46(3):281-8 [15195798.001]
  • [Cites] CA Cancer J Clin. 2004 Sep-Oct;54(5):273-80 [15371285.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 20;96(20):1549-56 [15494605.001]
  • [Cites] Public Health Rep. 2004 Nov-Dec;119(6):521-35 [15504444.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2420-3 [4230121.001]
  • [Cites] South Med J. 1976 Dec;69(12):1598-1602 [1019679.001]
  • [Cites] JAMA. 1988 May 13;259(18):2715-9 [2833632.001]
  • [Cites] Am J Epidemiol. 1990 Jul;132(1):1-8 [2356803.001]
  • [Cites] Am J Epidemiol. 1990 Jul;132(1 Suppl):S43-7 [2162625.001]
  • [Cites] Am J Epidemiol. 1990 Jul;132(1 Suppl):S6-13 [2356837.001]
  • [Cites] Lancet. 1990 Sep 8;336(8715):577-82 [1975376.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]
  • [Cites] Environ Health Perspect. 1990 Nov;89:145-51 [2088741.001]
  • [Cites] Sci Total Environ. 1992 Dec 15;127(1-2):173-85 [1480954.001]
  • [Cites] BMJ. 1993 Apr 3;306(6882):930 [8490436.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] Br J Cancer. 1995 Dec;72(6):1339-49 [8519643.001]
  • [Cites] J Chromatogr Sci. 2000 Feb;38(2):49-54 [10677832.001]
  • (PMID = 17366836.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Environmental Pollutants; 0 / Metals; 0 / Pesticides; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ PMC1797848
  •  go-up   go-down


30. Amirghofran Z, Bahmani M, Azadmehr A, Javidnia K: Induction of apoptosis in leukemia cell lines by Linum persicum and Euphorbia cheiradenia. J Cancer Res Clin Oncol; 2006 Jul;132(7):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in leukemia cell lines by Linum persicum and Euphorbia cheiradenia.
  • PURPOSE: In the present study two medicinal herbs Linum persicum and Euphorbia cheiradenia that are native to Iran were tested for their possible anticancer effect and induction of apoptosis on human tumor cell lines including leukemia cell lines.
  • METHODS: The effect of methanolic extracts of the herbs on the inhibition of cell proliferation was assessed by MTT colorimetric assay.
  • K562 and Jurkat cell lines treated with the extracts were analyzed for the induction of apoptosis by flow cytometry using propidium iodide staining.
  • DNA fragmentation analysis was performed.
  • RESULTS: Various concentrations of L. persicum and E. cheiradenia showed inhibitory effects on different cell lines.
  • Two leukemic lines including K562 and Jurkat were the most sensitive cells for L. persicum with IC50 of 0.1 and 10 mug/ml, respectively.
  • In the cultures of tumor cell lines treated with E. cheiradenia, the main inhibitory effects was for Jurkat cells with IC50 of 12.5 microg/ml.
  • Results indicated a dose-dependent accumulation of cells in the sub-G1 phase.
  • Study of internucleosomal DNA fragmentation showed a typical DNA laddering in agarose gels for both extracts.
  • CONCLUSION: The present study showed cytotoxic activity of both herbs on tumor cell lines and suggests that this effect may in part be due to the induction of apoptosis in leukemic cells.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Apoptosis. Euphorbia. Flax. Leukemia / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Colorimetry / methods. Coloring Agents. DNA Fragmentation. Dose-Response Relationship, Drug. Flow Cytometry. HeLa Cells. Humans. Jurkat Cells. K562 Cells. Phytotherapy / methods. Plant Extracts / therapeutic use. Tetrazolium Salts. Thiazoles

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2004 Dec;3(12):1651-8 [15634659.001]
  • [Cites] Science. 1976 Feb 13;191(4227):571-2 [1251193.001]
  • [Cites] Immunol Res. 2005;33(2):149-66 [16234581.001]
  • [Cites] J Pharm Sci. 1975 Jan;64(1):95-8 [1169315.001]
  • [Cites] Phytochemistry. 2000 May;54(2):115-20 [10872202.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2833-9 [15087400.001]
  • [Cites] J Nat Prod. 2004 Feb;67(2):269-72 [14987068.001]
  • [Cites] J Nat Prod. 2004 May;67(5):902-4 [15165162.001]
  • [Cites] Fitoterapia. 2005 Jan;76(1):50-3 [15664462.001]
  • [Cites] Neoplasma. 2005;52(5):425-9 [16151578.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Feb;3(1):67-81 [12570662.001]
  • [Cites] Leuk Lymphoma. 2002 May;43(5):983-7 [12148909.001]
  • [Cites] J Pharm Biomed Anal. 2004 May 28;35(3):441-7 [15137970.001]
  • [Cites] Nucleic Acids Res. 1994 Dec 11;22(24):5506-7 [7816645.001]
  • [Cites] Bioorg Med Chem. 2003 Nov 17;11(23):5221-7 [14604686.001]
  • [Cites] J Nat Prod. 2001 Aug;64(8):1064-8 [11520228.001]
  • [Cites] Chem Pharm Bull (Tokyo). 2003 Apr;51(4):431-4 [12673000.001]
  • [Cites] Zhong Yao Cai. 2002 Feb;25(2):135-9 [14740647.001]
  • [Cites] J Med Chem. 2002 Jun 6;45(12):2425-31 [12036352.001]
  • [Cites] Biochem Pharmacol. 2002 Mar 1;63(5):951-7 [11911847.001]
  • [Cites] J Nat Prod. 1992 Jan;55(1):102-10 [1602298.001]
  • [Cites] J Nat Prod. 1991 May-Jun;54(3):823-9 [1955882.001]
  • [Cites] Appl Microbiol Biotechnol. 2001 Mar;55(2):135-42 [11330705.001]
  • (PMID = 16477442.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Coloring Agents; 0 / Plant Extracts; 0 / Tetrazolium Salts; 0 / Thiazoles; EUY85H477I / thiazolyl blue
  •  go-up   go-down


31. Schneider T, Karl S, Moore LR, Chalmers JJ, Williams PS, Zborowski M: Sequential CD34 cell fractionation by magnetophoresis in a magnetic dipole flow sorter. Analyst; 2010 Jan;135(1):62-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential CD34 cell fractionation by magnetophoresis in a magnetic dipole flow sorter.
  • Cell separation and fractionation based on fluorescent and magnetic labeling procedures are common tools in contemporary research.
  • These techniques rely on binding of fluorophores or magnetic particles conjugated to antibodies to target cells.
  • Cell surface marker expression levels within cell populations vary with progression through the cell cycle.
  • In an earlier work we showed the reproducible magnetic fractionation (single pass) of the Jurkat cell line based on the population distribution of CD45 surface marker expression.
  • Here we present a study on magnetic fractionation of a stem and progenitor cell (SPC) population using the established acute myelogenous leukemia cell line KG-1a as a cell model.
  • The cells express a CD34 cell surface marker associated with the hematopoietic progenitor cell activity and the progenitor cell lineage commitment.
  • The CD34 expression level is approximately an order of magnitude lower than that of the CD45 marker, which required further improvements of the magnetic fractionation apparatus.
  • The cells were immunomagnetically labeled using a sandwich of anti-CD34 antibody-phycoerythrin (PE) conjugate and anti-PE magnetic nanobead and fractionated into eight components using a continuous flow dipole magnetophoresis apparatus.
  • The CD34 marker expression distribution between sorted fractions was measured by quantitative PE flow cytometry (using QuantiBRITE PE calibration beads), and it was shown to be correlated with the cell magnetophoretic mobility distribution.
  • A flow outlet addressing scheme based on the concept of the transport lamina thickness was used to control cell distribution between the eight outlet ports.
  • The fractional cell distributions showed good agreement with numerical simulations of the fractionation based on the cell magnetophoretic mobility distribution in the unsorted sample.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biochem Biophys Methods. 2000 Jul 10;44(1-2):115-30 [10889282.001]
  • [Cites] J Chromatogr A. 2000 Dec15;903(1-2):99-116 [11153960.001]
  • [Cites] Nat Biotechnol. 2001 May;19(5):461-5 [11329017.001]
  • [Cites] Cytometry. 2001 Dec 15;46(6):336-9 [11754202.001]
  • [Cites] Anal Chem. 2002 Jun 1;74(11):2451-7 [12069222.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1819-27 [12324512.001]
  • [Cites] Anal Chem. 2003 Mar 15;75(6):1365-73 [12659197.001]
  • [Cites] J Am Chem Soc. 2003 Oct 22;125(42):12704-5 [14558807.001]
  • [Cites] Anal Chem. 2003 Dec 1;75(23):6687-95 [14640746.001]
  • [Cites] Lab Chip. 2003 Feb;3(1):22-7 [15100801.001]
  • [Cites] Blood. 1980 Aug;56(2):265-73 [6967340.001]
  • [Cites] Anal Chem. 1987 Jan 1;59(1):28-37 [3826632.001]
  • [Cites] J Chromatogr. 1990 Apr 20;504(2):247-58 [2341520.001]
  • [Cites] Electrophoresis. 1992 Sep-Oct;13(9-10):674-6 [1459090.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Leuk Lymphoma. 1995;18 Suppl 1:25-30 [7496351.001]
  • [Cites] ASAIO J. 1996 Sep-Oct;42(5):M666-71 [8944964.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3960-6 [9166833.001]
  • [Cites] J Biochem Biophys Methods. 1998 Sep 24;37(1-2):11-33 [9825297.001]
  • [Cites] Anal Chem. 1999 Sep 1;71(17):3799-807 [10489528.001]
  • [Cites] Analyst. 2005 Apr;130(4):427-32 [15776150.001]
  • [Cites] Cytometry A. 2005 Aug;66(2):103-8 [15973696.001]
  • [Cites] Lab Chip. 2006 Jan;6(1):24-38 [16372066.001]
  • [Cites] Anal Chem. 2006 Feb 1;78(3):695-701 [16448041.001]
  • [Cites] J Biochem Biophys Methods. 2006 Jul 31;68(1):1-21 [16675023.001]
  • [Cites] Nature. 2006 Jun 29;441(7097):1075-9 [16810242.001]
  • [Cites] Biotechnol Bioeng. 2007 Apr 15;96(6):1139-54 [17009321.001]
  • [Cites] Lab Chip. 2007 Dec;7(12):1681-8 [18030387.001]
  • [Cites] Nature. 2007 Dec 20;450(7173):1235-9 [18097410.001]
  • [Cites] Lab Chip. 2008 Aug;8(8):1386-93 [18651083.001]
  • [Cites] Anal Chem. 2008 Aug 15;80(16):6365-72 [18510341.001]
  • [Cites] Anal Chem. 2008 Sep 15;80(18):7105-15 [18698797.001]
  • (PMID = 20024182.001).
  • [ISSN] 1364-5528
  • [Journal-full-title] The Analyst
  • [ISO-abbreviation] Analyst
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA062349-15; United States / NCI NIH HHS / CA / R01 CA062349; United States / NCI NIH HHS / CA / CA62349; United States / NCI NIH HHS / CA / R01 CA062349-15
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Immobilized; 0 / Antigens, CD34; 11016-17-4 / Phycoerythrin
  • [Other-IDs] NLM/ NIHMS183388; NLM/ PMC3509203
  •  go-up   go-down


32. Vlaanderen J, Vermeulen R, Heederik D, Kromhout H, ECNIS Integrated Risk Assessment Group, European Union Network Of Excellence: Guidelines to evaluate human observational studies for quantitative risk assessment. Environ Health Perspect; 2008 Dec;116(12):1700-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines to evaluate human observational studies for quantitative risk assessment.
  • BACKGROUND: Careful evaluation of the quality of human observational studies (HOS) is required to assess the suitability of HOS for quantitative risk assessment (QRA).
  • In particular, the quality of quantitative exposure assessment is a crucial aspect of HOS to be considered for QRA.
  • OBJECTIVE: We aimed to develop guidelines for the evaluation of HOS for QRA and to apply these guidelines to case-control and cohort studies on the relation between exposure to benzene and acute myeloid leukemia (AML).
  • METHODS: We developed a three-tiered framework specific for the evaluation of HOS for QRA and used it to evaluate HOS on the relation between exposure to benzene and AML.
  • RESULTS: The developed framework consists of 20 evaluation criteria.
  • A specific focus of the framework was on the quality of exposure assessment applied in HOS.
  • Seven HOS on the relation of benzene and AML were eligible for evaluation.
  • Of these studies, five were suitable for QRA and were ranked based on the quality of the study design, conduct, and reporting on the study.
  • CONCLUSION: The developed guidelines facilitate a structured evaluation that is transparent in its application and harmonizes the evaluation of HOS for QRA.
  • With the application of the guidelines, it was possible to identify studies suitable for QRA of benzene and AML and rank these studies based on their quality.
  • Application of the guidelines in QRA will be a valuable addition to the assessment of the weight of evidence of HOS for QRA.
  • [MeSH-major] Guidelines as Topic. Risk Assessment / methods
  • [MeSH-minor] Benzene / toxicity. Carcinogens / toxicity. Case-Control Studies. Cohort Studies. Humans. Leukemia, Myeloid, Acute / chemically induced

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1994 Sep;26(3):383-400 [7977412.001]
  • [Cites] Leuk Lymphoma. 1994 Jun;14(1-2):91-102 [7920231.001]
  • [Cites] Am J Public Health. 1995 Apr;85(4):484-91 [7702110.001]
  • [Cites] Epidemiology. 2007 Nov;18(6):805-35 [18049195.001]
  • [Cites] Br J Ind Med. 1987 Jun;44(6):382-95 [3606967.001]
  • [Cites] Int J Epidemiol. 1988 Dec;17(4):970-4 [3225115.001]
  • [Cites] Environ Health Perspect. 1989 Jul;82:189-91 [2792040.001]
  • [Cites] Regul Toxicol Pharmacol. 1999 Dec;30(3):259-67 [10620475.001]
  • [Cites] Ann N Y Acad Sci. 1999;895:141-55 [10676414.001]
  • [Cites] Ann Occup Hyg. 2000 Jun;44(4):301-20 [10831734.001]
  • [Cites] Environ Health Perspect. 2000 Oct;108(10):997-1002 [11049823.001]
  • [Cites] Food Chem Toxicol. 2002 Feb-Mar;40(2-3):387-424 [11893402.001]
  • [Cites] Am J Ind Med. 2002 Aug;42(2):87-97 [12125084.001]
  • [Cites] Ann Occup Hyg. 2002 Apr;46(3):279-85 [12176715.001]
  • [Cites] Ann Occup Hyg. 2002 Apr;46(3):287-97 [12176716.001]
  • [Cites] Occup Environ Med. 2003 Sep;60(9):676-9 [12937190.001]
  • [Cites] Epidemiology. 2003 Sep;14(5):569-77 [14501272.001]
  • [Cites] Am J Ind Med. 2004 Jan;45(1):113-22 [14691975.001]
  • [Cites] Occup Environ Med. 2004 Mar;61(3):270-4 [14985523.001]
  • [Cites] Arch Environ Health. 1978 Jan-Feb;33(1):3-10 [629594.001]
  • [Cites] Br J Ind Med. 1986 Oct;43(10):685-91 [3465366.001]
  • [Cites] N Engl J Med. 1987 Apr 23;316(17):1044-50 [3561457.001]
  • [Cites] Occup Environ Med. 1995 Jun;52(6):380-4 [7627314.001]
  • [Cites] Regul Toxicol Pharmacol. 1995 Apr;21(2):307-21 [7644720.001]
  • [Cites] Stat Med. 1997 Mar 15;16(5):505-13 [9089959.001]
  • [Cites] Epidemiology. 1997 May;8(3):318-20 [9115030.001]
  • [Cites] Occup Environ Med. 1997 Mar;54(3):152-66 [9155776.001]
  • [Cites] Occup Environ Med. 1997 Mar;54(3):167-75 [9155777.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 16;89(14):1065-71 [9230889.001]
  • [Cites] J Expo Anal Environ Epidemiol. 1997 Oct-Dec;7(4):411-37 [9306230.001]
  • [Cites] Am J Ind Med. 1998 Jul;34(1):49-56 [9617387.001]
  • [Cites] J Environ Health. 2004 Nov;67(4):16-9 [15552701.001]
  • [Cites] Chem Biol Interact. 2005 May 30;153-154:23-32 [15935797.001]
  • [Cites] Scand J Work Environ Health. 2005;31 Suppl 1:110-4; discussion 63-5 [16190157.001]
  • [Cites] Risk Anal. 2005 Dec;25(6):1545-57 [16506981.001]
  • [Cites] Regul Toxicol Pharmacol. 2006 Apr;44(3):294-310 [16497421.001]
  • [Cites] Hum Exp Toxicol. 2006 Mar;25(3):147-55 [16634334.001]
  • [Cites] Int Arch Occup Environ Health. 2006 Sep;79(8):621-9 [16506045.001]
  • [Cites] Health Phys. 2006 Dec;91(6):582-91 [17099402.001]
  • [Cites] Regul Toxicol Pharmacol. 1992 Apr;15(2 Pt 1):180-221 [1626069.001]
  • [Cites] J Toxicol Environ Health. 1992 Jul;36(3):177-231 [1629933.001]
  • [Cites] Am J Epidemiol. 1993 Feb 15;137(4):463-71 [8460627.001]
  • [Cites] Risk Anal. 1994 Apr;14(2):147-54 [8008923.001]
  • [Cites] Risk Anal. 1994 Apr;14(2):155-61 [8008924.001]
  • [Cites] Am J Ind Med. 1994 Sep;26(3):401-11 [7977413.001]
  • (PMID = 19079723.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; J64922108F / Benzene
  • [Other-IDs] NLM/ PMC2599766
  • [Keywords] NOTNLM ; benzene / epidemiology / evidence-based medicine / human observational studies / quantitative risk assessment
  •  go-up   go-down


33. Mennink-Kersten MA, Ruegebrink D, Wasei N, Melchers WJ, Verweij PE: In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol; 2006 May;44(5):1711-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis.
  • Aspergillus markers are becoming increasingly important for the early diagnosis of invasive aspergillosis.
  • The kinetics of release of these surrogate markers, however, is largely unknown.
  • We investigated the release of beta-(1-5)-galactofuranosyl (galf) antigens (Platelia Aspergillus), 1,3-beta-D-glucan (BG) (Fungitell), and DNA (PCR) in an in vitro model of Aspergillus fumigatus.
  • The results showed that release is correlated to the growth phase of the fungus, which depends on available nutrients.
  • Whereas galf antigens and BG are released during logarithmic growth, DNA is released only after mycelium breakdown.
  • During early logarithmic growth, galf antigens seem to be released somewhat earlier than BG.
  • Furthermore, galf antigen concentrations of more than 120,000 times the serum cutoff value (0.5 ng/ml) can be measured, while BG concentrations reach a value only 978 times the serum cutoff value (60 pg/ml).
  • During lytical growth, release of galf antigens further increased to a maximum level, which depended on pH.
  • After that, the concentration of galf antigens stayed high (pH 7.4) or decreased to zero within 4 days (pH 5.0).
  • In contrast to galf antigens, BG concentration decreased after 1 day of growth.
  • The decrease of galf components seems to be due to the enzyme beta-galactofuranosidase, which is able to destroy galf epitopes and whose activity fluctuates in the culture filtrates in parallel with galf antigen concentration.
  • Fungal DNA seems to be released only due to autolysis caused by nutrient limitation.
  • In conclusion, several factors clearly influence the release of surrogate markers in vitro.
  • These same factors might also play a role at the infection site of Aspergillus disease in humans.
  • [MeSH-major] Aspergillosis / diagnosis. Aspergillus fumigatus / metabolism
  • [MeSH-minor] Antigens, Fungal / metabolism. Biomarkers / metabolism. DNA, Fungal / genetics. DNA, Fungal / metabolism. Galactose / analogs & derivatives. Galactose / immunology. Galactose / metabolism. Glycoside Hydrolases / metabolism. Humans. beta-Glucans / metabolism

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2733-41 [15184460.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):463-8 [15160907.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 15;170(6):580-1 [15355869.001]
  • [Cites] J Clin Microbiol. 2004 Sep;42(9):4154-7 [15365004.001]
  • [Cites] J Biol Chem. 1977 May 25;252(10):3219-26 [863879.001]
  • [Cites] J Appl Bacteriol. 1989 Apr;66(4):311-7 [2502527.001]
  • [Cites] Infect Immun. 1992 Jun;60(6):2237-45 [1375195.001]
  • [Cites] J Bacteriol. 1992 Oct;174(19):6096-102 [1383191.001]
  • [Cites] J Med Vet Mycol. 1992;30(4):275-80 [1432487.001]
  • [Cites] J Clin Microbiol. 1994 Jul;32(7):1710-7 [7929762.001]
  • [Cites] Infect Immun. 1994 Dec;62(12):5424-33 [7960122.001]
  • [Cites] Lancet. 1995 Jan 7;345(8941):17-20 [7799700.001]
  • [Cites] J Clin Microbiol. 1995 Feb;33(2):497-500 [7714217.001]
  • [Cites] J Med Vet Mycol. 1995 Jan-Feb;33(1):9-14 [7650587.001]
  • [Cites] J Clin Lab Anal. 1995;9(5):334-9 [8531015.001]
  • [Cites] Carbohydr Res. 1999 Aug 15;320(3-4):176-82 [10573856.001]
  • [Cites] Lancet Infect Dis. 2004 Jun;4(6):349-57 [15172343.001]
  • [Cites] J Clin Microbiol. 1995 Dec;33(12):3150-3 [8586691.001]
  • [Cites] J Bacteriol. 1997 Feb;179(4):1186-92 [9023201.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):315-21 [9030754.001]
  • [Cites] J Bacteriol. 1997 May;179(10):3154-63 [9150209.001]
  • [Cites] Glycobiology. 1997 Jun;7(4):463-8 [9184826.001]
  • [Cites] Clin Infect Dis. 1998 Jun;26(6):1407-12 [9636871.001]
  • [Cites] J Clin Microbiol. 1999 Apr;37(4):925-30 [10074503.001]
  • [Cites] J Clin Microbiol. 2005 Jan;43(1):299-305 [15634986.001]
  • [Cites] Eukaryot Cell. 2005 Jul;4(7):1308-16 [16002656.001]
  • [Cites] Clin Infect Dis. 2005 Sep 1;41(5):654-9 [16080087.001]
  • [Cites] Lancet Infect Dis. 2005 Oct;5(10):609-22 [16183515.001]
  • [Cites] J Clin Microbiol. 2000 Apr;38(4):1434-8 [10747121.001]
  • [Cites] Lancet. 2000 Feb 5;355(9202):423-4 [10841117.001]
  • [Cites] Medicine (Baltimore). 2000 Jul;79(4):250-60 [10941354.001]
  • [Cites] J Clin Microbiol. 2000 Oct;38(10):3830-3 [11015412.001]
  • [Cites] J Clin Microbiol. 2000 Oct;38(10):3900-1 [11015433.001]
  • [Cites] Med Mycol. 2000;38 Suppl 1:147-59 [11204140.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1604-10 [11238098.001]
  • [Cites] J Microbiol Methods. 2001 Apr;44(3):263-9 [11240049.001]
  • [Cites] Br J Haematol. 2001 Apr;113(1):180-4 [11328298.001]
  • [Cites] Biochim Biophys Acta. 2001 Feb 16;1525(1-2):19-28 [11342249.001]
  • [Cites] J Bacteriol. 2001 Jul;183(13):3991-8 [11395463.001]
  • [Cites] Biochim Biophys Acta. 2001 Aug 15;1527(3):112-22 [11479027.001]
  • [Cites] Nat Struct Biol. 2001 Oct;8(10):858-63 [11573090.001]
  • [Cites] Clin Infect Dis. 2001 Nov 1;33(9):1504-12 [11588697.001]
  • [Cites] Carbohydr Res. 2002 May 13;337(10):891-7 [12007471.001]
  • [Cites] J Clin Microbiol. 2002 Jun;40(6):2224-7 [12037092.001]
  • [Cites] Eur J Med Res. 2002 May 31;7(5):227-35 [12069913.001]
  • [Cites] J Infect Dis. 2002 Nov 1;186(9):1297-306 [12402199.001]
  • [Cites] J Clin Microbiol. 2003 Aug;41(8):3922-5 [12904419.001]
  • [Cites] Clin Infect Dis. 2003 Oct 1;37 Suppl 3:S155-6 [12975750.001]
  • [Cites] Glycobiology. 2003 Oct;13(10):681-92 [12851285.001]
  • [Cites] J Clin Microbiol. 2004 Feb;42(2):844-6 [14766869.001]
  • [Cites] Br J Haematol. 2004 Apr;125(2):196-202 [15059142.001]
  • [Cites] Clin Infect Dis. 2004 Jul 15;39(2):199-205 [15307029.001]
  • (PMID = 16672397.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Fungal; 0 / Biomarkers; 0 / DNA, Fungal; 0 / beta-Glucans; 9051-97-2 / beta-1,3-glucan; EC 3.2.1.- / Glycoside Hydrolases; EC 3.2.1.146 / exo-beta-D-galactofuranosidase; X2RN3Q8DNE / Galactose
  • [Other-IDs] NLM/ PMC1479172
  •  go-up   go-down


34. McAleer J, Weber P, Sun J, Butler JE: Antibody repertoire development in fetal and neonatal piglets. XI. The thymic B-cell repertoire develops independently from that in blood and mesenteric lymph nodes. Immunology; 2005 Feb;114(2):171-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody repertoire development in fetal and neonatal piglets. XI. The thymic B-cell repertoire develops independently from that in blood and mesenteric lymph nodes.
  • The origin and function of thymic B cells is currently unresolved.
  • In the present study we compared V(H) gene repertoire diversification in >3500 cloned VDJs (from 11 animals at three time-points, using three to five animals per time-point) that were expressed with immunoglobulin (Ig)M, IgD, IgG, IgA and IgE in thymus, mesenteric lymph nodes (MLN) and peripheral blood B cells (PBB) of newborn piglets and 5-week-old isolator piglets maintained germfree (GF) or colonized with Escherichia coli.
  • The results showed that the repertoire expressed with IgM, IgD, IgG and IgA in PBB and MLN remained polyclonal, undiversified and unselected in piglets maintained GF for 5 weeks, that age and colonization resulted in significant repertoire diversification of IgG and IgA in the MLN and of IgG in blood, that the thymic B-cell repertoire was polyclonal, unaffected by colonization and showed no clonal selection in any isotype, and that the thymic IgA and IgE repertoires were more diverse at birth than the repertoire of any isotype in MLN or PBB.
  • IgD was seldom recovered from the PBB of newborn piglets or at any time-point in thymus, but was recovered in the MLN of all 11 animals examined.
  • The IgD and IgM repertoires in all tissues remained polyclonal and unselected, although V(H) usage by IgD transcripts did not always parallel that of IgM in the same tissue.
  • Therefore, isotype-switched B cells in the thymic medulla cannot be accounted for by immigration of B cells diversified by colonization of the gut, and thymic B cells undergo switch recombination and repertoire diversification before birth without clonal selection.
  • [MeSH-major] B-Lymphocytes / immunology. Immunoglobulin A. Immunoglobulin G. Swine / embryology. Swine / immunology. Thymus Gland / embryology
  • [MeSH-minor] Animals. Animals, Newborn. Antibody Diversity. Fetal Development / immunology. Germ-Free Life. Immunoglobulin Class Switching. Immunoglobulin Heavy Chains. Immunoglobulin Joining Region. Immunoglobulin Variable Region. Reverse Transcriptase Polymerase Chain Reaction

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Anat. 2001 Apr;198(Pt 4):491-5 [11327211.001]
  • [Cites] J Immunol. 1965 Jan;94:172-6 [14253516.001]
  • [Cites] J Immunol. 2001 Aug 15;167(4):1935-44 [11489973.001]
  • [Cites] J Immunol. 2001 Sep 15;167(6):3239-49 [11544311.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):926-34 [11567221.001]
  • [Cites] J Exp Med. 2001 Oct 1;194(7):1003-12 [11581321.001]
  • [Cites] Int Immunol. 2002 Jan;14(1):87-99 [11751756.001]
  • [Cites] Immunobiology. 2001 Dec;204(4):425-33 [11776397.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] Annu Rev Immunol. 2002;20:301-22 [11861605.001]
  • [Cites] Science. 2002 Nov 15;298(5597):1395-401 [12376594.001]
  • [Cites] J Immunol. 2002 Dec 15;169(12):6822-30 [12471114.001]
  • [Cites] J Immunol. 2003 Feb 15;170(4):1781-8 [12574342.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1312-8 [12874220.001]
  • [Cites] J Immunol. 1972 Apr;108(4):1132-5 [4554012.001]
  • [Cites] J Immunol. 1972 Jul;109(1):38-46 [4624676.001]
  • [Cites] Vet Immunol Immunopathol. 1982 Jan;3(1-2):95-146 [7048722.001]
  • [Cites] Cell. 1986 Jan 31;44(2):251-9 [3484682.001]
  • [Cites] J Invest Dermatol. 1988 Jan;90(1):73-7 [2961816.001]
  • [Cites] J Immunol. 1988 May 1;140(9):3228-32 [3129515.001]
  • [Cites] J Exp Med. 1988 Jun 1;167(6):2011-6 [3133445.001]
  • [Cites] Immunogenetics. 1988;28(4):255-9 [2843460.001]
  • [Cites] Thymus. 1988-1989;12(2):77-87 [3150631.001]
  • [Cites] J Exp Med. 1991 Mar 1;173(3):549-59 [1900075.001]
  • [Cites] Leuk Res. 1991;15(1):59-63 [1900090.001]
  • [Cites] Genes Dev. 1991 Aug;5(8):1367-76 [1714414.001]
  • [Cites] Leuk Lymphoma. 1995 Jul;18(3-4):357-60 [8535206.001]
  • [Cites] Immunology. 1996 Mar;87(3):487-92 [8778038.001]
  • [Cites] Immunity. 1996 Jun;4(6):603-13 [8673707.001]
  • [Cites] Immunology. 1996 Jul;88(3):331-9 [8774347.001]
  • [Cites] J Immunol. 1997 Jun 1;158(11):5554-9 [9164980.001]
  • [Cites] Stem Cells. 1997;15(6):430-6 [9402655.001]
  • [Cites] Vet Immunol Immunopathol. 1997 Sep 19;58(3-4):301-8 [9436273.001]
  • [Cites] J Immunol. 1998 May 15;160(10):4801-9 [9590227.001]
  • [Cites] Anal Biochem. 1998 Jun 15;260(1):71-9 [9648655.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):5070-8 [9794445.001]
  • [Cites] Eur J Immunol. 1999 Apr;29(4):1219-27 [10229089.001]
  • [Cites] Blood. 2000 Apr 15;95(8):2610-6 [10753841.001]
  • [Cites] J Immunol. 2000 May 15;164(10):5221-6 [10799882.001]
  • [Cites] Immunology. 2000 May;100(1):119-30 [10809967.001]
  • [Cites] Immunobiology. 2000 Apr;201(5):515-26 [10834310.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1832-9 [10925261.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):6999-7010 [11120827.001]
  • [Cites] Dev Immunol. 2000;8(1):61-74 [11293812.001]
  • [Cites] Blood. 2001 May 1;97(9):2708-15 [11313262.001]
  • [Cites] Curr Opin Immunol. 1999 Apr;11(2):172-9 [10322151.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] J Immunol. 1957 Jan;78(1):56-62 [13406266.001]
  • [Cites] Mol Immunol. 2000 Dec;37(17):1025-34 [11399320.001]
  • (PMID = 15667562.001).
  • [ISSN] 0019-2805
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin G; 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin Joining Region; 0 / Immunoglobulin Variable Region
  • [Other-IDs] NLM/ PMC1782081
  •  go-up   go-down


35. Wlodkowic D, Darzynkiewicz Z: Microfluidics: Emerging prospects for anti-cancer drug screening. World J Clin Oncol; 2010 Nov 10;1(1):18-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microfluidics: Emerging prospects for anti-cancer drug screening.
  • Cancer constitutes a heterogenic cellular system with a high level of spatio-temporal complexity.
  • Recent discoveries by systems biologists have provided emerging evidence that cellular responses to anti-cancer modalities are stochastic in nature.
  • To uncover the intricacies of cell-to-cell variability and its relevance to cancer therapy, new analytical screening technologies are needed.
  • The last decade has brought forth spectacular innovations in the field of cytometry and single cell cytomics, opening new avenues for systems oncology and high-throughput real-time drug screening routines.
  • The up-and-coming microfluidic Lab-on-a-Chip (LOC) technology and micro-total analysis systems (μTAS) are arguably the most promising platforms to address the inherent complexity of cellular systems with massive experimental parallelization and 4D analysis on a single cell level.
  • The vast miniaturization of LOC systems and multiplexing enables innovative strategies to reduce drug screening expenditures while increasing throughput and content of information from a given sample.
  • Small cell numbers and operational reagent volumes are sufficient for microfluidic analyzers and, as such, they enable next generation high-throughput and high-content screening of anti-cancer drugs on patient-derived specimens.
  • Herein we highlight the selected advancements in this emerging field of bioengineering, and provide a snapshot of developments with relevance to anti-cancer drug screening routines.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10687-90 [10995481.001]
  • [Cites] Nature. 2001 Jun 28;411(6841):1016 [11429594.001]
  • [Cites] Anal Chem. 2002 Jun 1;74(11):2451-7 [12069222.001]
  • [Cites] Biochim Biophys Acta. 2002 Aug 31;1564(2):412-20 [12175924.001]
  • [Cites] Electrophoresis. 2003 Nov;24(21):3563-76 [14613181.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):44-9 [15102465.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4220s-4226s [15217962.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):83-7 [15608628.001]
  • [Cites] Lab Chip. 2005 Feb;5(2):129-31 [15672124.001]
  • [Cites] Cytometry A. 2005 Jun;65(2):124-32 [15825181.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5628-34 [16131075.001]
  • [Cites] Anal Chem. 2005 Dec 15;77(24):8050-6 [16351155.001]
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):210-8 [16518374.001]
  • [Cites] Nature. 2006 Jul 27;442(7101):368-73 [16871203.001]
  • [Cites] Nature. 2006 Jul 27;442(7101):403-11 [16871208.001]
  • [Cites] Lab Chip. 2006 Aug;6(8):974-80 [16874365.001]
  • [Cites] Lab Chip. 2006 Nov;6(11):1445-9 [17066168.001]
  • [Cites] Cell Prolif. 2006 Dec;39(6):495-505 [17109634.001]
  • [Cites] Lab Chip. 2007 Apr;7(4):423-40 [17389958.001]
  • [Cites] Ann N Y Acad Sci. 2007 Mar;1098:467-75 [17435153.001]
  • [Cites] Lab Chip. 2007 May;7(5):544-6 [17476370.001]
  • [Cites] Biomed Microdevices. 2008 Apr;10(2):221-31 [17876707.001]
  • [Cites] Biosens Bioelectron. 2008 Oct 15;24(2):290-6 [18511254.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18165-70 [19015523.001]
  • [Cites] Lab Chip. 2008 Dec;8(12):1999-2014 [19023463.001]
  • [Cites] Lab Chip. 2008 Dec;8(12):2015-31 [19023464.001]
  • [Cites] Lab Chip. 2009 May 7;9(9):1254-60 [19370245.001]
  • [Cites] Annu Rev Biomed Eng. 2009;11:235-57 [19413510.001]
  • [Cites] Anal Chem. 2009 Jul 1;81(13):5517-23 [19514700.001]
  • [Cites] Anal Chem. 2009 Aug 15;81(16):6952-9 [19572560.001]
  • [Cites] Leuk Res. 2009 Nov;33(11):1440-7 [19595459.001]
  • [Cites] Lab Chip. 2009 Sep 21;9(18):2659-64 [19704981.001]
  • [Cites] Mol Biosyst. 2009 Oct;5(10):1105-11 [19756299.001]
  • [Cites] Curr Opin Pharmacol. 2009 Oct;9(5):580-8 [19775937.001]
  • [Cites] Lab Chip. 2009 Oct 21;9(20):2881-9 [19789739.001]
  • [Cites] Cancer Res. 2009 Nov 15;69(22):8814-21 [19887613.001]
  • [Cites] Anal Chem. 2009 Dec 1;81(23):9828-33 [19902928.001]
  • [Cites] Apoptosis. 2010 Apr;15(4):401-11 [20091232.001]
  • [Cites] Cytometry A. 2010 Apr;77(4):399-405 [20131407.001]
  • [Cites] Cytometry A. 2010 Jul;77(7):591-606 [20235235.001]
  • [Cites] Anal Bioanal Chem. 2010 Sep;398(1):193-209 [20419489.001]
  • [Cites] Electrophoresis. 2009 Dec;30(24):4166-71 [19938185.001]
  • [Cites] J Chromatogr A. 2003 Feb 14;987(1-2):197-204 [12613812.001]
  • [Cites] Anal Biochem. 2004 Apr 1;327(1):14-22 [15033506.001]
  • [Cites] Lab Chip. 2003 Feb;3(1):22-7 [15100801.001]
  • [Cites] Biomed Microdevices. 2004 Mar;6(1):11-21 [15307440.001]
  • [Cites] Physiol Meas. 2005 Jun;26(3):R73-98 [15798290.001]
  • [Cites] J Biomol Screen. 2005 Dec;10(8):795-805 [16234347.001]
  • [Cites] Cytometry A. 2006 Jan;69(1):36-40 [16541487.001]
  • [Cites] Leuk Lymphoma. 2006 Oct;47(10):2194-202 [17071495.001]
  • [Cites] Rev Sci Instrum. 2008 Apr;79(4):046104 [18447562.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2008;2008:4824-7 [19163796.001]
  • [Cites] Drug Discov Today. 2009 Nov;14(21-22):1037-44 [19647096.001]
  • [Cites] Clin Lab Med. 2009 Sep;29(3):555-60 [19840687.001]
  • [Cites] Chem Biol. 2003 Feb;10(2):123-30 [12618184.001]
  • [Cites] Cytometry A. 2003 Oct;55(2):119-25 [14505317.001]
  • (PMID = 21603306.001).
  • [ISSN] 2218-4333
  • [Journal-full-title] World journal of clinical oncology
  • [ISO-abbreviation] World J Clin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA028704
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3095457
  • [Keywords] NOTNLM ; Anti-cancer drugs / Cancer / Cancer therapy / Cytometry / Cytomics / Drug screening / Lab-on-a-chip / Microfluidics
  •  go-up   go-down


36. Samanic C, Rusiecki J, Dosemeci M, Hou L, Hoppin JA, Sandler DP, Lubin J, Blair A, Alavanja MC: Cancer incidence among pesticide applicators exposed to dicamba in the agricultural health study. Environ Health Perspect; 2006 Oct;114(10):1521-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no apparent risk for non-Hodgkin lymphoma.

  • MedlinePlus Health Information. consumer health - Farm Health and Safety.
  • MedlinePlus Health Information. consumer health - Pesticides.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Dicamba .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):313-8 [12198579.001]
  • [Cites] Ann Occup Hyg. 2002 Mar;46(2):245-60 [12074034.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1375-82 [15367570.001]
  • [Cites] Am J Epidemiol. 2004 Nov 1;160(9):876-85 [15496540.001]
  • [Cites] Food Cosmet Toxicol. 1965 Aug;3(2):299-304 [5861114.001]
  • [Cites] Environ Mol Mutagen. 1990;15(3):131-5 [2331981.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6585-91 [2208120.001]
  • [Cites] Am J Ind Med. 1990;18(3):295-301 [2220834.001]
  • [Cites] Toxicol Lett. 1991 Dec;59(1-3):175-85 [1755024.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2447-55 [1568215.001]
  • [Cites] J Toxicol Environ Health. 1992 Oct;37(2):277-91 [1404486.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):153-6 [8481493.001]
  • [Cites] J Biochem Mol Toxicol. 1998;12(6):339-44 [9736482.001]
  • [Cites] Int J Oncol. 1999 Jan;14(1):79-84 [9863012.001]
  • [Cites] J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2004 May;22(1):37-55 [15845221.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):516-25 [15951670.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Dec 1;161(2):209-18 [10581215.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1155-63 [11700263.001]
  • [Cites] Epidemiology. 2002 Jan;13(1):94-9 [11805592.001]
  • [Cites] Nagoya J Med Sci. 2002 Nov;65(3-4):85-94 [12580534.001]
  • (PMID = 17035136.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides; SJG3M6RY6H / Dicamba
  • [Other-IDs] NLM/ PMC1626435
  •  go-up   go-down


37. Fadul CE, Kingman LS, Meyer LP, Cole BF, Eskey CJ, Rhodes CH, Roberts DW, Newton HB, Pipas JM: A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol; 2008 Nov;90(2):229-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint was tumor response, assessed by MRI.
  • RESULTS: Twenty-six patients with a median age of 55 years were enrolled, with fourteen evaluable for the primary outcome, although all patients were included for secondary endpoints.

  • Genetic Alliance. consumer health - Glioblastoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Aug 12;356(9229):566-7 [10950238.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):708-15 [10673511.001]
  • [Cites] J Neurooncol. 2001 Jan;51(1):41-5 [11349879.001]
  • [Cites] J Neurooncol. 2001 Aug;54(1):31-8 [11763420.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] Oncology (Williston Park). 2002 Apr;16(4 Suppl 3):23-6 [12014864.001]
  • [Cites] Cancer. 2003 May 1;97(9 Suppl):2381-6 [12712460.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2299-304 [12805330.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2940-9 [12912940.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6621-8 [14528287.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1745-8 [14534892.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):21-7 [14769136.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):44-54 [14769140.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):365-75 [15015670.001]
  • [Cites] Neurology. 2004 Aug 10;63(3):535-7 [15304589.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;39(5):417-23 [9054955.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2044-6 [15470485.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):295-301 [15864130.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 25;821(2):221-8 [15936253.001]
  • [Cites] J Pharm Biomed Anal. 2005 Sep 1;39(1-2):299-304 [16085147.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1549-51 [16350272.001]
  • [Cites] Mayo Clin Proc. 2005 Dec;80(12):1568-74 [16342649.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1258-60 [16636248.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16687729.001]
  • [Cites] N Engl J Med. 2006 May 11;354(19):2079-80 [16696148.001]
  • [Cites] Am J Hematol. 2006 Jun;81(6):420-2 [16680743.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1883-90 [16986123.001]
  • [Cites] Clin Adv Hematol Oncol. 2006 Sep;4(9):658-9 [17099621.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2339-43 [17107907.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):271-7 [17031561.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4722-9 [17947719.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):216-22 [18314417.001]
  • [Cites] J Neurooncol. 2008 Aug;89(1):113-8 [18438609.001]
  • [Cites] Neuro Oncol. 2006 Apr;8(2):189-93 [16533878.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] Cancer Treat Rev. 2000 Oct;26(5):351-62 [11006136.001]
  • (PMID = 18661102.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA023108
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ NIHMS539769; NLM/ PMC3885231
  •  go-up   go-down


38. Bock O, Neuse J, Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H: Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status. Am J Pathol; 2006 Aug;169(2):471-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Collagenases / genetics. Mutation / genetics. Primary Myelofibrosis / enzymology. Primary Myelofibrosis / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics

  • Genetic Alliance. consumer health - Myelofibrosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Mol Diagn. 2006 May;8(2):170-7 [16645202.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):248-58 [16397238.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3374-80 [11071630.001]
  • [Cites] J Immunol. 2001 Mar 1;166(5):3491-8 [11207308.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):116-7 [11476553.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):195-204 [11722433.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Methods. 2001 Dec;25(4):409-18 [11846610.001]
  • [Cites] Br J Haematol. 2002 Dec;119(3):709-12 [12437648.001]
  • [Cites] Am J Clin Pathol. 2003 Jan;119(1):152-8 [12520711.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Eur J Haematol. 2003 Oct;71(4):276-82 [12950237.001]
  • [Cites] Acta Haematol. 2004;111(3):155-9 [15034237.001]
  • [Cites] Cell Adhes Commun. 1993 Sep;1(2):93-9 [8081879.001]
  • [Cites] Cell. 1998 Feb 6;92(3):391-400 [9476898.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4641-51 [9845530.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2627-36 [10194442.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1227-37 [15284024.001]
  • [Cites] J Cell Biol. 2004 Nov 22;167(4):757-67 [15545316.001]
  • [Cites] Lancet. 2005 Mar 19-25;365(9464):1054-61 [15781101.001]
  • [Cites] J Pathol. 2005 Apr;205(5):548-57 [15726648.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] N Engl J Med. 2005 Apr 28;352(17):1779-90 [15858187.001]
  • [Cites] Nature. 2005 Apr 28;434(7037):1144-8 [15793561.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4508-15 [15705794.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4187-90 [15817681.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):76-82 [15982347.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1128-32 [16079113.001]
  • [Cites] Leuk Lymphoma. 2005 Sep;46(9):1261-8 [16109602.001]
  • [Cites] J Exp Med. 2005 Sep 5;202(5):663-71 [16147977.001]
  • [Cites] Semin Hematol. 2005 Oct;42(4):248-58 [16210038.001]
  • [Cites] FEBS Lett. 2005 Oct 24;579(25):5487-93 [16213498.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3370-3 [16037387.001]
  • [Cites] J Cell Physiol. 2006 Jan;206(1):1-8 [15920734.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8520-30 [16293880.001]
  • [Cites] Nat Cell Biol. 2000 Oct;2(10):737-44 [11025665.001]
  • (PMID = 16877349.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ PMC1780160
  •  go-up   go-down


39. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V: A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood; 2007 Sep 15;110(6):1762-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro investigations with clofarabine in combination with cyclophosphamide in primary cells have demonstrated synergistic cytotoxicity and inhibition of DNA repair.